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ABSTRACT OF DISSERTATION

TARGETING MALADAPTIVE PLASTICITY AFTER SPINAL CORD INJURY TO
PREVENT THE DEVELOPMENT OF AUTONOMIC DYSREFLEXIA
Vital autonomic and cardiovascular functions are susceptible to dysfunction
after spinal cord injury (SCI), with cardiovascular dysregulation contributing to
morbidity and mortality in the SCI population. Autonomic dysreflexia (AD) is a
condition that develops after injury to the sixth thoracic spinal segment or higher
and is characterized by potentially dangerous and volatile surges in arterial
pressure often accompanied with irregular heart rate, headache, sweating,
flushing of the skin, and nasal congestion. These symptoms occur in response to
abnormal outflow of sympathetic activity from the decentralized spinal cord
typically triggered by noxious, yet unperceived nociceptive stimulation beneath the
level of lesion. Maladaptive plasticity of primary afferents and spinal interneurons
influencing sympathetic preganglionic neurons is known to contribute to the
development of AD. However, there are currently no treatments capable of
targeting this underlying pathophysiology. The goal of this work was to test
pharmacological agents for their potential to modify intraspinal plasticity
associated with AD in order to prophylactically prevent the development of this
condition altogether.
We first tested whether the drug rapamycin (RAP), a well-studied inhibitor
of the growth promoting kinase “mammalian target of rapamycin” (mTOR), could
prevent aberrant sprouting of primary c-fiber afferents in association with reduced
indices of AD severity. Naïve and T4-transected rats undergoing 24/7
cardiovascular monitoring were treated with rapamycin (i.p.) for 4 weeks before
tissue collection. RAP attenuated intraspinal mTOR activity after injury, however it
also caused toxic weight loss. RAP treated SCI rats developed abnormally high
blood pressure both at rest and during colorectal distension (CRD) induced AD, as
well as more frequent bouts of spontaneous AD (sAD). These cardiovascular
alterations occurred without altered intraspinal c-fiber sprouting. Our finding that
rapamycin exacerbates cardiovascular dysfunction after SCI underscores the
importance of screening potential pharmacological agents for cardiovascular side

effects and suggests that the mTOR pathway plays a limited or dispensable role
in c-fiber sprouting after SCI.
We next examined the effects of the antinociceptive drug gabapentin (GBP)
on AD development. Our previous work demonstrated that a single acute
administration of GBP can reduce the severity of AD. The mechanism of action,
however, remains unclear. Emerging evidence suggests that GBP may act by
blocking de novo synaptogenesis. We investigated whether continuous GBP
treatment could attenuate the development of AD by modifying synaptic
connectivity between primary afferents and ascending propriospinal neurons. SCI
rats were treated with GBP every six hours for four weeks. We found that GBP
reduced blood pressure during CRD stimulation and prevented bradycardia
typically observed during AD. However, GBP treated rats also had a higher sAD
frequency and failed to return to pre-injury body weight. Moreover, SCI reduced
the density of putative excitatory (VGLUT2+) and inhibitory (VGAT+) synaptic
puncta in the lumbosacral cord, although GBP did not alter these parameters. Our
results suggest that continuous GBP treatment alters hemodynamic control after
SCI and that decreased synaptic connectivity may contribute to the development
of AD.
These studies demonstrate the need for further research to better
understand the cellular signaling driving maladaptive plasticity after SCI as well as
the complex and dynamic changes in intraspinal synaptic connectivity contributing
to the development of AD. Moreover, GBP treatment may offer clinical benefit by
reducing blood pressure during AD, however the optimal dosage must be identified
to avoid undesired side-effects.

KEYWORDS: Spinal cord injury, autonomic, rapamycin, gabapentin, synapse,
plasticity
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CHAPTER 1
INTRODUCTION

1.1 Introduction to the Autonomic Nervous System
1.1.1 Evolution and History of the Autonomic Nervous System
The mammalian nervous system is a highly interconnected network of
central and peripheral neurons with a multitude of functions that ultimately
promote the survival and reproduction of the organism. This system of neurons,
local and long-distance projections, and supporting cells enables the animal to
respond behaviorally and physiologically to environmental challenges. These
responses can be classified as voluntary or involuntary such as voluntary
locomotion by an animal escaping a predator by its own volition, or involuntary
responses such as an automatic increase in heart rate and blood pressure
priming the animal’s body for intense physical activity while escaping or fighting
the predator. Such involuntary actions are a product of the autonomic nervous
system (ANS).
The ANS is a multifaceted regulatory system found in all vertebrates
(Nilsson, 1983; Nilsson, 2011) that serves essential bodily functions and
maintains physiological homeostasis. As reviewed by Ackerknecht (1974), a
vague conceptual understanding of the ANS has been traced as far back as
ancient Greece. Galen (A.D. 130-200) described the theory of “sympathy” in
reference to the coordinated functions he observed amongst the organs of the
viscera (Debru, 1997). This concept, along with our understanding of physiology
and neuroanatomy, has been developed and refined throughout the past
millennium. The modern descriptions of the ANS started with physiologists
Walter Gaskell and John Langley (Ackerknecht, 1974). The term “autonomic
nervous system” was first applied over a century ago by Dr. Langley as a means
of describing a system that is largely reflexive and self-governed. Prior to Langley
(1898), the term “visceral nervous system” was widely used after being
introduced by Dr. Gaskell (Gaskell, 1886) to describe the system of fibers
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dispersed throughout the visceral organs. However, Langley contended that the
term ‘visceral nervous system’ failed to depict the autonomous functioning and
widespread innervation of both visceral and non-visceral tissues (Langley, 1898).
Gaskell and Langley also defined the three divisions of the ANS as still in
use today. These are the sympathetic, parasympathetic and enteric nervous
systems, the distinction of which was made on the basis of anatomical patterns
and differential pharmacological responses in the peripheral ANS. Sympathetic
and parasympathetic activity produces antagonistic effects on target tissues, with
the actions of one system counterbalancing the other. Activity of the sympathetic
nervous system promotes a physiological state of “fight or flight”, with increased
firing of sympathetic nerves producing increases in heart rate, myocardial
contractility, shifting of blood from the viscera towards major skeletal muscles,
dilation of the pupils, bronchodilation, sweating of the skin, increased fat and
glycogen mobilization, and decreased digestive activity. These actions prepare
the organism for high-intensity exercise needed to escape a potential threat.
On the other hand, a shift towards predominantly parasympathetic activity
reduces heart rate, facilitates sexual arousal, stimulates digestive activity, and
regulates defecation and urination. These functions promote a state of “rest and
digest” or “feed and breed” when the animal is in an environment lacking threats
or stressful stimuli. The third and last branch of the ANS is the enteric nervous
system which is a vast network of neurons dispersed throughout the
gastrointestinal system. This system has hundreds of millions of neurons and is
sometimes referred to as the body’s “second brain” due to its size and
complexity. Rather than being intimately integrated with the CNS as the
sympathetic and parasympathetic systems, the enteric nervous system functions
largely independently and contains its own sensory neurons, local interneurons
and efferent neurons controlling smooth muscle and secretory functions (Costa
et al., 2000; Furness, 2012; Furness et al., 2014; Rao and Gershon, 2016). While
this is a vast and fascinating system with many essential roles, this chapter will
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focus on the sympathetic and parasympathetic divisions of the ANS which are
critical for understanding cardiovascular control.
1.1.2 Anatomical Organization of the Autonomic Nervous System
The rodent and human ANS is comprised of peripheral effector cells
whose activity is modulated by a network of central neurons which integrate and
process a variety of inputs. During development, cells and neurons of the
peripheral ANS arise from the neural crest and migrate to their final position as
their axons grow towards target tissues under the guidance of chemoattractants
and growth factors. Meanwhile, precursors of the central autonomic neurons of
the brain and spinal cord grow into the neural tube formation along with the rest
of the nascent central nervous system (Le Douarin and Smith, 1988; SieberBlum, 2000). Collectively, the central nuclei comprising the ANS are known as
the central autonomic network (CAN) (Benarroch, 1993; Cersosimo and
Benarroch, 2013). As reviewed by Cersosimo and Benarroch (2013), this
network includes numerous structures in the forebrain, brainstem and spinal
cord, including the insular cortex, anterior cingulate cortex, amygdala,
hypothalamus, periaqueductal gray, parabrachial nucleus, nucleus tractus
solitarius, rostral and caudal ventrolateral medulla, ventromedial medulla, caudal
raphe, medullary reticular formation, intermediolateral cell column and sacral
parasympathetic nucleus (Cersosimo and Benarroch, 2013). Primary regions
comprising the sympathetic branch include the locus ceruleus, rostral and caudal
ventrolateral medulla, serotonergic raphe nuclei of the brainstem and the
intermediolateral cell column of the thoracolumbar spinal cord. Major regions
involved in the parasympathetic branch include the central nucleus of the
amygdala, dorsal motor nucleus of the vagus, nucleus ambiguus, raphe nuclei,
periaqueductal gray, the parabrachial nucleus and nuclei within sacral spinal cord
segments. In addition, the CAN receives input from regions involved in cognition
and emotion, such as projections from the amygdala to the lateral hypothalamus
(Lane et al., 2009; LeDoux et al., 1988). Such connections between the limbic
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system and regions involved in cognition provide the physical basis for
autonomic responses to fearful or stressful situations.
Peripheral outflow of the ANS follows a distinct anatomical organization.
The parasympathetic system has a “craniosacral” arrangement, whereby
parasympathetic signals flow out of the CNS through cranial nerves and sacral
spinal cord segments. In contrast, the sympathetic system has a strict
“thoracolumbar” outflow from the thoracic and upper lumbar spinal segments
(Figure 1.1). Notably, although the craniosacral and thoracolumbar classification
of the sympathetic and parasympathetic systems has been used for many
decades after being introduced by Langley, some researchers have recently
argued based on the similarities in developmental marker expression profiles,
that the sacral outflow is sympathetic leaving the cranial nerves as the only
conduit for parasympathetic outflow (Espinosa-Medina et al., 2016). This
assertion led to a heated debate, with a series of rebuttals supporting the original
description of sacral parasympathetic outflow by Langley (Horn, 2018; Janig and
Neuhuber, 2017; Neuhuber et al., 2017). Notably, similar efforts to rename the
anatomical organization of the ANS have been made previously, with Nilsson
suggesting the use of “cranial autonomic” and “spinal autonomic” outflow as a
more practical convention that disregards the distinction between sympathetic
and parasympathetic outflow (Nilsson, 1983). The persistent discontent with the
classification of peripheral ANS outflow exemplifies the challenges of accurately
classifying this complex and multifaceted system.
In comparison to the somatic motor system outflow, which generally goes
directly from spinal motoneurons to the peripheral target muscles, sympathetic
and parasympathetic outflow is comprised of two neurons: a preganglionic
neuron in the brain or spinal cord that projects to a peripheral ganglionic neuron,
which in turn projects its postganglionic fiber to the final target tissue (Figure
1.1). One exception to this pattern is seen in the sympathetic innervation of the
adrenal medulla. In this case, the central sympathetic preganglionic neuron
sends its axon through the sympathetic ganglia without synapsing until it reaches
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the adrenal medulla. For this reason, the secretory adrenal gland is sometimes
described as a modified sympathetic ganglia (Ehrlich et al., 1994).
Virtually every peripheral tissue in the body is innervated by the ANS, with
a number of organs receiving dual innervation from both sympathetic and
parasympathetic nerves. From an evolutionary perspective, the dual-innervation
of critical organs such as the heart occurred early in vertebrate evolution and has
been retained, perhaps because it gives the organism the advantage of being
able to reciprocally regulate sympathetic and parasympathetic activity, providing
rapid and finely-tuned responses and adaptations (Burnstock, 1969). A
characteristic feature common to the sympathetic and parasympathetic branches
is a basal level of ongoing neural activity such that both systems maintain some
level of “tone” (Laskey and Polosa, 1988). This arrangement adds an additional
level of control; rather than having a unidirectional control ability, the sympathetic
and parasympathetic systems can each increase or decrease their firing rate to
produce a wider range of activity. The overall balance of sympathetic and
parasympathetic tone on a target organ determines its functional state and can
shift dramatically in response to physiological disturbances.
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Figure 1.1. Anatomical organization of sympathetic and parasympathetic
outflow. Diagrammatic representation of the anatomical organization of the
peripheral autonomic nervous system. Sympathetic innervation of peripheral
tissues follows a “thoracolumbar” pattern of outflow from central sympathetic
preganglionic neurons distributed throughout the T1-L2 spinal segments (shaded
grey). In contrast, the parasympathetic nervous system follows a “craniosacral”
pattern of outflow from cranial nerves III, VII, IX, and X, as well as sacral spinal
segments. Notably, both systems have a similar sequence of neural connections
from the final central sympathetic or parasympathetic neurons in the brain or
spinal cord, to a peripheral ganglionic neuron which then innervates the target
6

organs. However, peripheral sympathetic neurons coalesce to form paravertebral
and prevertebral ganglia located proximal to the vertebral column whereas
peripheral parasympathetic ganglia form more distally and have longer
preganglionic projections.
1.1.3 Autonomic Control of the Heart
The mammalian cardiovascular system (CVS) is comprised of the heart
and vasculature. This closed-loop system functions to deliver oxygen, nutrients
and hormones to all organs while simultaneously removing metabolic wastes.
Furthermore, the CVS has auxiliary roles in thermoregulation, fluid balance and
immune function (Secomb, 2016). Cardiac muscles contract rhythmically to
produce pressure pulses that generate the flow of oxygenated blood throughout
an extensive arterial supply. Large elastic arteries, such as the aorta, expand
with blood during the systolic phase and subsequently relax to produce a steady
flow of blood through smaller downstream blood vessels during diastole, a
phenomenon known as the Windkessel effect. After infiltrating and passing
through the tissues, the low-pressure venous system collects deoxygenated
blood to return to the lungs and heart for re-oxygenation and re-circulation.
Because the level of activity in a muscle or organ can change dramatically
during normal behavior, the CVS must be able to rapidly alter the rate, volume
and distribution of blood flow to match the metabolic needs of specific regions of
the body. To accomplish this, the CVS is modulated through a combination of
neural, humoral and local autoregulatory mechanisms which allow for both rapid
and long-term adaptations. At the local level of the heart, a set of intrinsic cardiac
nerves surrounds the myocardium and comprises an electrical conduction
system referred to by some researchers as the heart’s “little brain” (Brack, 2015;
Wake and Brack, 2016). Notably, this intrinsic network contains a cluster of
pacemaking cells in the sinoatrial node which can produce rhythmic contractions
even in the absence of extrinsic autonomic control (Sebastian et al., 2013).
Experimental autonomic blockade in humans using pharmacological adrenergic
and cholinergic blockers results in an intrinsic basal heart rate averaging 100
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bpm, indicating that the human heart is primarily under parasympathetic control
at rest when the heart rate is typically 70 bpm (Jose and Collison, 1970; Jose
and Taylor, 1969; Marcus et al., 1990).
Although the heart’s intrinsic electrical system can produce a stable
cardiac rhythm, it does not have the ability to independently adjust output to
match the highly dynamic metabolic needs of the body. Instead, the heart is
under constant autonomic influence via dual innervation by sympathetic and
parasympathetic nerves. Parasympathetic and sympathetic modulation of the
heart must be appropriately balanced to match the cardiac output with the
metabolic demands of the entire body. Cardiac output is a function of heart rate
(HR) and stroke volume:
𝐶𝑎𝑟𝑑𝑖𝑐 𝑂𝑢𝑡𝑝𝑢𝑡 = 𝐻𝑒𝑎𝑟𝑡 𝑅𝑎𝑡𝑒 𝑥 𝑆𝑟𝑜𝑘𝑒 𝑉𝑜𝑙𝑢𝑚𝑒
This formula demonstrates that cardiac output can be increased by elevating the
heart rate or the volume of blood ejected per beat. As described below, both of
these parameters can be reciprocally altered by sympathetic and
parasympathetic stimulation.
Parasympathetic supply to the heart courses through efferent fibers of the
vagus nerve (cranial nerve X; Figure 1.2), with origins in the nucleus ambiguus
and dorsal motor nucleus of the vagus located in the medulla oblongata (Ciriello
and Calaresu, 1982; Jamali et al., 2017). A relatively minor proportion of cardiac
parasympathetic innervation also runs through the laryngeal nerve, which itself is
a bifurcation of the vagus nerve complex (Armour et al., 1997). Dense
parasympathetic innervation from the vagus nerve is observed in the cardiac
atria and, although there is a common misconception that the ventricles lack
parasympathetic innervation (Coote, 2013), a sparse amount of vagal fibers have
indeed been observed in the ventricles (Higgins et al., 1973; Loffelholz and
Pappano, 1985).
Increased activity of vagal parasympathetic fibers produces negative
chronotropic effects (decreased heart rate) and, to a lesser degree, negative
inotropic (decreased contractility) effects (Machhada et al., 2016). Upon firing,
parasympathetic nerve terminals release acetylcholine (ACh) which binds to
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muscarinic acetylcholine receptors expressed on cardiomyocytes and cardiac
pacemaker cells in the sinoatrial (SA) and atrioventricular (AV) nodes (Dhein et
al., 2001). Muscarinic ACh receptors are members of the g-protein coupled
receptor (GPCR) family, which is a large family of metabotropic receptors
featuring a characteristic seven-pass transmembrane domain. There are 5
subtypes of muscarinic ACh receptors(M1-M5), of which the M2 is most important
for cardiac functioning. Upon binding of ACh released from parasympathetic
fibers, M2 receptors on the heart signal through the Gi second messenger
cascade to open g protein-coupled inwardly rectifying potassium channels
(GIRKs). The subsequent increase in inward potassium current through GIRKs
results in hyperpolarization that promotes an increased inter-beat interval
(decreased heart rate) and decreased force of contraction (Hartzell, 1988;
Harvey and Belevych, 2003; Harvey and Hume, 1989; Lanzafame et al., 2003;
Nishimaru et al., 2000).
In contrast to the vagal parasympathetic supply of the heart, which
projects directly from the brainstem to the heart, cardiac sympathetic innervation
first runs through the spinal cord. All sympathetic outflow originates from
sympathetic preganglionic neurons (SPN) dispersed throughout the thoracic and
upper lumbar spinal cord. As discussed by Deuchars and Lall (2015), a number
of tracing and labeling methods have been employed to visual the SPN including
visualization of sympathectomy-induced chromatolysis, retrograde tracing, and
immunolabeling with choline acetyltransferase (ChAT). The SPN are distributed
into four spinal nuclei: the intermediolateral cell column (IML), intercalated
nucleus, central autonomic region and thoracolumbalis pars funicularis
(Deuchars and Lall, 2015). Most attention is typically given to the IML, given that
approximately 75% of all SPN are concentrated in this nucleus. The IML is
located in the lateral horns of the thoracolumbar cord, forming bilateral clusters
with a “ladder-like” architecture among segments (Deuchars and Lall, 2015;
Markham and Vaughn, 1990; Rando et al., 1981). Cardiac SPN that control the
heart are distributed throughout the T1-T6 spinal segments (Coote, 1988; Coote
and Chauhan, 2016). As with all SPN, the cardiac SPN exit the cord through the
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ventral root system to synapse with sympathetic ganglia in the periphery. These
ganglia contain the final effector neurons that send postganglionic axons to
innervate the target tissues. Greater than 90% of the post-ganglionic fibers
innervating the heart arise from the middle and inferior/stellate cervical ganglia,
with the remaining postganglionic fibers originating from the superior cervical
ganglia and the 4th through 6th thoracic sympathetic ganglia (Pardini et al., 1989,
1990). In addition to direct sympathetic innervation of the heart, the sympathetic
system also alters cardiovascular function through circulating catecholamines
released from the adrenal medulla (Adameova et al., 2009). This is another
notable distinction between sympathetic and parasympathetic control of the
heart, as parasympathetic modulation is restricted to direct innervation.
The terminals of cardiac sympathetic fibers primarily release
norepinephrine, which is a catecholamine that binds to and activates adrenergic
receptors (AR) throughout the heart. The ARs are divided into a-AR and b-AR
subtypes and, similar to the muscarinic ACh receptors, are members of the
GPCR family. While the heart expresses both a-ARs and b-ARs, approximately
90% are b-ARs (O'Connell et al., 2014). The b-ARs include b1, b2 and the b3ARs, of which the b1-ARs are the most widely expressed accounting for roughly
80% of b-ARs (O'Connell et al., 2014; Post et al., 1999). When activated by
norepinephrine released from sympathetic terminals, or circulating epinephrine
released from chromaffin cells of the adrenal medulla, the ARs have positive
chronotropic, inotropic and lusitropic (rate of cardiac relaxation) actions. These
effects are mediated by an array of intracellular changes resulting from g-protein
signaling initiated by ligand binding. For example, AR activation increases
intracellular cAMP and PKA activity leading to enhanced
phosphorylation/activation of calcium channels, and contractile proteins. Notably,
phospholamban is an inhibitor of the cardiac sarcoplasmic reticulum Ca++
ATPase (SERCA) pump in its non-phosphorylated state. Upon phosphorylation,
the SERCA becomes disinhibited which allows for more rapid calcium
sequestration that is responsible for the positive lusitropic effect of increased
sympathetic tone (Hagemann and Xiao, 2002).
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1.1.4 Autonomic Control of the Vascular System
The vascular system is a large and dynamic collection of blood vessels
which bifurcates in an iterative fashion, with each subsequent iteration
decreasing in diameter to form the microcirculation serving every organ. Far from
a passive set of tubes, this system is highly dynamic and responsive to the needs
of a given tissue. Blood vessels are critical for the delivery of oxygen, nutrients
and hormones as well as the removal of metabolic wastes such as carbon
dioxide. Moreover, the vascular system plays a major role in determining blood
pressure and cardiac preload/afterload. The total peripheral resistance (TPR) to
blood flow is a major factor in determining arterial pressure, with increases in
TPR resulting in higher blood pressure. TPR is highly responsive to changes in
the diameter of blood vessels. In fact, as described by Poiseuille’s law, the
relationship between TPR and vessel diameter is linked to the fourth power,
demonstrating the powerful relationship between vessel diameter and blood
pressure (Thomas, 2011).
Two systems contribute to the regulation of blood vessel diameter: 1) local
autoregulation of regional blood flow and 2) autonomic-mediated control through
direct neural innervation and indirect circulatory factors released from the adrenal
medulla. Autoregulation occurs most notably in the critical renal, cardiac and
cerebral vascular beds, and occurs through local monitoring of the levels of
oxygen and metabolic wastes which indicate whether an increase or decrease of
blood flow/vessel diameter is necessary. In addition to localized autoregulation,
vascular smooth muscles of critical blood vessels throughout the body also
receives autonomic. This allows for the rapid neural control of peripheral
resistance and blood pressure, as well as the ability to allocate cardiac output to
match the metabolic demands of specific tissues. Postganglionic sympathetic
fibers arising from cardiovascular SPN innervate the smooth muscle of arteries,
veins and large-diameter arterioles. Upon firing, norepinephrine released from
these fibers activates a-ARs in the smooth muscle resulting in increased calcium
release and contraction of the smooth muscle. In this fashion, increased
sympathetic tone decreases vessel diameter to increase total peripheral
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resistance and blood pressure. Catecholamines released from the adrenal gland
produce similar vasoconstriction, however, because these effects are more
widespread due to their release into the circulation (Guyton and Hall, 2006).
While much attention is paid to the sympathetic innervation of the
vasculature, less is generally given to parasympathetic innervation. Indeed,
sympathetic and parasympathetic systems are both involved in vascular
regulation (Kaji et al., 1991; Ruocco et al., 2002; Sheng and Zhu, 2018). Notably,
however, the parasympathetic vascular supply is limited to a few particular
vascular beds in the cutaneous circulation, salivary glands and genitalia (Amiya
et al., 2014; Emmelin, 1987; Ruocco et al., 2002; Sheng and Zhu, 2018). In
comparison, the sympathetic innervation of arterial and venous circulation is
extensive and plays a more critical role in regulating blood pressure and blood
flow (Ruffolo et al., 1991; Sheng and Zhu, 2018).
Examination of adrenoceptor expression profiles reveal tissue-specific
distribution patterns, allowing for the selective control of regional blood vessels in
response to globally circulating catecholamines. Large coronary arteries, for
example, express both a-AR and b-AR, whereas small coronary vessels only
express b-AR (Bohr, 1967). Splanchnic and skeletal muscle vascular beds in
humans express predominantly b-ARs, dilating in response to epinephrine. In
contrast, the vessels of the renal and skin circulatory beds express
predominantly a-ARs and constrict in response to epinephrine. With this pattern,
epinephrine released into the circulation from adrenal chromaffin cells would tend
to shunt blood away from the skin and kidneys towards skeletal muscle to
increase muscle blood flow during the fight-or-flight response (Guimaraes and
Moura, 2001). Sympathetic innervation is also observed in the cerebral
vasculature, although the degree of innervation varies considerably across
species. Whereas some species have a dense sympathetic cerebrovascular
innervation, humans have a relatively low density of sympathetic nerve bundles
surrounding cerebral arteries which is correlated with weak changes in
cerebrovascular diameter upon sympathetic nerve stimulation (Bevan et al.,
1998).
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Figure 1.2. Autonomic Control of the Cardiovascular System. Dual
sympathetic and parasympathetic innervation of the heart provides rapid
neuronal control of cardiac function. While sympathetic cardiac innervation is
mediated through sympathetic post-ganglionic fibers, parasympathetic supply
comes directly from the vagus nerve (cranial nerve X). Cardiac sympathetic
preganglionic neurons (SPN) are located primarily in the intermediolateral cell
column of the first through sixth thoracic (T1-T6) spinal segments and project to
sympathetic ganglia to form the cardiac plexus. These SPNs are stimulated by
supraspinal regions including the rostral ventrolateral medulla (RVLM), which in
turn receives inhibitory inputs from the caudal ventrolateral medulla (CVLM). The
CVLM receives excitatory drive from neurons within the nucleus tractus solitarius
(NTS) which are, in turn, stimulated by pressure sensitive baro-afferents located
in the carotid sinus and aortic arch. With this arrangement, increased blood
pressure results in inhibition of the RVLM and reduced vasomotor tone as part of
13

the baroreflex. SPN of the thoracolumbar cord innervate the adrenal medulla,
stimulating the release of catecholamines into the circulation, as well as the
extensive mesenteric vasculature to modify vascular diameter and total
peripheral resistance.
1.2 Introduction and Overview of Spinal Cord Injury
1.2.1 Etiology and Prevalence of Spinal Cord Injury
Traumatic spinal cord injury (SCI) can wreak havoc on multiple body
systems and functions, often resulting in the loss of motor and sensory functions
as well as the development of neuropathic pain, irregular cardiovascular control,
and disrupted autonomic function. The primary causes of traumatic SCI are
automobile accidents, sports injuries, accidental falls, acts of violence and workrelated accidents (Lee et al., 2014a). The worldwide incidence of traumatic injury
to the spinal vertebral column is estimated at 10.5 patients per 100,000
individuals, with over 750,000 new cases each year. 30- 40% of these cases also
involve SCI, defined by damage to the cord tissue itself (Kumar et al., 2018).
Males are disproportionately affected with the male:female ratio ranging between
approximately 3:1 globally (Kumar et al., 2018) to as high as 7:1 regionally in
Brazil (Santos et al., 2009). There is indication that there is an increase in SCI
among older individuals and an increase in the relative number of new injuries
resulting in high-level tetraplegia (McCaughey et al., 2016). These trends are
speculated to further increase an already significant financial burden of the
lifetime costs of medical care for an individual with SCI, which can accumulate
into several millions of dollars over a lifetime (McCaughey et al., 2016).
Based on current (2018) data from the National Spinal Cord Injury
Statistical Center, the largest portion (47%) of new SCI cases since 2015
involves damage to the cervical spinal segment resulting in incomplete
tetraplegia. The mechanisms of the primary injury are variable, ranging from
complete cord transection to contusion or compression injury caused by fractured
or dislocated vertebrae. The majority of cases involve contusion or compression
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injury, resulting in a large degree of heterogeneity in functional deficits among the
SCI population (Iencean, 2003).
While the primary mechanical insult is virtually unavoidable due to the
inadvertent nature of SCI, secondary damage processes occurring over the
hours and weeks after injury are potentially targetable processes that are the
focus of much SCI research (Orr and Gensel, 2017). In the immediate aftermath
of injury, a number of toxic interactions occur related to the release of free
radicals, excitotoxic damage, and calcium overload. The respiratory capacity of
mitochondria is greatly diminished, leading to inadequate energy production and
additional apoptotic cell death (Sullivan et al., 2007). In the days and weeks after
injury, neuroinflammatory processes occur, some of which are beneficial for
functional recovery but some of which contribute to irreversible tissue loss
(reviewed in Gensel and Zhang, 2015). At the level of neuronal networks, the
loss of descending innervation promotes undirected compensatory fiber
sprouting and synaptic remodeling in an uncoordinated and abnormal fashion,
resulting in aberrant connectivity contributing to neuropathic pain, spasticity and
cardiovascular dysfunction (Beauparlant et al., 2013; Brown and Weaver, 2012).
1.2.2 Effects of Spinal Cord Injury on the Autonomic Nervous System
The spinal cord functions both as a highway connecting the brain with the
periphery as well as an independent control center capable of integrating
numerous inputs and mediating reflex-level autonomic responses. While
sensorimotor detriments are the most outwardly apparent effect of SCI, there can
also be a plethora of cardiovascular and autonomic disruptions. Notably, the
efferent sympathetic supply and sacral portion of the parasympathetic innervation
flows out through the spinal cord (Figure1.1). Accordingly, damage to the cord
often results in disrupted communication between supraspinal control centers
and preganglionic neurons of the cord, which contributes to irregular autonomic
and cardiovascular control in SCI (Weaver et al., 2012). Importantly,
cardiovascular and autonomic dysfuntions are a major impact of SCI that present
considerable hindrances to quality of life for those living with SCI (Anderson,
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2004), demonstrating the clinical significance of developing therapeutic strategies
to treat such dysfunction.
Arguably the most insidious manifestation of disrupted cardiovascular
control is autonomic dysreflexia (AD), defined as abnormal and potentially
harmful surges in blood pressure typically in response to noxious afferent stimuli
below the lesion triggering unrestrained sympathetic reflexes. The earliest
descriptions of AD were by two wartime doctors, Henry Head and George
Riddoch, who observed “mass reflex” activity of sympathetic outflow in a subset
of patients with SCI (Feustel, 1976; Guttmann and Whitteridge, 1947). Decades
later, this phenomena came to be understood as autonomic hyperreflexia
(Feustel, 1976) and today is referred to as AD (Karlsson, 1999). As discussed in
depth in Chapter 2, AD develops in many patients with injury to the sixth thoracic
segment or higher and presents a considerable health concern and detriment to
a patient’s quality of life, making this an important topic of SCI research.
1.3 Central Hypothesis of Dissertation
A number of mechanisms are thought to contribute to the development of
AD, including maladaptive sprouting of primary afferent fibers and propriospinal
relay neurons (Figure 1.3). Previous experiments from our lab have
demonstrated that the degree of sprouting correlates with the severity of AD,
indicating maladaptive sprouting as a targetable process to modulate the
development of AD (Cameron et al., 2006; Hou et al., 2009). Therefore, the
overall hypothesis tested in this dissertation is that pharmacological targeting of
cellular processes thought to underlie maladaptive plasticity can prophylactically
block the development of AD.
First, the drug rapamycin (RAP) was administered in rats using a wellestablished T4-transection SCI model widely used for experimental investigation
of AD. RAP is an FDA-approved immunosuppressant drug that inhibits the
mammalian target of rapamycin (mTOR) pathway. Recently, the mTOR signaling
complex has gained much interest in the field of neuroscience for its purported
role in functional and structural plasticity. As presented in Chapter 3, we first
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tested the hypothesis that chronic RAP treatment after SCI can suppress
maladaptive plasticity of primary afferents activating propriospinal neurons, and
the development of AD. Next, the drug gabapentin (GBP) was investigated for its
potential to prevent aberrant synaptogenesis believed to coincide with
maladaptive sprouting. GBP is a well-established drug developed decades ago
as an analogue of g-aminobutyric acid (GABA) and initially intended to treat
epilepsy and neuropathic pain. Previous studies from our lab (Rabchevsky et al.,
2011; Rabchevsky et al., 2012) showed that acute treatment with GBP
attenuates the severity of AD and spasticity in SCI rats. In lieu of reports
suggesting that prolonged GBP treatment can suppress excitatory
synaptogenesis in the brain and spinal cord (Crosby et al., 2015; Yu et al., 2018),
we administered GBP continuously (every 6 hours) after SCI to determine if
prolonged GBP treatment can mitigate the development of AD by suppressing
aberrant synaptogenesis believed to contribute to AD pathophysiology (Chapter
4). Cardiophysiological and histological analyses were conducted in both studies
to determine if these drugs present clinically viable approaches in the
prophylactic prevention of AD development.
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Figure 1.3. Maladaptive plasticity is associated with the development of AD
weeks after spinal cord injury (SCI). In the uninjured Naïve rat spinal cord
(left), sympathetic preganglionic neurons (SPN; dark green) distributed
throughout the intermediolateral cell column of the thoracic cord receive inputs
from descending vasomotor control centers in the brain, as well as from
ascending propriospinal neurons (light green) which may be activated by primary
afferents (purple). In the acute phase following high-thoracic SCI (middle),
descending fibers are severed leaving the caudal SPN partially denervated. The
resultant segregation of SPN from supraspinal control allows sympathetic
reflexes to occur unopposed. In the chronic stage of SCI (right), sprouting is
observed in the central projections of c-fiber afferents and ascending
propriospinal neurons projecting rostrally towards the SPN. This maladaptive
plasticity is associated with the development of AD and may present a clinically
viable target for the treatment or prophylactic prevention of this syndrome.
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CHAPTER 2
Autonomic Dysreflexia After Spinal Cord Injury: Systemic
Pathophysiology and Methods of Management
2.1 Introduction to autonomic dysreflexia (AD)
In addition to motor and sensory deficits, traumatic spinal cord injury (SCI)
causes a constellation of interrelated autonomic and cardiovascular
abnormalities. Cardiovascular complications secondary to SCI are among the
leading causes of mortality and morbidity in this population, underscoring the
necessity to understand and properly manage resultant comorbidities (Cragg et
al., 2013; Garshick et al., 2005; Myers et al., 2007; Sabre et al., 2013). In
humans, SCI at or above the sixth thoracic (T6) spinal cord segment often results
in the development of a potentially life-threatening syndrome called autonomic
dysreflexia (AD). AD is clinically defined as acute hypertension generated by
unmodulated sympathetic reflexes below the injury level that is often
accompanied by baroreceptor-mediated bradycardia, which provides short-term
control of blood pressure (Karlsson, 1999). In response to hypertension, the
baroreflex system normally lowers blood pressure by reducing heart rate and
decreasing activity of vasoconstrictor sympathetic preganglionic neurons (SPN)
located throughout the thoracolumbar spinal cord that regulate peripheral
vascular resistance. However, while vagal parasympathetic innervation of the
heart remains intact after SCI, the disruption of descending vasomotor pathways
to SPN produces an incomplete compensatory decrease in peripheral vascular
resistance so that hypertension persists until the triggering stimulus is removed.
Typically, AD is precipitated by noxious visceral or somatic stimulation
below the level of injury that activates a massive sympathetic reflex causing
widespread vasoconstriction. While the most common triggers are overdistension of the bowel or bladder (Canon et al., 2015; Lindan et al., 1980; Snow
et al., 1978), other noxious stimuli including skin lacerations, ingrown toenails,
pressure sores, tight clothing and certain medical procedures such as bladder
catheterization and cystometry are also reported to cause AD (reviewed in
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Karlsson, 1999). During an episode of AD, arterial blood pressure can reach
devastating levels, with systolic values as high as 325 mmHg (McBride et al.,
2003), exemplifying that AD is a hypertensive crisis that requires immediate
medical attention (Muzumdar, 1982; Showkathali and Antionios, 2007; Verghese,
1989). Severe cases that do not receive rapid and appropriate treatment can
have serious consequences such as hypertensive encephalopathy, stroke,
cardiac arrest, seizure and even death (Bjelakovic et al., 2014; Colachis and
Clinchot, 1997; Eltorai et al., 1992; Fausel and Paski, 2014; Jain et al., 2013;
Valles et al., 2005). Bouts of AD can arise multiple times daily due to the noxious
yet unperceived afferent stimulation produced by normal, intermittent filling of the
bladder and bowels (Fougere et al., 2016a; Hubli et al., 2015; Popok et al.,
2016). In light of this, it is perhaps not surprising that eliminating AD is one of the
highest priorities of the SCI population, based on a large national survey
(Anderson, 2004) which reported that both quadriplegics and paraplegics
prioritize the recovery of bowel/bladder function and elimination of AD over
regaining walking movements, highlighting the need for research strategies to
mitigate the development of AD altogether.
This chapter provides a clinical description of AD along with its
pharmacological management, and discuss the underlying pathophysiological
changes that contribute to such dangerous, episodic hypertension after high-level
SCI. We further describe recent studies revealing body-wide disturbances that
result from chronic recurring episodes of AD, including vascular, cardiac and
immunological dysfunctions. Contemporary research strategies will be
considered to understand more comprehensively the underlying mechanisms,
the full physiological impact of this syndrome that typically occurs multiple times
daily, and potential therapeutic approaches to abrogate its development.
2.2 Clinical description of autonomic dysreflexia
2.2.1 Who is at risk of developing AD?
The T6 spinal segment is critical to the development of AD (Lindan et al.,
1980; Mathias and Frankel, 1988; Snow et al., 1978), as damage at or above this
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level interrupts descending modulation of the thoracolumbar SPN that regulate
vasomotor tone, notably in the extensive splanchnic vascular bed (Blackmer,
2003; Gao et al., 2002). These vessels are innervated by the splanchnic nerves
arising from the T5-T12 levels (see (Loukas et al., 2010) and receive
approximately 25% of the cardiac output (Greenway and Lister, 1974; Rowell,
1990), which can have a large influence on total peripheral resistance and blood
pressure. There are, however, uncommon reports of AD occurring after lesions
below T6 but the magnitude of hypertension and changes in heart rate tend to be
relatively mild since some degree of control over splanchnic sympathetic outflow
remains intact (Moeller and Scheinberg, 1973).
Not all individuals with SCI at or above the T6 level develop AD, with the
prevalence reported between 48% and 91% (Curt et al., 1997; Lindan et al.,
1980; Snow et al., 1978). This discrepancy is likely attributed to differences in the
completeness of SCI, time elapsed since injury, and differences in the criteria
used to confirm the presence of AD used among studies (Furusawa et al., 2011).
Indeed, the clinical definition of AD is somewhat inconsistent (see section 2.2).
Interestingly, AD has been documented in cases of non-traumatic abnormalities
of the spinal cord such as intramedullary astrocytoma (Furlan et al., 2003) and
multiple sclerosis (Kulcu et al., 2009), indicating that disruption of descending
vasomotor pathways in any manner may contribute to the development of this
syndrome.
2.2.2 Characteristic features of AD
The magnitude of hypertension required to be considered AD varies
across studies. Snow et al. (1978) classified AD in adults as an increase of 40
mmHg systolic blood pressure whereas Popok et al. (2016) defined AD as an
increase of 20 mmHg systolic blood pressure. Others (Lindan et al., 1980)
diagnosed AD as a sudden rise in both systolic and diastolic blood pressure of
any magnitude. Veteran’s Affairs guidelines recommend that AD in adults is
considered following abrupt elevation in systolic blood pressure of 20-40 mmHg
above baseline, whereas in pediatric SCI an increase of 15-20 mmHg systolic
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pressure warrants consideration (Canon et al., 2015; Consortium for Spinal Cord,
2002).
In addition to elevated blood pressure, individuals with an acute episode of
AD can experience a diverse set of symptoms including debilitating headache,
sweating, flushing of the skin above the injury level, piloerection, stuffy nose,
blurred vision and anxiety (Karlsson, 1999). While these symptoms are not
simultaneously present in all cases, headache and sweating above the lesion
occurs 88% of the time (Lindan et al., 1980). Although the classical definition of
AD is acute hypertension coincident with bradycardia (Erickson, 1980; Guttmann
and Whitteridge, 1947; Trop and Bennett, 1991), the importance of heart rate in
the diagnosis of AD is a matter of controversy. Lindan et al. (1980) reported an
equal incidence of bradycardia and tachycardia (increase in heart rate) in
documented cases of AD, whereas others report that tachycardia is more
common (Hickey et al., 2004; Kewalramani, 1980; Scott and Morrow, 1978).
Whether an episode of AD is concomitant with an increase or decrease in heart
rate may depend on the injury level (Collins et al., 2006; Karlsson, 1999;
Krassioukov et al., 2003). As suggested by Karlsson (1999), activation of
sympathetic circuits in the spinal cord below a cervical injury may propagate
rostrally towards cardiac-innervating SPN (i.e., T1-T4), explaining why
tachycardia is frequently observed during AD. However, the correlation between
injury level and the direction of heart rate change during episodes of AD has not
been formally investigated.
2.2.3 Temporal development of AD after SCI
AD most often presents in the chronic phase of SCI, with a majority of
cases first occurring 3-6 months after injury in humans (Lindan et al., 1980).
While it may also occur in earlier stages of injury, the incidence of early AD is
relatively low, with only 5.7% of individuals with SCI above T6 having clinically
documented AD within the first month post-injury (Krassioukov et al., 2003).
Though uncommon, the manifestation of AD in the early stage of injury is
significant considering that treatment of acute, high-level SCI often includes
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pressor agents to help combat the profound hypotension associated with such
injuries (reviewed in Ploumis et al., 2010). In cases of acute AD occurring within
days of injury, systolic blood pressure as high as 210 mmHg has been reported
(Silver, 2000), suggesting that concurrent vasopressor support may compound
damage during episodic hypertension.
In experimental SCI, the development of telemetric monitoring techniques,
along with the advent of computer algorithms capable of processing large
amounts of hemodynamic data, have allowed for detailed analysis of the
temporal development of AD in conscious animals (Laird et al., 2006; Mayorov et
al., 2001; Rabchevsky et al., 2012; West et al., 2015). In both rats and mice with
high-thoracic SCI, spontaneous AD triggered by naturally occurring stimuli
emerges in a biphasic pattern with a transient surge of events occurring within
the first week, followed by a gradual rise in frequency beginning around 2-weeks
post-injury (Rabchevsky et al., 2012; West et al., 2015; Zhang et al., 2013).
Moreover, the magnitude of change in systolic pressure during these events
increases over time (West et al., 2015). These observations generally
correspond to the development of AD in humans, where the initial disruption to
descending vasomotor pathways allows for early AD (Krassioukov et al., 2003)
before maladaptive changes in viscerosympathetic circuitry associated with more
frequent and severe cases occur during the more chronic stages (West et al.,
2015). Recent capabilities of screening ambulatory blood pressure recordings for
daily AD events in humans (Hubli and Krassioukov, 2014; Popok et al., 2016) will
enable detailed analyses of temporal progression of this syndrome in humans, as
well as the efficacy of drugs to reduce the frequency or magnitude of recurrent
AD.
2.3 Mechanisms contributing to AD
2.3.1 Loss of supraspinal control
Within the intact nervous system, supraspinal vasomotor neurons residing
in the paraventricular nucleus, rostral ventrolateral medulla, rostral ventromedial
medulla, caudal raphe nuclei and A5 cell group (Calaresu and Yardley, 1988;
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Chalmers et al., 1994; Hosoya et al., 1991; Jansen et al., 1995; Llewellyn-Smith,
2009; Strack et al., 1989; Sved et al., 2001) send projections to the
intermediolateral cell column (IML), which is comprised of spinal nuclei
containing sympathetic preganglionic neurons (SPN) that extends throughout the
T1-L2 segments (Pyner and Coote, 1994; Tang et al., 1995; Zagon and Smith,
1993). These supraspinal neurons modulate the tonic firing of SPN which, in turn,
send projections to the peripheral sympathetic chain ganglia or directly to the
adrenal medulla (Figure 2.1). The sympathetic ganglia act as the final
sympathetic effector cells and innervate blood vessels throughout the body,
whereas stimulation of the adrenal medulla secretes epinephrine and
norepinephrine (NE) into the circulation. Together, this provides both direct and
indirect control of blood vessel diameter and peripheral resistance to facilitate
hemodynamic homeostasis (reviewed in Thomas, 2011).
After high-level SCI, the descending autonomic pathways responsible for
supraspinal modulation of SPN become interrupted, reducing sympathetic tone
below the injury (Stjernberg et al., 1986) and leaving SPN under the control of
spinal influences alone. In the initial “spinal shock” phase of injury, which can last
for weeks in humans (Ditunno et al., 2004), this loss of descending control
manifests as significantly reduced blood pressure and depression of sympathetic
reflexes (Frankel et al., 1972). Over time, however, plasticity of SPN and
reorganization of spinal circuitry create a hyper-excitable state that contributes to
the aberrant reflex activation of SPN in response to afferent stimulation (Figure
2.1) (Krassioukov et al., 2002; Llewellyn-Smith and Weaver, 2001; Rabchevsky,
2006). Because of the interruption to descending modulatory pathways, which
would normally inhibit the SPN during hypertension via the baroreflex (Guyenet
and Cabot, 1981), AD persists until the stimulus is withdrawn.
2.3.2 Synaptic reorganization of sympathetic preganglionic neurons (SPN)
The damage to descending vasomotor pathways caused by SCI leaves
many SPN partially denervated, causing a number of histological and functional
changes in these neurons in both the human and rat (Krassioukov et al., 1999;
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Krassioukov and Weaver, 1995, 1996). Whereas SPN activity is normally
regulated by a confluence of supraspinal and intraspinal inputs, their ongoing
activity after complete SCI depends solely on the influence of spinal sympathetic
interneurons (Schramm, 2006). Spinally derived sources of input to SPN include
interneurons residing in laminae V, VII and X (Cabot et al., 1994; Cano et al.,
2001; Clarke et al., 1998; Deuchars et al., 2001; Deuchars and Lall, 2015; Joshi
et al., 1995; Tang et al., 2004a). While there are no direct synaptic inputs to SPN
from primary afferents, it is thought that sensory neurons can influence the SPN
via such spinal interneurons (Laskey and Polosa, 1988; Schramm, 2006). The
integration of supraspinal and intraspinal inputs on SPN is complex and involves
both monosynaptic and polysynaptic pathways (reviewed in Deuchars and Lall
(2015).
After experimental T4 spinal cord transection in adult rats, profound
morphological changes occur to SPN within the IML below the lesion. Within 3
days of injury, the dendritic length and diameter of SPN soma decrease
dramatically in response to the degeneration of terminals with supraspinal origins
(Llewellyn-Smith and Weaver, 2001). By two-weeks, however, the somatic size
and dendritic arbor of SPN appears normal again (Krassioukov and Weaver,
1996; Krenz and Weaver, 1998a). These dynamic changes in gross SPN
morphology correspond temporally with the evolution of cardiovascular
dysfunction in rats with high-level SCI, where pronounced resting hypotension
occurs in the first days, followed by a gradual increase in basal blood pressure
and the appearance of recurrent AD by two weeks post-injury (Laird et al., 2006;
Mayorov et al., 2001; Rabchevsky et al., 2012; West et al., 2015).
While atrophied SPN regain a normal morphology in the weeks after
injury, experimental evidence suggests that a radical reorganization of synaptic
inputs controlling their activity occurs. Weaver et al. (1997) demonstrated altered
expression patterns of GAP-43 (growth associated protein-43), a marker of
reactive sprouting, in both mature axons and growth cones in close apposition to
SPN caudal to a complete mid-thoracic transection weeks after injury. Because
of the complete transection model used and absence of degenerating
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supraspinal axons in the IML after 7 days, the source of these GAP-43
immunoreactive axons was limited to spinal neurons below the injury, suggesting
reorganization of intraspinal sympathetic circuits that may contribute to the
exaggerated sympathetic reflex during an AD event. Llewellyn-Smith and Weaver
(2001) also observed a switch in the ratio of synapses on SPN containing
glutamate or g-aminobutyric acid (GABA), indicating a shift in the balance of
excitatory and inhibitory influences, respectively. Specifically, T4-transection
caused a decrease in the percentage of glutamatergic inputs versus an increase
in the percentage of GABAergic inputs on SPN in the IML at the T8 spinal level
after two-weeks, implying a predominantly inhibitory synaptic integration. While
this observation is consistent with the resting hypotension and reduced
sympathetic outflow seen after SCI, how this relates to the intense sympathetic
outbursts that occur in response to noxious visceral stimulation is uncertain.
Recent work by Huang et al. (2016) indicates that complete high-thoracic (T2)
spinal cord transection in rats causes GABA neurotransmission to convert from
an inhibitory to excitatory role in nociceptive circuits. While the influence of SCI
on GABAergic regulation of SPNs was beyond the scope of this work, it provides
evidence that GABAergic inputs onto SPN may provide excitatory drive after SCI
(Rabchevsky, 2006).
An alternative explanation may be that glutamatergic synapses on SPN
are the predominate input recruited by noxious visceral stimulation. It has been
documented that glutamatergic signaling through both NMDA and AMPA
receptors is important for the initiation of AD in response to noxious colorectal
distension (CRD) (Maiorov et al., 1997). Ueno et al. (2016) recently
demonstrated that chemogenetic silencing of Vglut2+ (vesicular glutamate
transporter 2) interneurons after T3 SCI suppressed anti-inflammatory
sympathetic reflexes related to AD (see section 5.2). This is further supported by
studies testing the anti-epileptic and neuropathic pain medication gabapentin
(GBP) as an experimental treatment for AD (Rabchevsky et al., 2011). GBP is
known to inhibit pre-synaptic glutamate release by binding to the a2d1 subunit of
voltage-gated calcium channels (Coderre et al., 2005, 2007; Gee et al., 1996;
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Shimoyama et al., 2000) and has been shown to reduce both the magnitude and
frequency of AD in rats with complete T4-transection, specifically after acute but
not chronic administration (Rabchevsky et al., 2011; Rabchevsky et al., 2012).
Notably, however, the site(s) of action and mechanism(s) through which GBP
mitigates AD remains uncertain. It is feasible that GBP acts by reducing
glutamatergic transmission at the level of both primary afferents entering the
spinal cord as well as glutamatergic spinal interneurons synapsing with SPN.
GBP has also been reported to inhibit excitatory synaptogenesis both in-vitro and
in-vivo by blocking the binding of synaptogenic thrombospondin proteins to the
a2d1 subunit (Eroglu et al., 2009). This suggests that GBP may work to reduce
aberrant excitatory synapse formation in viscerosympathetic circuits after SCI.
However, the short 2-3 hour half-life of GBP in rats (Radulovic et al., 1995;
Vollmer et al., 1986) likely explains why once daily GBP treatment is insufficient
to significantly reduce the frequency of spontaneous AD in the hours following
administration; and likely insufficient to alter putative synaptic formation
(Rabchevsky et al., 2012). Further studies into the synaptic mechanisms
controlling SPN during noxious stimulation, as well as the precise means through
which GBP mitigates AD may help identify novel therapeutic targets for
prophylactically preventing the development of this syndrome.
2.3.3 Primary afferent sprouting
Intraspinal sprouting of primary afferent nociceptive fibers is also thought
to contribute to the development of AD. After experimental SCI, the central
arbors of unmyelinated c-fiber afferents expressing calcitonin gene-related
peptide (CGRP), a marker of nociceptive fibers, sprout into the dorsal horn
caudal to the injury (Hou et al., 2009; Krenz and Weaver, 1998b). The extent of
CGRP+ fiber sprouting into the lumbosacral spinal cord correlates with the
magnitude of AD elicited by noxious CRD (Cameron et al., 2006; Krenz et al.,
1999), suggesting that enhanced sprouting of nociceptive fibers increases reflex
activation of SPN through propriospinal “relay” neurons (Figure1, see section
4.4). Increased CGRP+ fiber density becomes apparent two weeks after
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experimental injury (Hou et al., 2009; Krenz and Weaver, 1998b), a time at which
AD develops reliably in spinal rats (Krassioukov and Weaver, 1995; Laird et al.,
2006). Importantly, increased CGRP+ fiber sprouting in the dorsal horn is also
seen in the chronic stages of human SCI, and in one case has been associated
with a well-documented history of AD (Ackery et al., 2007).
The sprouting of c-fibers appears to be primarily dependent on nerve
growth factor (NGF) signaling. After transection or contusion SCI, resident
neurons and glia upregulate the expression of intraspinal NGF rostral and caudal
to the lesion (Bakhit et al., 1991; Brown et al., 2004). Blockade of NGF signaling
through intrathecal delivery of anti-NGF antibodies for two-weeks after T4transection SCI effectively mitigates injury-induced sprouting of CGRP+ fibers
throughout the spinal cord. Furthermore, animals receiving anti-NGF therapy had
less severe AD in response to noxious CRD (Krenz et al., 1999), although this
treatment did not abolish it completely. Cameron et al. (2006) used a proof-ofprinciple approach to overexpress NGF in the cord after T4-transection using
adenovirus injections into either the T13/L1 or L6/S1 spinal levels innervating the
distal colon and found that the pressor and bradycardic responses to CRD were
significantly exacerbated. Conversely, injured cords injected with adenovirus
encoding semaphorin 3a, a specific chemorepellant for both c-fibers and
sympathetic fibers (Tang et al., 2004b), had significantly diminished pressor and
bradycardic responses during CRD. Such exacerbations or ameliorations were
significantly correlated with increased or decreased CGRP+ fiber sprouting,
respectively.
2.3.4 Propriospinal plasticity
Plasticity of ascending lumbosacral propriospinal fibers that relay pelvic
sensory information rostrally towards SPN in the thoracic cord is also thought to
contribute to the development of AD. There is compelling evidence for functional
plasticity of propriospinal interneurons which comprise spinal sympathetic circuits
after transection SCI in the rat. Krassioukov et al. (2002) investigated the
response of sympathetically-correlated interneurons to both noxious and
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innocuous stimuli hours following T3 transection (acute) as well as after one
month (chronic). In the chronic but not acute stage of injury, interneurons whose
electrical activity was cross-correlated with that of simultaneously recorded renal
sympathetic nerve activity were excited by noxious CRD and cutaneous pinching,
as well as non-noxious brushing of the skin caudal to the injury. This seminal
study showed that in the weeks after injury, plasticity occurs within
somatosensory relay neurons that influence the activity of SPN.
This electrophysiological evidence was supported histologically following
anterograde tracer injections into the lumbosacral cord after complete T4transection which significantly increased labeling of ascending propriospinal
fibers originating in the dorsal gray commissure (DGC), notably found in
juxtaposition to thoracic SPN labeled with Fluorogold (Hou et al., 2008). The
DGC is a region in which pelvic visceral afferents terminate and send relay
projections rostrally toward supraspinal targets (Al-Chaer et al., 1996; Hosoya et
al., 1994; Matsushita, 1998; Pascual et al., 1993; Vizzard, 2000). Hou et al.
(2008) found that a single session of prolonged, intermittent CRD performed two
weeks after injury caused enhanced neuronal activation throughout the
lumbosacral DGC, as indicated by increased expression of the immediate early
gene c-fos in comparison to sham animals in which intact descending modulation
prevents such expression. It remains unclear, however, whether the DGC
neurons project directly to SPN or whether they project to excitatory interneurons
to indirectly modulate the excitability of SPN (Rabchevsky, 2006).
Collectively, these findings support a model of AD in which plasticity of
ascending propriospinal fibers, in conjunction with sprouting of primary afferents,
creates an amplification of afferent stimuli below the injury such that noxious
inputs are more likely to activate SPN to initiate unmodulated sympathetic
reflexes leading to AD episode (Figure 2.1). Previous technical limitations made
it difficult to directly test the neuroanatomical basis of the AD reflex in live
animals. However, with the recent development of elegant genetic and
chemogenetic silencing techniques (Kinoshita et al., 2012; Stachniak et al., 2014;
Zhu and Roth, 2014), it may now be feasible to directly assess the role of specific
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populations of ascending propriospinal neurons in conveying lumbosacral
afferent input to rostral segments containing cardiovascular SPN (Figure 2.1;
see section 2.5).
2.3.5 Peripheral adrenergic hypersensitivity
In addition to maladaptive plasticity of viscerosympathetic circuitry, there is
also evidence of peripheral changes responsible for the exaggerated pressor
response to afferent stimulation. In quadriplegics, resting blood pressure and
plasma catecholamine levels are both significantly lower than in intact subjects
(Mathias et al., 1976). This is consistent with the observation that sympathetic
outflow below the lesion is lower both acutely and chronically after SCI (Mathias
et al., 1979; Wallin and Stjernberg, 1984), which would be expected to produce
lower concentrations of circulating catecholamines (Goldstein et al., 1983).
However, it has been demonstrated that the vasomotor response to
intravenously infused NE is enhanced in quadriplegics with a documented history
of AD. Specifically, by measuring the diameter of the dorsal foot vein before and
after local intravenous administration of NE, Arnold et al. (1995) found that the
concentration of NE required to induce a 50% reduction in resting vessel
diameter was significantly lower in tetraplegics compared to normal controls (1.6
mg/min vs. 10.9 ng/min). Similarly, Krum et al. (1992b) found that the dose of
intravenously infused phenylephrine (a peripheral a-adrenergic receptor agonist)
required to produce a pressor response of 20 mmHg is significantly lower in
functionally complete quadriplegics compared to normal individuals. Furthermore,
Krum et al. (1992a) reported that even modest increases in plasma NE during
bladder cystometry after high-level SCI were sufficient to produce a significant
pressor response greater than 20 mmHg systolic. Taken together, these studies
indicate that SCI promotes hypersensitivity of the vasculature to catecholamines
released through aberrant, unmodulated sympathetic reflexes, and that this
hypersensitization may contribute to the severity of episodic hypertension after
SCI.
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There is indication that peripheral sensitization following SCI is limited to
the vasculature caudal to the lesion and not within rostral vascular beds in which
central sympathetic control remains intact. Following T4 transection in rats,
Rummery et al. (2010) found evidence of enhanced neurovascular transmission
in the saphenous artery which receives sympathetic outflow from the lower
thoracolumbar cord. However, SCI-related neurovascular potentiation was not
seen in the median artery which receives sympathetic outflow from the cord
rostral to the lesion. Brock et al. (2006) similarly found that T4 transection in rats
leads to increased neurovascular transmission within the mesenteric vasculature,
with perivascular nerve stimulation producing a five-fold increase in contraction of
mesenteric arteries seven weeks after SCI. This increased reactivity of
mesenteric arteries was blunted by the adrenergic antagonist prazosin, further
implicating that peripheral hypersensitization is secondary to changes in
adrenergic transmission after injury. While the mechanism of this phenomena is
not fully known, Brock et al. (2006) suggest that decreased norepinephrine
reuptake is a contributing factor. Alternatively, Al Dera et al. (2012) report that
complete SCI in rats also alters the role of L-type calcium channels in
vasoconstriction, with their activation playing a larger role in smooth muscle
contraction of tail arteries isolated after injury. Whether or not these two
mechanisms are unique to specific vascular beds caudal to the lesion remains
unclear.
Consistent with the hypothesis that SCI causes enhanced adrenergic
sensitivity in peripheral vasculature, Lee et al. (2016) demonstrated increased
protein expression of the a-adrenergic receptor in the femoral artery of rats after
T10 spinal contusion. Furthermore, this increased receptor expression
corresponded to an enhanced pressor response and vasoconstriction of isolated
femoral arteries in response to phenylephrine stimulation. Whether or not the
time-course of these changes corresponds to the timeline over which AD
develops in rodents or humans remains unknown. Moreover, it is unclear
whether these findings are applicable to AD since it does not develop after T10
contusion SCI. Although there is compelling evidence that peripheral
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sensitization contributes to this syndrome, many questions remain regarding the
underlying cellular processes and time-course over which adrenergic hyperresponsiveness develops, as well as the relative contribution compared to central
maladaptive plasticity discussed.
2.4 Clinical management of AD
A variety of non-pharmacological and pharmacological strategies can be
used to treat AD. Since AD often resolves once the inciting stimulus is removed,
the current standard of care recommends identifying and eliminating the inciting
factors, when possible, before pharmacological approaches are considered
(Consortium for Spinal Cord, 2002). Immediate measures involve assessment of
resting arterial pressure and monitoring for other symptoms associated with AD
(see section 2.2). If hypertension is observed, it is advised to move patients into
an upright position to facilitate the lowering of arterial pressure through
hydrostatic redistribution of blood to the lower extremities. This postural
maneuver causes a reduction of blood pressure in high-level SCI patients
(Krassioukov and Harkema, 2006), although the efficacy to alleviate hypertension
specifically during AD has not yet been formally investigated (Krassioukov et al.,
2009). Since filling of the bladder and impaction of the bowel are the most
common triggers of AD (Lindan et al., 1980), bladder voiding or bowel care
routines should next be considered along with a general inspection for other
possible sources of noxious stimulation such as pressure sores, tight clothing
and skin laceration. Given that blood pressure can fluctuate rapidly in patients
with AD, it is important to monitor blood pressure every 2-5 minutes for resolution
or exacerbation of hypertension during physical examination (Consortium for
Spinal Cord, 2002).
While some cases of AD are mild and resolve relatively easily, more
severe cases can produce profound levels of hypertension and have no readily
identifiable cause. Furthermore, it may be difficult to identify and remove the
triggering stimuli, particularly for individuals with high thoracic and cervical
injuries who have limited dexterity and mobility. Therefore, a variety of drugs and

32

medical procedures have been employed for the control of AD, primarily through
managing hypertension. Some of the most common remedies are briefly
discussed below.
2.4.1 Nitrates
Organic nitrates, such as nitroglycerine paste, are currently the most
commonly prescribed medications for mitigating acute episodes of AD (Braddom
and Rocco, 1991; Caruso et al., 2015). Nitrates are a class of drugs that are
converted to or release nitric oxide (NO), an endogenous molecule that induces
smooth muscle relaxation in the vasculature (Moncada and Higgs, 1993). For
acute episodes of AD, it is recommended to apply 2% nitroglycerin paste onto
the skin above the level of SCI (Braddom and Rocco, 1991). Vasodilation and
subsequent reduction of blood pressure occurs rapidly after transdermal
application and the paste can be wiped off once the therapeutic effect has been
achieved (Grobecker, 1990). Moreover, a variety of oral and transdermal patch
preparations are available and easy for patients and caregivers to administer. In
severe cases of AD that are difficult to control, notably in a clinical setting,
intravenous sodium nitroprusside may also be used to rapidly resolve
hypertension (Valles et al., 2005).
2.4.2 Nifedipine
Nifedipine is an L-type calcium (Ca2+) channel blocker that reduces the
influx of Ca2+ into vascular smooth muscle cells, leading to a reduction in
peripheral resistance and consequently blood pressure. Despite few controlled
clinical trials, nifedipine has been widely used to treat AD in SCI patients
(Braddom and Rocco, 1991; Caruso et al., 2015; Dykstra et al., 1987; Esmail et
al., 2002; Krassioukov et al., 2009; Thyberg et al., 1994). In a survey of clinicians
with extensive experience treating AD, Braddom and Rocco (1991) found that
nifedipine was the most commonly prescribed agent to manage minor or severe
symptoms of AD. More recently, nitrates have become slightly more prominent
than nifedipine in treating minor or severe episodes of AD (Caruso et al., 2015),
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likely stemming from safety concerns regarding the use of nifedipine during
hypertensive crises because it may overshoot the therapeutic drop in blood
pressure and cause severe hypotension and ischemia (Chobanian et al., 2003).
Although there are no formal descriptions in the literature of adverse effects
related to the use of nifedipine specifically for AD, it is possible that it may reduce
arterial pressure below the range for critical renal, cerebral and cardiac vascular
beds to autoregulate their perfusion, particularly since many with AD are
predisposed to resting and orthostatic hypotension (Furlan and Fehlings, 2008).
2.4.3 Prazosin
The adrenergic receptor antagonist, prazosin, is another drug used to treat
AD (Krum et al., 1992c; Phillips et al., 2015). Prazosin is an antihypertensive
agent that works by specifically blocking

1-adrenergic receptors located on

peripheral vasculature (Cavero and Roach, 1980). Unlike other hypertension
medications, prazosin has little effect on cardiac function or resting blood
pressure (Jaillon, 1980), making it safer to use in patients with chronic
hypotension. Krum et al. (1992c) reported that, compared to placebo treatment,
twice daily prazosin significantly decreased the magnitude of hypertension and
severity of secondary symptoms during AD caused by a variety of genitourinary
and colorectal stimuli. More recently, Phillips et al. (2015) reported that prazosin
reduced the magnitude of hypertension during AD during sperm retrieval
procedures involving penile vibrostimulation, which is a well-documented cause
of AD. Collectively, research on the use of prazosin indicates that it may be
useful as a prophylactic treatment for AD triggered by a variety of iatrogenic
stimuli (Krum et al., 1992c; Phillips et al., 2015) .
2.4.4 Botulinum toxin
Conservative pharmacological approaches are not always effective, and
some individuals require more aggressive treatments (Krassioukov et al., 2009).
One such treatment is botulinum toxin (BTX), a neurotoxin derived from
Clostridium botulinum that suppresses neuromuscular transmission by cleaving
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synaptic proteins required for neurotransmitter exocytosis (reviewed in (Dolly,
2003). Due to its ability to temporarily cause detrusor muscle paralysis by
preventing parasympathetic post-ganglionic acetylcholine release, delivery of
BTX into the detrusor muscle has been used to treat bladder dysfunction
secondary to SCI, such as neurogenic detrusor overactivity (NDO) (Dykstra,
2003; Dykstra et al., 1988; Orasanu and Mahajan, 2013; Schurch et al., 2005).
As these conditions disrupt normal micturition and can lead to noxious distension
of the bladder, they are associated with the occurrence of AD. While there have
been no large-scale clinical trials for BTX as a prophylactic treatment of AD,
there is indication that this could be a safe and tenable approach to minimize AD
associated with bladder dysfunction and certain medical procedures such as
cystoscopy. Schurch et al. (2000) reported a disappearance of AD caused by
bladder voiding in a small subset of patients receiving BTX injections into the
detrusor muscle to treat neurogenic bladder, though the duration of this
improvement was not specified. Recently, Fougere et al. (2016a) conducted a
small clinical trial specifically to assess the efficacy of intradetrusor injections of
BTX to reduce bladder-related AD and observed a decrease in the severity of AD
during cystometric filling of the bladder. Moreover, ambulatory blood pressure
recordings revealed a decrease in the frequency of daily bladder-related AD for
at least one month, accompanied by an increase in quality of life measures. Such
reports indicate that BTX treatment may be a safe and potentially long-lasting
means of prophylactically treating bladder-related AD. Notably, the duration of
effect after BTX treatment is limited due to a combination of compensatory
sprouting of peripheral nerve terminals and the gradual recovery of synaptic
proteins necessary for neurotransmitter release (Dolly, 2003). While the duration
of detrusor paresis is approximately 9 months (Schurch et al., 1996), it remains
unknown how long intradetrusor BTX treatment can provide relief of AD.
In addition to temporary paralysis of bladder smooth muscle, there is also
evidence that BTX treatment reduces AD by modulating sensory transmission
into the spinal cord. Apostolidis et al. (2005) reported that intradetrusor injections
of BTX in patients with NDO caused a decrease in the expression of both
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purinoceptors (P2X3) and capsaicin receptors (TRPV1) in sensory fibers
innervating the bladder, and that this decrease was correlated temporally with a
significant improvement in bladder function. These receptors are involved in
bladder nociception (Birder et al., 2002; Cockayne et al., 2000), suggesting that
decreased afferent signaling contributes to the improvement in urodynamic
function after BTX treatment. In an experimental model, Elkelini et al. (2012)
instilled BTX into the bladder of rats after T4-transection and observed a
significant reduction in the magnitude of AD induced by bladder distension during
cystometry, which was associated with reduced NGF expression in the bladder
and sensory neurons in the dorsal root ganglia. As NGF regulates c-fiber density
in the bladder (Schnegelsberg et al., 2010), it is also possible that BTX reduces
bladder-related AD by decreasing the innervation or distribution of nociceptive
fibers. Notably, intradetrusor BTX treatment has also been used to alleviate
refractory AD in a pediatric SCI patient (Lockwood et al., 2016).
2.5 Systemic effects of recurrent AD
2.5.1 Cardiovascular Changes
Emerging evidence suggests that the recurrence of AD, which can occur
more than 40 times a day for some individuals (Hubli et al., 2015), adversely
affects multiple physiological systems over time. Alan et al. (2010) demonstrated
that repeated instances of AD after experimental SCI exacerbate injury-induced
peripheral vascular dysfunction. Isolated mesenteric arteries from rats which
underwent 30-minutes of continuous CRD daily for two-weeks after T3
transection SCI had a more pronounced vasoconstrictor response to
phenylephrine (an a1-adrenergic agonist) compared to arteries from animals with
SCI only. This suggests that injury-induced adrenergic hypersensitization, which
itself is a mechanism involved in the etiology of AD (see section 3.2), is
exacerbated by repeated instances of AD and may help explain why the severity
of AD increases over time (West et al., 2015). If this is the case, it should be
possible to dampen the temporal increase in AD severity by pharmacologically
controlling adrenergic hypersensitization. However, as discussed in section 4.5,
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the cellular processes leading to adrenergic hyper-responsiveness have yet to be
elucidated.
Repetitive surges in blood pressure from recurrent AD may also induce
maladaptive structural changes in peripheral vasculature (West et al. (2013).
Vascular remodeling is a dynamic process that responds to changes in shear
stress from normal hemodynamic fluctuations as well as hypertensive disease
(Baeyens et al., 2015; Schiffrin, 2004; Silver and Vita, 2006). While SCI alone is
associated with changes in vascular structure, this is believed to be an
adaptation to the decreased metabolic demands of atrophied tissue below the
injury (Olive et al., 2003). The hypothesis that blood pressure fluctuations from
recurrent AD cause further remodeling of peripheral vasculature requires
additional study, particularly since structural changes to resistance vessels, such
as alterations in the ratio of wall thickness/lumen diameter, are strongly
associated with cardiovascular disease (Rizzoni et al., 2003).
Deleterious changes in cardiac function are also associated with daily
repeated bouts of experimental AD. West et al. (2016) investigated the effects of
recurrent AD on cardiac structure and function in rats following T3 transection.
Beginning 2-weeks after injury, rats received 60-minutes of repetitive CRD daily
for 4 weeks. In-vivo echocardiography revealed that animals with daily induced
AD (SCI-AD) had diminished basal contractility and their hearts developed
significantly lower left ventricular pressure with a slower rate of ventricular
contraction. These alterations in cardiac mechanics were accompanied by a
dampened inotropic response to b-adrenergic stimulation during isoproterenol
challenge in the SCI-AD group compared to SCI alone, despite no differences in
b-adrenergic receptor expression. Taken together, this data suggests that
recurrent AD leads to aberrant cardiac mechanics, which may be due to
desensitization of adrenergic receptors in the heart. Notably, these experimental
findings were corroborated with clinical data which indicated a relationship
between the number of daily AD events and impaired cardiac mechanics in a
small sample of humans with mid-cervical SCI (C4-C8). As suggested by the
authors (West et al., 2016), this consequence of recurrent AD may also
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contribute to the increased risk of cardiovascular disease in people with SCI
(Cragg et al., 2013; Garshick et al., 2005).
In addition to peripheral vasculature, there are emerging reports of
associations between AD and cerebrovascular function. Phillips et al. (2016)
found that high-thoracic SCI in rats causes maladaptive changes in middle
cerebral artery (MCA) structure and function. Seven weeks after T3 transection,
ex-vivo analysis of MCA revealed decreased vessel compliance and diminished
vascular reactivity to vasoconstrictive 5-hydroxytryptamine. The functional
changes in MCA preparations were seen in conjunction with increased collagen
deposition and wall thickness, suggesting that arterial stiffening and structural
remodeling after SCI may impair cerebral autoregulation. Considering that T3
transection in rats reliably causes AD to develop within two weeks, and given the
seven-week duration of this study, it is likely that recurrent AD contributed to
these findings. Potential changes in cerebrovascular function may help explain
cognitive dysfunction which has been documented after high-level SCI (Davidoff
et al., 1990; Phillips et al., 2014; Wecht and Bauman, 2013). Phillips et al. (2016)
provided preliminary data suggesting that cerebral autoregulation is capable of
maintaining sufficient blood flow to the brain during mild and slowly evolving
episodes of AD, though it remains unknown if the cerebral vasculature can
respond appropriately during more severe and rapidly occurring episodes.
Ultimately, it will be important for future studies to determine whether recurrent
AD causes structural and functional modifications to peripheral and cerebral
vasculature since these maladaptations have been proposed to contribute to
cardiovascular and cognitive dysfunction after SCI (Phillips et al., 2016; Wecht
and Bauman, 2013).
2.5.2 Immunomodulatory effects of AD
In addition to cardiovascular anomalies, AD is linked to aberrant
functioning of the immune system (Ueno et al., 2016; Zhang et al., 2013).
Compared to the general population, people with chronic SCI have a weakened
immune system capacity (Campagnolo et al., 1994; Iversen et al., 2000) and are
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more susceptible to lethal infections such as pneumonia (Brommer et al., 2016).
This phenomenon, known as spinal cord injury-induced immune depression
syndrome (SCI-IDS) (Riegger et al., 2007), is dependent on the level of SCI, with
injuries above the level of the major sympathetic outflow being associated with
more severe immunosuppression (Brommer et al., 2016; Campagnolo et al.,
1997; Iversen et al., 2000; Lucin et al., 2007; Zhang et al., 2013). Iversen et al.
(2000) collected blood and bone marrow samples from individuals with SCI and
observed diminished lymphocyte activity and impaired proliferation of
hematopoietic progenitor cells, particularly in tetraplegics with mid-cervical
injuries. Similarly, Lucin et al. (2007) found that T3 but not T9 transection in mice
causes a loss of splenocytes and B cells in association with enhanced levels of
splenic NE and blood cortisol levels.
In intact subjects, the immune system is modulated by the hypothalamicpituitary-adrenal axis (HPA) and sympathetic nervous system (SNS) (reviewed in
(Irwin and Cole, 2011). In response to physical or psychological stress, the
anterior pituitary gland releases adrenocorticotropic hormone to stimulate the
release of glucocorticoids (GCs) from the adrenal cortex into the blood. There is
also evidence for direct neural innervation of the adrenal cortex by SPN
(Engeland and Arnhold, 2005), suggesting that sympathetic activity during AD
may also promote GC release. GCs subsequently bind to the intracellular
glucocorticoid receptor in leukocytes to alter the transcriptional programming and
limit inflammatory responses (reviewed in (Rhen and Cidlowski, 2005).
Additionally, activation of the SNS modulates the immune system through the
release of NE directly into lymphoid tissues, where it binds to b2-adrenergic
receptors on a variety of immune cells, including lymphocytes and macrophages.
Like GCs, NE can have immunosuppressive effects on a variety of immune cells,
including B and T lymphocytes, by activating intracellular signaling cascades
such as the cyclic adenosine monophosphate (cAMP) pathway. Ultimately, the
result of such stimulation is to shunt cellular activity away from a proinflammatory state (reviewed in (Lorton and Bellinger, 2015).

39

Because of the immunosuppressive role of SNS stimulation, it is thought
that SCI-IDS is caused by heightened sympathetic activity and catecholamine
release during recurrent bouts of AD. Zhang et al. (2013) reported a causal link
between AD and chronic immunosuppression. The temporal development of AD
in mice with T3 transection SCI corresponded to an elevated level of circulating
GCs and accumulation of NE within the spleen, along with a profound loss of
greater than 50% of splenic leukocytes by 5-weeks post-injury. Compared to
sham operated or low thoracic (T9) SCI mice which do not develop AD, those
with spontaneously occurring AD measured telemetrically and quantified with a
computer detection algorithm had a limited capacity to produce antibodies after
injection of immunogenic ovalbumin. Additionally, this immunodeficiency was
exacerbated by experimentally inducing AD with repeated bouts of noxious CRD.
The immunosuppressive effects associated with established AD were reversed
after treating injured mice with a cocktail of a selective b2-adrenergic receptor
antagonist and a GC receptor antagonist, concluding that immunosuppression
after T3 SCI in mice is caused by AD-related elevations in NE and GC. Notably,
however, this treatment cocktail was not reported to alter the occurrence of AD.
These experimental findings in mice were corroborated with data from a midcervical SCI patient showing that tapping of the abdomen overlying the urinary
bladder, which stimulated an episode of AD, caused an increase in
catecholamine release with a concomitant reduction in lymphocyte proliferation.
More recently, Ueno et al. (2016) used an inducible chemogenetic silencing
approach in mice with T3 SCI to inhibit glutamatergic interneurons thought to
facilitate reflex activation of SPN innervating the spleen. After silencing these
neurons daily for 2-weeks, the quantity of splenic B and T cells was restored to
pre-injury levels. Together, these studies may explain why individuals with highlevel SCI, many of whom experience AD, have increased susceptibility to a
variety of infectious diseases, and further implies that controlling or preventing
AD is essential for overall well-being.
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Importantly, the immunomodulatory effects of recurrent AD may only be a
contributing factor to SCI-IDS rather than the primary driver. For example, direct
sympathetic innervation of the bone marrow (Bjurholm et al., 1988; Denes et al.,
2005) is thought to help regulate hematopoiesis and immune function in the
normal, uninjured state (reviewed in Jung et al., 2017). Therefore, dysregulated
activity of decentralized sympathetic fibers innervating bone marrow following
SCI may also contribute to SCI-IDS. Moreover, it is well documented that SCI
leads to decreased bone density as a result of diminished gravitational load
(Biering-Sorensen et al., 1990; Zehnder et al., 2004). As the bone marrow is a
major site of hematopoiesis, it is possible that bone atrophy after SCI
compromises the hematopoietic niche, which may help to explain the reduced
immune cell production seen after injury (Iversen et al., 2000). The relative
contribution of these potential mechanisms warrants future investigation.
2.6 Emerging research strategies
Important questions remain regarding the underlying mechanisms
responsible for episodic AD that develops after SCI. While strong correlative
evidence supports a role in maladaptive plasticity of lumbosacral primary
afferents and ascending propriospinal neurons, the relative contribution of these
modified pathways to the AD syndrome is unclear. Recently developed genetic
and chemogenetic neuronal silencing techniques should allow future
investigations aimed at dissecting the precise role of these distinct
neuroanatomical pathways. For example, Kinoshita et al. (2012) injected a
complimentary set of viral vectors into regions of the spinal cord containing the
terminals and soma of propriospinal neurons thought to be critical for the
execution of dexterous hand movements. In their model, a highly efficient
retrogradely transported lentiviral vector carrying enhanced tetanus toxin (HiRETeTeNT) under the control of the tetracycline-responsive element was injected into
the spinal segments containing the terminals of their target neurons. In addition,
a second adeno-associated viral (AAV) vector carrying a reverse tetracycline
transactivation sequence (AAV-rtTAV) was injected into the spinal cord segment
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containing the cell bodies of those same neurons. With this approach, it was
possible to silence neurons by inducing the expression of tetanus toxin through
systemic delivery of doxycycline. Notably, only the neurons which were doubly
infected with both HiRET-eTeNT and AAV-rtTAV were silenced, providing a
reversible and spatially targeted method for investigating the role of specific
neural pathways. Based on such an approach, it is feasible to doubly infect and
silence ascending propriospinal relay neurons which originate in the lumbosacral
cord that project rostrally towards thoracic SPN to directly test their contribution
to AD induced through stimulation of lumbosacral afferents (Figure 2.1). As
discussed in section 2.5.2, Ueno et al. (2016) employed a novel chemogenetic
silencing approach to prevent the development of SCI-IDS associated with AD by
blocking neurotransmission of glutamatergic spinal interneurons, though it is
unknown whether this approach would also ameliorate hemodynamic changes
during AD. Moreover, this method silenced all glutamatergic interneurons in the
injected regions (T5-T7) and, therefore, does not allow for the precise dissection
of specific neuroanatomical pathways.
Alternatively, a recent report by Iyer et al. (2016) demonstrated the ability
to silence specific nociceptive primary afferents using a chemogenetic method in
which AAV carrying the engineered inhibitory hMD4(Gi) DREADD receptor
(designer receptor exclusively activated by a designer drug) was injected directly
into the sciatic nerve. Upon activation with the highly specific ligand clozapine-noxide (CNO), the hMD4(Gi) receptor hyperpolarizes neurons through induction of
the G-protein inward-rectifying potassium channel (Armbruster et al., 2007). They
demonstrated that intraperitoneal injection of clozapine-n-oxide (CNO)
significantly increased mechanical and thermal nociceptive thresholds in the foot
pads of animals with DREADD infected afferents. Because the genetic and
chemogenetic silencing methods discussed here have distinct ligand-receptor
interactions, it may be possible within a single animal to serially silence
propriospinal relay neurons and primary afferents to directly investigate their
contributions to both spontaneous and CRD-induced AD.
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In addition to further mechanistic studies, it will also be important to fully
elucidate the systemic effects of recurrent AD. The metabolic consequences of
sporadic, uncontrolled fluctuations in catecholamines and GCs released during
AD are not well known. As suggested by Karlsson (1999), frequent daily bouts of
AD accompanied with such abnormal surges in GCs and catecholamines may
contribute to the high reported incidence of metabolic abnormalities in persons
with SCI (Duckworth et al., 1980; Gorgey et al., 2014; Maruyama et al., 2008;
Yekutiel et al., 1989). Considering that GC and catecholamines have a number of
effects on energy metabolism in various tissues throughout the body, including
the liver, spleen, pancreas, adipose tissue and skeletal muscle (reviewed in
(Barth et al., 2007; Vegiopoulos and Herzig, 2007), it is possible that recurring
AD predisposes or exacerbates the development of metabolic disease, such as
insulin resistance and dyslipidemia. In support of this, Bluvshtein et al. (2011)
reported that post-prandial insulin resistance is present in tetraplegics with
cervical SCI, but not in paraplegics with thoracic SCI that preserves some level of
supraspinal control over sympathetic outflow. Moreover, manual percussion of
the abdomen overlying the bladder in people with high-thoracic or cervical SCI
was found to activate lipolysis in tissues below the injury level in association with
increased blood pressure and catecholamine release (Karlsson et al., 1997).
Whether a relationship exists between the magnitude and frequency of AD and
the incidence of insulin resistance or abnormal lipid metabolism has not yet been
formally investigated.
2.7 Conclusions
AD can have a significant impact on the quality of daily living and, if not
treated properly and timely, this hypertensive syndrome can have deleterious
cardiophysiological and systemic consequences. The most common treatment
paradigms involve vasoactive drugs intended to resolve the acute hypertensive
crises rather than preventing them from occurring, though some evidence
suggests that prazosin and botulinum toxin may provide prophylactic
management of AD associated with normal and iatrogenic urogenital stimulation.
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While well documented, the intracellular signaling processes underlying
adrenergic hypersensitization in the context of AD are unknown. Recent
methodological advances should allow for more detailed investigation into the
relative contribution of specific propriospinal neurons and primary afferent fibers
to this aberrant viscerosympathetic reflex after SCI. The widespread
physiological consequences of recurrent AD, which can happen dozens of times
daily, have only recently been investigated. Animal models and clinical data
indicate that repeated episodes of AD exacerbate peripheral adrenergic
hypersensitization, suppress immune function, compromise cardiac mechanics,
and potentially alter cerebrovascular and cognitive function. However, the
potential effects of recurrent AD on peripheral and central vasculature structure,
as well as widespread metabolism have only begun to be investigated. In light of
recent data describing profound systemic effects of chronic AD, it is increasingly
important to develop more targeted therapies capable of preventing the
development of this syndrome and its associated maladies altogether in order to
improve quality of lives for individuals with SCI who are predisposed to this
syndrome.
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Figure 2.1. Diagrammatic representation of the neuroanatomical circuitry
thought to be involved in autonomic dysreflexia triggered by pelvic visceral
stimulation. Descending vasomotor fibers (blue) originating in the brainstem and
hypothalamus modulate the tonic activity of sympathetic preganglionic neurons
(SPN; red) throughout the intermediolateral cell column (IML) in the
thoracolumbar spinal cord. After complete spinal cord injury at or above the T6
segment, SPN which innervate the adrenal medulla and blood vessels below the
injury are segregated from descending control pathways, allowing for
unrestrained sympathetic reflex activity that leads to hypertension. Injury further
leads to maladaptive sprouting of both primary afferent c-fibers (purple) and
ascending propriospinal tracts (green) originating in the lumbosacral dorsal gray
commissure (DGC). These ascending “relay” neurons are thought to convey
sensory information from the bladder and colon (i.e., distension) rostrally towards
SPN. Emerging neuronal silencing techniques may allow for investigations into
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the role of specific neuroanatomical pathways involved in AD. One example
might be to employ double infection of ascending lumbosacral propriospinal
neurons with the HiRET-eTeNT vector (red syringe), which is retrogradely
transported (dotted black lines) from nerve terminals in the IML to lumbosacral
DGC also infected with AAV-rtTAV vector (blue syringe). Doxycycline-induced
silencing of these neurons could then allow for direct investigation into their roles
in facilitating AD during pelvic visceral stimulation.
Note:
This chapter has been reprinted with permission from Elsevier: Eldahan,
K.C., Rabchevsky, A.G., 2018. Autonomic dysreflexia after spinal cord injury:
Systemic pathophysiology and methods of management. Auton Neurosci 209,
59-70.

Copyright © Khalid C. Eldahan 2019
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CHAPTER 3
Rapamycin Exacerbates Cardiovascular Dysfunction After Complete
High-Thoracic Spinal Cord Injury
3.1 Introduction
In addition to loss of sensory and motor function, traumatic spinal cord injury
(SCI) can also disrupt central autonomic pathways that are important for
maintaining cardiovascular homeostasis. Autonomic dysreflexia (AD) is an
abnormal hypertensive syndrome that presents in many individuals with a spinal
cord injury (SCI) above the sixth thoracic (T6) spinal level; the majority of cases
(Devivo, 2012). Injuries above this level segregate critical spinal sympathetic
preganglionic neurons (SPN) involved in blood pressure regulation from important
vasomotor nuclei in the brainstem and hypothalamus, leaving them susceptible to
unrestrained reflex activation by stimuli below the lesion level. Notably, SPNs
below T6 control vasomotor tone of the extensive mesenteric vasculature, which
accounts for approximately 30% of the total blood volume (Greenway and Lister,
1974; Rowell, 1990). Noxious distension of the bladder or bowel are among the
most common triggers of AD (Lindan et al., 1980; Snow et al., 1978), though a
variety of other noxious and non-noxious stimuli are also known to precipitate an
event (Karlsson, 1999; Marsh and Weaver, 2004). AD presents as episodic
hypertension accompanied with baroreflex-mediated bradycardia, although
tachycardia may alternatively be present (Lindan et al., 1980). While the severity
of hypertension during an AD episode can vary widely, if not treated promptly and
properly then severe episodes can lead to stroke, hypertensive encephalopathy,
seizures, cardiac arrest, and even death(Bjelakovic et al., 2014; Colachis and
Clinchot, 1997; Eltorai et al., 1992; Fausel and Paski, 2014; Jain et al., 2013; Valles
et al., 2005).
A contributing factor to the development of AD is maladaptive plasticity of
sympathetic reflex circuitry (Krassioukov et al., 2002). After transection SCI, the
sprouting of unmyelinated afferent c-fibers carrying nociceptive signals from the
pelvic viscera into the lumbosacral cord, as well as ascending propriospinal fibers
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which project rostrally and relay these signals towards SPNs in the thoracic cord,
are associated temporally with the development of AD (Cameron et al., 2006;
Hou et al., 2008; Krenz et al., 1999). Moreover, the extent of nociceptive afferent
fiber sprouting, which is dependent upon injury-induced elevations in nerve
growth factor (Brown et al., 2004; Krenz et al., 1999), positively correlates with
the extent of mean arterial pressure (MAP) increases during AD induced
experimentally through noxious colorectal distension (CRD) (Cameron et al.,
2006; Krenz et al., 1999). While therapeutic strategies aimed at mitigating such
maladaptive plasticity are attractive for their potential to prevent or reduce the
development of AD, no such treatments exist in the clinical setting.
Recently, the mammalian target of rapamycin (mTOR) has gained
considerable interest as a target to modulate post-traumatic plasticity within the
central nervous system. Considered a “master regulator” of protein synthesis,
mTOR is expressed ubiquitously in eukaryotic cells and integrates a variety of
environmental cues such as nutrient availability and growth factors to coordinate
important cellular processes such as cell growth, proliferation and autophagy
(Dibble and Manning, 2013; Laplante and Sabatini, 2012; Sandsmark et al.,
2007). Several lines of evidence indicate that mTOR is also a critical mediator of
neuronal sprouting and regeneration after neurotrauma. Following crush injury of
the optic nerve in mice, deletion of phosphatase and tensin homologue (PTEN),
a negative regulator of mTOR, promotes robust regeneration in an mTORdependent manner (Sun et al., 2011). Genetic mouse models of enhanced
mTOR activity after SCI via PTEN deletion in the motor cortex demonstrate
increased regeneration and compensatory sprouting of injured descending
corticospinal tract axons (Jin et al., 2015; Liu et al., 2010). Moreover,
pharmacological inhibition of mTOR signaling with rapamycin after traumatic
brain injury has been shown to decrease seizure frequency and associated
maladaptive sprouting of hippocampal mossy fibers (Guo et al., 2013). Together,
these studies suggest that this highly conserved signaling pathway which is
present in all mammalian cells (Schmelzle and Hall, 2000) may also be involved
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in the sprouting of ascending afferent pathways underlying the development of
AD.
In addition to its involvement in CNS structural plasticity, mTOR regulates
nociceptive sensitivity in both the normal and injured states. In naïve rats,
pharmacological blockade of spinal mTOR with rapamycin prevents the
development of neuronal hyperexcitability and behavioral hypersensitization
associated with pain induced by injection of formalin into the hindpaw (Asante et
al., 2009). In rats with cyclophosphamide-induced cystitis, a condition
characterized by bladder hyperactivity and pelvic pain, rapamycin significantly
reduces the expression of CGRP and substance P in the spinal cord dorsal horn
(Liang et al., 2016). Furthermore, inhibition of mTOR following SCI in rats treated
with rapamycin attenuates the development of neuropathic pain in correlation
with reduced expression of both calcitonin gene related peptide (CGRP) and
substance P, two neuropeptides involved in the regulation of nociceptive
sensitivity (Wang et al., 2016). Collectively, these studies suggest that mTOR is
involved in the regulation of both intraspinal plasticity and nociceptor sensitivity,
but it is not yet known whether mTOR modulates the sprouting of sensory and/or
propriospinal pathways after SCI in relation to the development of AD. Therefore,
in contrast to SCI studies attempting to promote sprouting and regeneration of
descending corticospinal tracts by enhancing mTOR activity, we carried out
experiments to test how the inhibition of mTOR after complete high-thoracic SCI
with the drug rapamycin alters the temporal development of AD, and whether it
modulates injury-induced maladaptive plasticity of primary afferent fibers and/or
propriospinal neurons.
3.2 Methods and Materials
Collectively, a total of 33 age and sex-matched rats were used for all
experiments, which includes n=23 for telemetric monitoring (n=3 naïve + vehicle,
n=3 naïve + rapamycin, n=7 SCI + vehicle, n=10 SCI + rapamycin) and n=10 for
western blot analysis (n=2 naïve, n=2 10 days post-injury [DPI], n=2 21 DPI, n=2
21 DPI + CRD, n=2 21 DPI + CRD + RAP).
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3.2.1 Cardiophysiological Monitoring
All animal housing conditions, surgical procedures, and postoperative care
were conducted according to the University of Kentucky Institutional Animal Care
and Use Committee and the National Institutes of Health animal care guidelines.
As described in detail (Rabchevsky et al., 2011; Rabchevsky et al., 2012), seven
days prior to SCI, naïve anesthetized (2% isoflurane) 3 to 3.5 month old female
Wistar rats (~275 grams, n=23) were implanted with telemetric blood pressure
transmitters (model HD-S10, Data Sciences International, Inc., St. Paul, MN) into
the descending aorta. The probes were secured to the abdominal wall with silk
sutures before closing the skin with 3-0 vicryl sutures and surgical staples.
Animals were then treated post-operatively, as described below. Blood pressure
was monitored 24/7 (500 Hz sampling rate) using the Dataquest A.R.T.
acquisition system (Data Sciences International, Inc., St. Paul, MN) beginning 2
days pre-injury through 4-weeks post-injury. Rats were single-housed, with each
cage placed directly on top of its corresponding data receiver plate (model RPC1, Data Sciences International, Inc., St. Paul, MN). Captured recordings were
binned into 24-hour segments for analysis of daily blood pressure, heart rate, and
spontaneous AD (sAD). As previously described in detail (Rabchevsky et al.,
2012), sAD was analyzed using a custom algorithm written and implemented in
Matlab software (The MathWorks, Inc., Natwick, MA). Briefly, this algorithm
simultaneously processes 24-hour mean arterial pressure (MAP) and heart rate
(HR) traces for instances where a rise in MAP of 10 mmHg or more above
baseline is accompanied by a decrease in HR of at least 10 beats per minute.
While this algorithm does not require such events to be sustained above baseline
for a specific duration, it does require the rise in MAP over baseline to occur
within a 35-second window. MAP rises that were accompanied by tachycardia
(an increase in HR) were not included in these detections. From the computer
automated AD event detections, a single human observer then manually
eliminated false-positive results stemming from technical artifacts that can arise
during normal rat movements and during planned CRD procedures.
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3.2.2 Spinal Cord Transections
One week following telemetry probe implantation, 17 out of 23 rats
undergoing cardiophysiological monitoring were were designated for the SCI
groups. These randomly selected telemetry rats were anesthetized (ketamine, 80
mg/kg; xylazine 7 mg/kg i.p.) and underwent a T3 laminectomy prior to complete
transection of the T4 spinal cord (T4Tx) using a scalpel blade, as previously
described (Cameron et al., 2006; Rabchevsky et al., 2012). In addition, 8 out of
10 non-telemetered rats from the western blot cohort were designated for T4Tx in
order to examine the effect of rapamycin treatment on mTOR activity after SCI.
Altogether, a total of 25 rats underwent T4Tx, including n=17 for telemetry
experiments and n=8 for western blot experiments. Two independent observers
confirmed complete spinal cord transection of each rat based on full separation
of the rostral and caudal stumps. Immediately afterwards, gelfoam was placed
into the transection site to achieve hemostasis and the overlying muscles were
sutured with 3-0 vicryl before stapling the skin with wound clips (Stoelting, Wood
Dale, IL).
3.2.3 Post-operative Care
All rats which underwent ketamine/xylazine anesthesia received i.p.
injections of yohimbine (3.2 mg/kg Lloyd Laboratories, Shenanhoah, IA) to
reverse the effects of xylazine. Injured rats were then housed one per cage with
food and water ad libitum. A heating pad was placed between each cage and its
corresponding data receiver plate for the duration of the study period.
Immediately post-op, rats were administered 10 mL of lactated Ringer’s solution,
s.c. Post-surgical pain management was achieved with twice daily
buprenorphine-HCl injections (0.03mg/kg, s.c.; Reckitt-Benckiser
Pharmaceuticals Inc., Richmond, VA) for three days. All rats received two daily
injections of the antibiotic cefazolin (33.3 mg/kg, s.c.; WG Critical Care, LLC,
Paramus, NJ) for 5-days post-surgery and injured rats received twice daily
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manual bladder expression for 2-3 weeks or until they regained spontaneous
bladder voiding reflexes without signs of urinary tract infection.
3.2.4 Rapamycin Administration and Colorectal Distension (CRD)
All rats were weighed prior to injections to ensure accurate drug dosage
throughout the study period. Rapamycin (RAP; 3 mg/kg, LC Labs, Woburn, MA)
or vehicle (4% ethanol, 5% polyethylene glycol-400, 5% polysorbate-80 in 0.1M
PBS) was injected i.p. immediately after injury and then every other day until
euthanasia at 10 and 21 days post-injury (DPI) for the western blot cohort, or 28
DPI for telemetered rats. In rodent SCI models, RAP has been administered at 6
mg/kg every other day(Liu et al., 2012), 3 mg/kg daily (Sun et al., 2013), or 1
mg/kg daily (Song et al., 2015). We chose a 3 mg/kg alternate day dosage based
on optimal effectiveness in blocking mTOR signaling (Zeng et al., 2008).
Moreover, we found that this dosage attenuates mTOR activity in the spinal cord
after T4Tx, as assessed by phosphorylation of the downstream S6 ribosomal
protein (see Figure 3.1).
On days 14, 21 and 28 post-SCI, naïve and injured rats undergoing
telemetric monitoring underwent 2 consecutive trials of CRD using a balloontipped catheter (Swan-Ganz, model# 111F7, Edwards Lifesciences, Irvine, CA)
inserted 2 cm into the rectum and secured to the tail with surgical tape, as
described(Rabchevsky et al., 2012). Additionally, non-telemetered western blot
rats designated for SCI + CRD similarly underwent two consecutive CRD trials at
21 DPI prior to euthanasia and tissue collection. Following catheterization, rats
were placed into cylindrical plastic restrainers (Cat # 51335, Stoelting, Wood
Dale, IL) to prevent them from tampering with the catheter. All rats were then left
in a quiet and dark environment to acclimate to the catheter and restrainer for 30
minutes before balloon inflation and CRD measurements. During each CRD trial,
the balloon was inflated with 2 mL of air for 60 seconds, followed by a 10-minute
rest interval. Using the Dataquest A.R.T. Acquisition software (Data Sciences
International, Inc., St. Paul, MN), “event markers” were placed at the beginning
and end of each CRD trial trace to demarcate CRD-induced cardiovascular
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changes. Immediately following the second CRD trial at 28 DPI, a final session of
prolonged, intermittent CRD was initiated to induce c-Fos expression as
described (Hou et al., 2008). Briefly, this procedure lasted 90 minutes with 30second inflation periods separated by 60-second rest periods. With this
paradigm, a total of 60 rounds of catheter inflation were performed. For all CRD
trials, the balloon catheter was fully inflated with 2 mL of air within 5 seconds.
For measurements of CRD-induced changes in blood pressure and heart
rate, the raw pulsatile arterial pressure data was averaged every 2 seconds and
converted into mean arterial pressure (MAP) traces for analysis in the Dataquest
A.R.T. Analysis software. The inter-beat interval was derived from the pulsatile
arterial pressure waveform and converted to beats per minute (BPM) to generate
a separate heart rate (HR) trace. For each trial, the absolute MAP and HR values
achieved during CRD stimulation were measured by averaging all data points
within the 60-second window of balloon inflation. Additionally, pre-CRD baseline
MAP and HR values were generated by averaging all data points within the 30second window immediately prior to the balloon inflation event marker, and CRDinduced changes in MAP and HR were then calculated as the difference between
the respective 30-second baselines and the values achieved during CRD. At
each time-point (14, 21, 28 DPI), the values of the two replicate CRD trials were
averaged for each rat in the data analyses.
3.2.5 Western Blot Analysis
For the cohort of age and sex-matched Wistar rats (n=10) used for
western blotting, the L6-S2 spinal cord segment was rapidly dissected and flash
frozen in liquid nitrogen, following CO2 euthanasia and decapitation. Samples
were mechanically homogenized in ice-cold RIPA buffer with 5mm sodium
fluoride and protease inhibitors (Cat# 11836153001, Sigma Aldrich, St. Louis,
MO) added to preserve protein phosphorylation status and maintain total protein
integrity. 1 mL of RIPA buffer was added per gram of tissue to manually grind
samples in a dounce homogenizer before brief (3 x 10 seconds) ultrasonic
homogenization. The Pierce BCA Protein Assay Kit (Cat# 23225, Thermo Fisher
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Scientific, Waltham, MA) was used to estimate the total protein concentration of
each sample, and 20 µg of total protein from each spinal cord sample were
suspended in Laemmli buffer under reducing conditions (5% b-mercaptoethanol)
and then separated by SDS–PAGE using Criterion 4-20% Criterion TGX precast
gels (Cat# 5671094, Bio-Rad, Hercules, CA). Separated proteins were
transferred onto nitrocellulose membranes using the Trans-Blot Turbo Transfer
System (Cat# 1704150, Bio-Rad, Hercules, CA). Nitrocellulose membranes were
blocked with non-fat dry milk (5% in TBST) for one hour at room temperature.
Blocked membranes were then incubated at 4° C overnight in primary antibody
diluted in blocking buffer. Following primary incubation, membranes were
washed for 3 x 20 minutes in TBST before incubating for 1 hour at room
temperature in secondary antibody diluted in blocking buffer. Excess secondary
antibody was then removed by washing for 3 x 20 minutes in TBST.
Immunolabeled membranes were developed using enhanced
chemiluminescence (Amersham ECL Advance Western Blotting Detection Kit,
GE Healthcare, UK) and imaged with the ChemiDoc MP system (Bio-Rad,
Hercules, CA). Quantification was then performed with ImageJ software (National
Institutes of Health, Washington, USA) by plotting individual lanes and
quantifying the area under the curve (Gassmann et al., 2009; Guo et al., 2013).
Antibodies were used according to manufacturer data sheets: pS6 (1:1,000; Cell
Signaling Technology # 2215), S6 (1:1,000; Cell Signaling Technology # 5G10),
α-Tubulin (mouse monoclonal 1:10,000; Abcam #ab7291), HRP conjugated goatanti-rabbit (1:5000; Jackson Immunoresearch Cat# 111-035-144), HRP
conjugated goat-anti-mouse (1:5000; Jackson Immunoresearch
Cat#115035166). All lanes were normalized to their respective α-Tubulin loading
control, and fold-changes were expressed relative to naïve values.
3.2.6 Tissue Fixation and Processing
At 28 DPI, all rats undergoing cardiophysiological monitoring were
euthanatized within 10 minutes following the 90-minute CRD protocol with an
overdose of sodium pentobarbital (Fatal Plus, Vortex Pharmaceuticals, Dearborn,
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MI) before perfusion transcardially with 0.1 M phosphate-buffered saline (PBS),
pH 7.4, followed by 4% paraformaldehyde in PBS (Cameron et al., 2006). A 3-cm
segment of cord measured from the conus medullaris was dissected and the
dura mater carefully removed before post-fixing in 4% PFA for 4 hours and
storing overnight in 0.1M PB at 4°C. Tissue was then cryopreserved with 20%
sucrose in 0.1M PBS solution with 0.002% sodium azide at 4°C until all cords
had sunk to the bottom of their container. Spinal cords were embedded in a
mixture of gum tragacanth (Sigma Aldrich, St. Louis, MO) and 20% sucrose in
0.1M PBS by evenly aligning 4-6 cords side by side within plastic cryomolds that
were then snap frozen in –40°C acetone and stored at –80°C until sectioning on
a cryostat (Microm Laborgerate, Walldorf, Germany). Frozen tissue blocks were
sectioned in the transverse plane at a thickness of 20 μm, and every fifth section
(100 μm spacing) was mounted onto one of three series of 10 slides (Superfrost,
Fisher Scientific, Waltham, MA), consecutively (i.e., 1-10 thoracolumbar; 1a-10a
lumbar; 1b-10b lumbosacral). Up to 15 consecutive rows of cryosections from
each block were placed onto each of 10 slides in all three series. In this manner,
0.5 mm separation is represented by two slides separated by 5 within the series
of 10 processed for histological analysis (i.e., slides 1 and 6, 1a and 6a, 1b and
6b). All slides were stored at -20°C until used for histological staining.
3.2.7 Immunohistochemistry and Microscopy
Mounted slides were removed from the freezer to thaw at room
temperature for 30 minutes before a series of 3 x 10-minute washes in 0.1M PBS
with gentle agitation to rehydrate tissue and remove excess embedding media.
They were then pre-incubated in blocking buffer consisting of 0.1M PBS
containing 0.3% Triton-X and 5% normal goat serum. Tissue was then incubated
with primary antibody overnight at 4°C in blocking buffer containing rabbit-anticalcitonin gene related peptide (CGRP; 35.3 ug/ml; Sigma #C8198) and mouseanti-cFos (2 ug/ml; Encor Biotechnology #MCA-2H2). Following primary antibody
incubation, slides were washed 3 x 10 minutes in 0.1M PBS. Next, slides were
incubated overnight at 4°C in blocking buffer containing goat-anti-rabbit
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conjugated to Alexa-488 (4 ug/ml; Life Technologies #A11008) or biotinylated
goat-anti-mouse (7.5 ug/ml; Vector #BA9200). The following day, slides were
washed 3 x 10 minutes in 0.1M PBS and cFos sections were shielded from light
and incubated for another 4 hours at room temperature with Texas Red
conjugated streptavidin (3.33 ug/ml, Vector #SA-5006) in 0.1M PBS. All slides
were washed 3 x 10 minutes in 0.1M PBS before cover-slipping with Vectashield
mounting media (Vector #H-1000) containing 5 uM Hoechts dye (#H3570,
Thermo Fisher) to stain nuclear DNA. All images acquired for both CGRP and cFos quantification were captured using an Olympus BX51 microscope paired with
an Olympus Magnafire digital camera (Melville, NY). Image exposure times were
kept constant to help maintain a consistent level of background staining.
3.2.8 Densitometric Analyses
For both cFos and CGRP densitometry analyses in the thoracic and
lumbosacral cord, five serial coronal sections (1mm spacing) centered on each of
the 3 levels evaluated (T5/T6, T13/L1 and L6/S1 segments) were used for each
rat. For cFos quantification, densitometry was performed using ImageJ software
(National Institutes of Health, Bethesda, MD, USA). All 24-bit RGB
photomicrographs were converted into 8-bit black and white images, and the
regions of interest (ROI) included the entire right dorsal horn for the L6/S1 level
(Figure 3.6a) or the dorsal gray commissure for T5/T6 and T13/L1 levels.
Thresholds for each cFos ROI were manually identified by a single experimenter
based on the lowest pixel value above which cFos+ nuclei were included, and
final values were expressed in arbitrary units. For CGRP quantification,
densitometry of digitized 24-bit RGB photographs from the thoracic and
lumbosacral levels was performed using Bioquant image analysis software (Nova
Prime; V6.70.10; Bioquant Image Analysis Corp., Nashville, TN) with the ROI
demarcated by laminae III-V in the dorsal gray matter for the L6/S1 level (Figure
3.7E) or laminae IV for the T5/T6 and T13/L1 levels (Figure 3.7A,C) to account
for differential cytoarchitecture. Thresholds for each CGRP ROI were chosen by
a single experimenter based on the pixel values above which the faintest CGRP+
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fibers were included. CGRP measurements were calibrated inside of Bioquant
software to express results in um2.
3.2.9 Statistical Analyses
All statistical analyses were conducted using Prism 6.0 software
(Graphpad Software, La Jolla, CA), with alpha set at 0.05. For measurements
over time of body weight, daily mean arterial pressure and heart rate, CRDinduced changes, and daily spontaneous AD data sets, two-way repeated
measures analysis of variance (ANOVA) were conducted followed by Sidak’s
post-hoc when appropriate. The Geisser-Greenhouse correction factor was used
for all repeated measures ANOVAs to adjust for deviations from the compound
symmetry assumption within our data. For analysis of c-Fos and CGRP
histological data, ANOVA and Sidak’s post-hoc were used, followed by unpaired
t-tests on collapsed data when warranted.
3.3 Results
We recorded a 30% attrition rate in the SCI + RAP group undergoing
telemetric monitoring, with 3/10 rats in this group dying of unknown causes within
3-weeks post-injury and the start of treatment. These animals were accordingly
excluded from all analyses, resulting in a final group size of n=7. Notably, no
unexpected attrition occurred in the naïve or SCI + vehicle groups, or in any of
the groups used for western blotting.
3.3.1 Rapamycin Mitigates Elevated mTOR Activity in the Injured Spinal Cord
We examined mTOR activity in the lumbosacral segments following SCI
and noxious CRD using Western blot assessments of phosphorylated S6
ribosomal protein (pS6), a widely used downstream marker of mTOR activity
(Guo et al., 2013; Harlan et al., 2013; Obara et al., 2011). Relative to naïve spinal
cords, those from 10 and 21 DPI showed heightened S6 phosphorylation in the
lumbosacral spinal cord (Figure 3.1). CRD at 21 DPI further augmented mTOR
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activity by approximately 2-fold, however prolonged RAP administration
prevented such increases, notably reducing pS6 levels below even naïve values.
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Figure 3.1. Effects of rapamycin treatment on mTOR activity after spinal
cord injury (SCI). Western blot analysis showed that while mTOR activity was
elevated by both SCI and CRD at 21 DPI, prolonged systemic treatment with
rapamycin (RAP; 3 mg/kg i.p., every other day) suppressed mTOR activity in the
lumbosacral spinal cord. The ratio of phosphorylated-S6 ribosomal protein to
total S6 was used as a downstream surrogate of mTOR activity. a-tubulin was
used as a loading control and values are expressed relative to naïve control
values. Vertical grey lines indicate where lanes containing groups which were not
included in this study were removed. Statistical analysis not performed due to the
low sample size (n=2 per group). Symbols are means ± SD.
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3.3.2 Rapamycin Treatment Impairs Normal Weight Gain and Exacerbates
Weight Loss After SCI
Body weight data was compared between vehicle control and RAP-treated
groups prior to and during prolonged RAP administration. In naïve rats, there
were significant effects of time (p<0.0001), treatment (p=0.0079), and interaction
(p<0.0001) on body weight (Figure 3.2A). Naïve + vehicle rats gained
approximately 30g of body weight by 10 DPI, whereas naïve + RAP rats
maintained stable body weights for the duration of the study and weighed
significantly less than naïve + vehicle rats beginning at 10 DPI (p<0.0001). In
injured rats, there were also significant effects of time (p<0.0001), treatment
(p=0.0002), and interaction (p<0.0001) on body weight (Figure 3.2B). SCI +
vehicle rats lost approximately 15g of body weight over the first 10 DPI, and
subsequently returned to their pre-injury weight by 16 DPI. Conversely, SCI +
RAP rats lost approximately 40g in the first 10 DPI and failed to return to preinjury weights by the end of the study (Figure 3.2B). Similar to the naïve groups,
a significant treatment effect to reduce weight was apparent by 10 DPI, which
remained significantly lower for the remainder of the study (p< 0.05).
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Figure 3.2. Body weight dynamics following prolonged rapamycin (RAP)
treatment and spinal cord injury (SCI). RAP treatment prevents weight gain in
both naïve and SCI rats. (A) RAP prevented the normal increase in body weight
over time in naïve, vehicle-treated rats. (B) After SCI, vehicle-treated rats started
to regain weight by 16 days post-injury (DPI), whereas RAP-treated rats lost
significantly more weight loss by 10 DPI and failed to approach pre-injury body
weights. n=3 naïve + vehicle; n=3 naïve + RAP (3 mg/kg); n=7 SCI + vehicle; n=7
SCI + RAP (3 mg/kg). Symbols are means ± SD, *p ≤ 0.05, Vehicle vs. RAP
treatment.
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3.3.3 Rapamycin Alters Daily Hemodynamic Measures Before and After SCI
We investigated the effect of prolonged rapamycin treatment on the
average daily mean arterial pressure (MAP) and heart rate (HR) in naïve and
injured rats over 4 weeks. In naïve rats, there was a significant effect of time on
daily MAP (Figure 3.3A; p<0.0001), but no differences in the average daily MAP
between naïve groups across time (p=0.4758). In SCI rats, there were significant
effects of time post-injury (Figure 3.3B; p<0.0001) and treatment (p=0.0003) on
daily MAP, along with a significant interaction between time and treatment
(p<0.0001). When compared to their respective pre-injury values, the average
daily MAP in both vehicle- and RAP-treated SCI groups declined significantly
(p<0.001) for two days post-injury before returning to pre-injury values (Figure
3B). RAP significantly elevated daily MAP above vehicle controls (p<0.05)
beginning at 9 DPI and lasting through the remainder of the study period; notably
being maintained well above pre-injury control values (Figure 3.3B).
In naïve rats, there were significant effects on daily HR based on time
post-injury (p<0.0001) and treatment (p=0.0133), as well as a significant
interaction (p=0.0008) (Figure 3.3C). Specifically, daily HR was significantly
lower in naïve rats with RAP treatment versus naïve + vehicle controls between 5
and 21 DPI (p<0.05). However, despite a trend for increased daily HR in SCI +
RAP rats during weeks 2 and 3 post-injury, there was no significant treatment
effect on HR (p=2.066). In sum, and paradoxically, RAP treatment in naïve rats
did not alter MAP but significantly lowered HR, whereas after SCI it significantly
increased daily MAP accompanied by only moderate HR increases.

61

130

120

120

110

110

M A P (m m H g )

M A P (m m H g )

130

100

90

N a iv e + V e h ic le
N a iv e + R A P

80

A

2

3

4

5

6

7

8

100

90

S C I + V e h ic le
SCI + RAP

80

70
-2 -1 1

*

9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

B

70
-2 -1 1

2

3

4

5

6

7

8

500

500

450

450

*

400

*

*

350

300

C

9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

DPI

H R (B P M )

H R (B P M )

DPI

400

350

300

250
-2 -1 1

2

3

4

5

6

7

8

9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

D

250
-2 -1 1

2

3

4

5

6

7

8

9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

DPI

DPI

Figure 3.3. Rapamycin (RAP) effects on cardiophysiology of naïve and
spinal cord injured (SCI) rats. (A) While chronic RAP treatment did not alter
daily mean arterial pressure (MAP) in naïve rats across days post-injury (DPI), it
caused significantly elevated MAP in SCI rats (B) beginning at 9 DPI to levels
much higher than naïve controls (horizontal dotted lines). (C) In naïve rats, RAP
significantly decreased heart rate (HR) across DPI, whereas highly elevated HR
starting days after SCI was unaltered by RAP (D). n=3 naïve + vehicle; n=3 naïve
+ RAP (3 mg/kg); n=7 SCI + vehicle; n=7 SCI + RAP (3 mg/kg). Symbols are
means ± SD, *p ≤ 0.05 Vehicle vs. RAP treatment.
3.3.4 Rapamycin Increases the Frequency of Spontaneous AD
We assessed the effects of RAP treatment on the daily frequency of
spontaneously occurring AD (sAD) in freely moving naive and SCI rats using our
sAD event detection algorithm applied to MAP and HR data corresponding to
each day pre- and post-injury (Figure 3.4). While there were negligible sAD
events detected in the naïve groups across all time points, there were significant
effects on the frequency of sAD events based on time post-injury (p<0.0001) and
treatment (p<0.0001), along with a significant interaction (p<0.0001). Notably, the
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RAP-treated SCI group showed significantly higher frequencies of daily sAD
compared to the SCI + vehicle group, such that by 16 DPI, a time by which AD
becomes fulminant in T4Tx rats, the SCI + RAP group had ~100 AD events/day
compared to ~20 events/day in the SCI + vehicle group.
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Figure 3.4. Rapamycin (RAP) treatment effects on the daily frequency of
spontaneously occurring AD (sAD) events. Compared to vehicle-treated naive
rats, the vehicle-treated SCI group had conspicuously more sAD events over all
days post-injury (DPI). However, RAP significantly increased the frequency of
sAD compared to vehicle-treated SCI rats. n=3 naïve + vehicle; n=3 naïve + RAP
(3 mg/kg); n=7 SCI + vehicle; n=7 SCI + RAP (3 mg/kg). Symbols are means ±
SD, *p ≤ 0.05 vs SCI + Vehicle.
3.3.5 Rapamycin Increases the Absolute Magnitude of CRD-Induced AD
We first examined the extent of MAP increase during CRD in relation to
30-second baselines, as is typically reported (Figure 3.5A), and found significant
effects of time (p<0.0001) and injury (p=0.0037), along with interaction of time
and injury (p=0.0292). When compared to naïve + vehicle, SCI + vehicle rats had
significantly reduced MAP increases during CRD at 14 and 21 DPI (p<0.05).
However, in both naïve and injured groups, RAP did not alter the extent of such
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MAP increases during CRD compared to respective 30-second baselines
(Figure 3.5A).
In both naïve and injured groups, there was an overall effect of time postinjury on HR changes during CRD (p=0.0052), but no significant treatment effects
(p>0.05; Fig 3.5B). Notably, irrespective of treatment, naïve rats responded to
CRD with pronounced tachycardia whereas injured rats showed bradycardia that
is characteristic of AD. Both SCI groups had significant drops in HR during CRD
compared to the naïve groups at 14 and 21 DPI (p < 0.005), with only a trend for
lower HR in the injured groups at 28 DPI (p=0.056).
While this would appear to indicate no effect of RAP on CRD-induced AD,
we next compared baseline MAP values of naïve and injured rats at rest during
the 30 seconds preceding CRD (Figure 3.5C). There was an overall significant
treatment effect on the pre-CRD baseline MAP values (p=0.0008), but no effect
of time post-injury (p=0.1291). The baseline MAP was significantly (p < 0.05)
lower in the SCI + vehicle groups compared to the naïve + vehicle groups at 14,
21 and 28 DPI. Critically, however, the SCI + RAP group had significantly higher
pre-CRD baseline MAP compared to the SCI + vehicle group at 14 and 21 DPI
(p<0.05), effectively normalizing pre-CRD baselines to naïve control levels.
Notably, the significant increase in pre-CRD MAP in SCI + RAP versus SCI +
vehicle rats is consistent with the significantly increased daily 24-hour MAP in
RAP- versus vehicle-treated SCI rats.
Accordingly, there were significant effects of RAP on the absolute
magnitude of MAP reached during CRD based on time (p<0.0001) and treatment
(p<0.0001), with no interaction (p=0.2455) (Figure 3.5D). SCI alone resulted in
significantly lower absolute MAP induced by CRD compared to both naïve
groups at 14, 21 and 28 DPI (p < 0.05). However, while RAP treatment did not
alter the absolute MAP reached during CRD in naïve rats, the SCI + RAP group
had a significantly higher MAP during CRD (125 mmHg) compared to SCI +
vehicle rats (143 mmHg) at 21 DPI (p < 0.05). While the absolute MAP reached
during CRD did not change over time in the naïve groups, there were significant
increases over time in both SCI groups. In the SCI + vehicle group, the absolute
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CRD-induced MAP increased significantly from 14 to 21 DPI (p<0.005), 14 to 28
DPI (p<0.0001), and 21 to 28 DPI (p<0.005). Similarly, the absolute CRDinduced MAP in the SCI + RAP group increased from both 14 to 21 DPI (p <
0.0005) and 14 to 28 DPI (p < 0.0001). While not statistically significant, there
was a trend for the CRD-induced MAP to increase from 21 to 28 DPI in the SCI +
RAP group (p=0.055).
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Figure 3.5. Effects of prolonged rapamycin (RAP) treatment on mean
arterial pressure (MAP) and heart rate (HR) during colorectal distension
(CRD). (A) In naïve rats, RAP treatment did not affect the extent of CRD-induced
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MAP change relative to baseline at any time point. SCI alone significantly
attenuated the extent of CRD-induced MAP changes at 14 and 21 days postinjury (DPI), but RAP treatment after SCI did not alter the extent of MAP
response to CRD at any time-point. (B) Naïve rats responded to CRD with
tachycardia, whereas injured rats displayed bradycardia that is characteristic of
AD. While the HR responses to CRD were diametrically opposite in injured
compared to naïve rats at all DPI, RAP treatment did not alter the extent of CRDinduced HR changes in either naïve or SCI groups. (C) RAP treatment did not
alter the baseline MAP in naïve rats at any time point. However, spinal cord injury
(SCI) significantly reduced the baseline MAP compared to the naïve + vehicle
group at 14, 21 and 28 DPI. In SCI rats, RAP significantly increased the BL-MAP
to naïve levels compared to the SCI + vehicle group at 14 and 21 DPI. (D) The
absolute MAP achieved during CRD was lower in SCI rats at all time points.
Whereas RAP treatment had no effect in naïve rats, it significantly increased the
CRD-induced MAP in injured rats at 21 DPI. n=3 naïve + vehicle; n=3 naïve +
RAP (3 mg/kg); n=7 SCI + vehicle; n=7 SCI + RAP (3 mg/kg). Symbols are
means ± SD, *p<0.05 vs. naïve + vehicle; # p<0.05 vs. SCI + vehicle.
3.3.6 Rapamycin Does Not Alter the Density of cFos or CGRP Immunolabeling
Following prolonged, intermittent CRD, we measured the density of c-Fos
immunolabeling in the dorsal gray commissure (DGC) at the T5/T6 and T13/L1
spinal cord levels (Figure 3.6A-D) which contain propriospinal interneurons that
relay noxious pelvic sensory information towards thoracic SPNs (Hou et al.,
2008; Lu et al., 2001; Matsushita, 1998), as well as the dorsal horn of the L6/S1
spinal cord (Figure 3.6E,F), which receives colorectal afferents. c-Fos is an
immediate early gene widely used as a marker of neuronal activation in response
to electrical or sensory stimulation (Dragunow and Faull, 1989). In naïve rats with
intact descending modulatory pathways, we observed sparsely distributed cFos+
nuclei throughout the thoracic DGC (Figure 3.6A,C) and lumbosacral dorsal horn
gray matter (Figure 3.6E) after prolonged CRD, which qualitatively increased in
density after SCI (Figure 3.6B,D,F). An ANOVA revealed that the density of c-
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Fos was unaltered by RAP treatment in the T5/T6, T13/L1 or L6/S1 spinal levels
(Figure 3.6G). When data were collapsed into two groups based on injury status
(naïve or injured), t-tests showed that SCI rats had significantly increased c-Fos
density at all three spinal levels when compared to naïve rats (p<0.05).
We also evaluated the density of CGRP+ fiber labeling in the thoracic and
lumbosacral dorsal horn to determine whether RAP altered sprouting of
unmyelinated primary afferents conveying noxious stimuli into the spinal cord. In
naïve rats, thoracic CGRP immunolabeling was primarily restricted to the
substantia gelatinosa and lamina IV (Figure 3.7A-D). In the lumbosacral cord,
CGRP+ labeling was typically located in the substantia gelatinosa, dorsal gray
commissure, and around the sacral parasympathetic nucleus (Figure 3.7E,F).
After injury, there were qualitative increases in fiber labeling throughout the
L6/S1 segments (Figure 3.7E) that were not apparent in the thoracic segments
(Figure 3.7B,D). An ANOVA across all groups at each level showed no
significant treatment effects in naïve or injured rats. When data were collapsed
into two groups based on injury status (naïve or injured), the lumbosacral
segment had significantly more CGRP+ fiber density after SCI compared to naïve
groups (p=0.0081; Figure 3.7G), but no injury effects were observed at either
thoracic level (p>0.05; Figure 3.7B,D).
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Figure 3.6. c-Fos immunostaining in spinal cross sections from the T5/T6,
T13/L1 and L6/S1 spinal segments of vehicle-treated naïve (A,C,E) and SCI
(B,D,F) rats following prolonged, intermittent colorectal distension (CRD).
At all levels examined, the loss of descending inhibitory inputs lead to an
increase in c-Fos expression throughout the dorsal gray commissure (DGC) of
thoracic (A-D) segments and the dorsal horn in the lumbosacral cord (E,F) after
SCI compared to naïve cords, but treatment with rapamycin (RAP) did not alter
expression qualitatively (G). The region of interest (ROI) used for quantification of
the T5/T6 and T13/L1 levels (yellow dotted lines in A, C) included the bilateral
DGC. For the L6/S1 level. the ROI (yellow dotted line in E) began at the central
canal (CC) and included the entire unilateral dorsal gray matter. Bar = 200 uM,
applies to all. (G) Densitometric analysis showed that CRD led to increased c68

Fos immunoreactivity at all levels in the SCI groups compared to naïve, but there
were no significant treatment effects within groups. When groups were collapsed
according to injury status, there was a significant increase in c-Fos density in the
thoracic DGC and lumbosacral dorsal horn after SCI. n=3 naïve + vehicle; n=3
naïve + RAP (3 mg/kg); n=7 SCI + vehicle; n=7 SCI + RAP (3 mg/kg). Symbols
are means ± SD. * p < 0.05 naïve vs. SCI groups.
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Figure 3.7. CGRP staining in spinal cross sections from the T5/T6, T13/L1
and L6/S1 segments of naïve (A,C,E) and injured (B,D,F) spinal cords four
weeks after SCI. CGRP+ fibers in thoracic segments (A-D) were located in the
substantia gelatinosa (laminae I-II) and laminae IV, whereas CGRP staining in
the lumbosacral cord (E,F) was primarily located in laminae I-II with fibers
extending throughout deeper dorsal laminae. After SCI, there was a qualitative
increase in the density of CGRP+ fibers located in the deeper dorsal horn
laminae of the L6/S1 spinal level (F), but not in the thoracic levels examined
(B,D).The region of interest (ROI) used for quantification included laminae IV of
the thoracic cord (yellow dotted lines in A,C) and laminae III-V of the lumbosacral
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cord (yellow dotted line in E). Bar = 200 uM, applies to all. (G) Densitometric
analysis showed that rapamycin (RAP) did not alter injury-induced sprouting of
CGRP+ c-fibers in the lumbosacral dorsal horn. No significant treatment effects
were observed in naïve or injured groups, however collapsed data sets revealed
a significant injury effect for increased CGRP+ fiber densities in the L6/S1
segment. CC=central canal. n=3 naïve + vehicle; n=3 naïve + RAP (3 mg/kg);
n=7 SCI + vehicle; n=7 SCI + RAP (3 mg/kg). Symbols are means ± SD. * p<
0.05 naïve vs. SCI groups.
3.4 Discussion
While the mTOR pathway has been targeted as a modulator of posttraumatic plasticity as well as pain development, no studies have examined the
effects of mTOR inhibition on cardiovascular and autonomic dysfunction after
SCI. Herein we report that prolonged every-other-day rapamycin treatment leads
to elevated resting blood pressure, increased blood pressure volatility, and
exacerbated weight loss after experimental SCI. While the extent of MAP
increases relative to 30-second baseline during noxious CRD was unaltered by
treatment, the baseline MAP preceding CRD was significantly higher at 14 and
21 DPI, and the absolute magnitude of CRD-induced MAP was significantly
higher three-weeks post injury in rapamycin treated rats.
It is unclear whether the higher resting blood pressure, in conjunction with
the increased frequency of sAD and decrease in body weight, contributed to the
higher attrition we recorded in rapamycin-treated rats after SCI. Since there
were no treatment effects on the sprouting of c-fiber afferents or c-Fos
expression in interneurons, these confounding cardiovascular effects of
rapamycin after SCI appear to result from other unidentified central and/or
peripheral mechanisms. Moreover, these results indicate that, unlike
hippocampal pathways after traumatic brain injury (Guo et al., 2013), intraspinal
plasticity of ascending nociceptive pathways contributing to AD after SCI is not
dependent upon mTOR signaling. Although we did not investigate the effects of a
single administration of rapamycin at a clinically relevant time-point, our data
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show that the adverse cardiovascular effects started soon after the first drug
administration. Notably, there were trends for increased daily MAP and sAD in
the SCI + rapamycin group as early as 2-3 days post-injury, and given our everyother-day treatment paradigm, this suggests that a single dosage immediately
after SCI can elicit adverse cardiovascular effects. This would again support a
mechanism that is not dependent upon inhibiting intraspinal plasticity, but rather
altering resistance of peripheral vasculature.
The marked increase in sAD events in SCI rats treated with rapamycin
may stem from a lowering of the threshold needed for afferent stimulation to
trigger an AD event. For instance, long-term treatment of cancer patients and
organ transplant recipients with mTOR inhibitors, including rapamycin and
closely associated derivatives such as everolimus, increases the incidence of
pain development (Budde et al., 2011; Massard et al., 2010; McCormack et al.,
2011; Molina et al., 2008). Moreover, rapamycin also induces significant tactile
hypersensitivity in both naïve and spinal nerve ligated rodents(Melemedjian et
al., 2013). Chronic mTOR inhibition can result in over-activation of the
extracellular signal-regulated kinase (ERK) signaling pathway in sensory
neurons, purportedly through disinhibition of the insulin receptor substrate (IRS)
which functions upstream of ERK (Melemedjian et al., 2013). Notably, ERK
activation is involved in the regulation of nociceptive neurons (Karim et al., 2001;
Melemedjian et al., 2010), suggesting that prolonged rapamycin treatment may
increase nociceptor sensitivity by inducing feedback stimulation of the ERK
pathway. Such feedback stimulation may lower the threshold of afferent
stimulation needed to trigger AD, thus increasing the frequency of sAD in
rapamycin-treated SCI rats independent of structural plasticity associated with
the development of AD (Cameron et al., 2006; Hou et al., 2008).
Conversely, a number of studies suggest that rapamycin treatment can
prevent the development of pain after SCI. A single intraperitoneal injection of
rapamycin given 4 hours after T10 contusion SCI in mice suppresses microglial
activation and neuropathic pain weeks after injury (Tateda et al., 2017). Similarly,
pharmacological inhibition of mTOR has been associated with reduced CGRP
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protein expression in the spinal cord after traumatic SCI in rats (Wang et al.,
2016). A single intrathecal infusion of rapamycin (10 µg) or LY294002 (10 µM),
an inhibitor of the upstream PI3K, administered after SCI attenuates injuryinduced increases in CGRP protein expression in the dorsal horn (Wang et al.,
2016). This finding was in correlation with reduced indices of neuropathic pain
after SCI, suggesting that acute and local rapamycin administration attenuates
the development of neuropathic pain after injury by disrupting the production or
release of CGRP in the spinal cord dorsal horn. Importantly, our findings instead
show that prolonged i.p. rapamycin administration does not change CGRP+ fiber
density in the lumbosacral cord but suggests that it may possibly increase
nociceptive neurotransmission as indicated by a significantly higher frequency of
spontaneous AD events. These opposing effects of rapamycin on CGRP
expression may be due to the difference in route and length of rapamycin
administration, possibly reflecting an unintended feedback stimulation of ERK
(Melemedjian et al., 2013) or other nociceptive signaling pathways in our chronic
treatment paradigm. In support of this notion, in-vitro and in-vivo studies suggest
that prolonged versus acute rapamycin administration has differential effects on
metabolism and cellular signaling (Fang et al., 2013; Sarbassov et al., 2006).
Regarding the significantly increased basal MAP with rapamycin
treatment, it is important to note that both resting and orthostatic hypotension are
clinically vital issues, particularly for individuals with severe cervical or highthoracic SCI (Frankel et al., 1972; Furlan and Fehlings, 2008). Therefore,
treatments capable of increasing resting MAP may be therapeutically valuable for
the SCI population. Similar to previous reports (Laird et al., 2006; Mayorov et al.,
2001; Rabchevsky et al., 2012; West et al., 2015), we observed that SCI resulted
in a decreased daily MAP lasting for several days that gradually returned to nearnormal levels within three weeks post-injury in vehicle-treated rats. Conversely,
the acute decrease in daily MAP after SCI was followed by significant elevations
in daily MAP in rapamycin-treated rats within approximately one week after
injury. In fact, the daily MAP levels reached were higher than pre-injury levels or
even controls, indicating that prolonged rapamycin treatment may alleviate
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symptoms associated with hypotension, such as weakness and dizziness. We
did not, however, examine daily systolic blood pressure to assess whether
prolonged rapamycin treatment after complete SCI significantly increases resting
systolic blood pressure to potentially harmful levels.
We observed that rapamycin significantly exacerbated injury-induced
weight loss and prevented rats from returning to their pre-injury weight. A
significant decrease in body weight has been observed in naïve male Wistar rats
treated daily for 3 weeks with Sirolimus (i.p. 2 mg/kg), which is a clinical
formulation of injectable rapamycin (Deblon et al., 2012). This was associated
with significantly decreased food intake, suggesting that the effects of rapamycin
on body weight are mediated through changes in appetite and energy intake.
Single i.p. injections of rapamycin are sufficient to reduce daily food intake and
weight gain for several days in naïve rats (Hebert et al., 2014). Notably, the
effects of such injections on body weight persisted for at least 10 weeks,
indicating that a singly dosage of rapamycin can cause a permanent shift in body
weight set point. Hypothalamic mTOR activity is thought to play a role in the
control of feeding, as intracerebroventricular delivery of rapamycin decreases
food intake in rats treated with the appetite-stimulating hormone, ghrelin (Martins
et al., 2012). Although we did not monitor food intake in our study, it is possible
that the effects of rapamycin we observed in both naïve and SCI rats are due, at
least in part, to changes in feeding behavior since rapamycin can cross the
blood-brain barrier (Cloughesy et al., 2008). Importantly, it is also possible that
the significant reduction in body weight following rapamycin treatment in our
study, in conjunction with the elevation in resting blood pressure, contributed
additional stress to the cardiovascular system. There are documented
associations between body size and arterial load (Chirinos et al., 2009),
indicating that the relatively rapid loss in body that we observed, in conjunction
with the elevated resting MAP, contributed to overall toxicity and the increased
attrition rate observed in the SCI + RAP group.
While the change in MAP relative to the baseline calculated from the 30
seconds prior to CRD was not altered by rapamycin treatment, the absolute

74

magnitude of blood pressure reached during CRD was significantly higher in SCI
+ rapamycin rats 3 weeks after injury. This elevation in absolute CRD-induced
MAP indicates that rapamycin treatment has cardiophysiological consequences
which could potentially increase the secondary consequences of AD, including
stroke or hypertensive encephalopathy (Bjelakovic et al., 2014; Valles et al.,
2005). There are other reports of hypertension induced by rapamycin in
otherwise healthy rats. Daily oral administration of 1 mg/kg rapamycin to male
Wistar rats for 7 weeks significantly elevated systolic (115 mmHg to 148 mmHg)
and diastolic (99 mmHg to 126 mmHg) blood pressure compared to vehicletreated rats (Reis et al., 2009). This rapamycin-induced hypertension was
associated with significantly elevated levels of plasma serotonin (5hydroxytryptamine; 5-HT). Because vasoactive plasma 5-HT can cause
vasoconstriction in multiple vascular beds (Watts et al., 2012), such rapamycininduced increases in plasma 5-HT may manifest as increased peripheral
vascular resistance and resting blood pressure. While we did not measure
plasma 5-HT, it is feasible that the increased resting MAP observed in our study
following prolonged rapamycin treatment was due to such alterations in plasma
5-HT. Given our peripheral (i.p.) route of drug administration, we are unable to
delineate whether the rapamycin-induced hypertension seen in our SCI model
was due to central or peripheral sites of action.
Although rapamycin treatment did not significantly increase daily HR after
injury, it is feasible that the slightly higher HR in rapamycin animals contributed to
the significant increase in daily MAP. One possible mechanism for such a
tachycardia-mediated increase in MAP is through increasing cardiac output (CO),
which can be described as the product of stroke volume (SV) and heart rate
(CO=SV x HR). In relation to MAP, which is broadly determined as the function of
cardiac output and peripheral resistance (MAP=CO x PR), the enhancement in
CO could increase MAP in the absence of modified peripheral resistance (Mayet
and Hughes, 2003). In our injury model, supraspinal sympathetic control of the
heart remains intact as the heart is innervated by T1-T3 SPNs (Sundaram et al.,
1989). Moreover, evidence suggests that mTOR activity in the hypothalamus is
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involved in the regulation of blood pressure and sympathetic nerve activity
(Harlan et al., 2013), and hypothalamic mTOR controls feeding behavior that
could partially explain both the decreased body weight and increased daily MAP
in SCI + rapamycin animals in our study.
Other studies have investigated rapamycin as a neuroprotective agent
after contusion SCI. A single 1 mg/kg (i.p.) dosage of rapamycin administered 4
hours after SCI in mice increases tissue sparing and functional recovery
correlated with augmented cell autophagy (Sekiguchi et al., 2012). Injections of
1 mg/kg (i.p.) of rapamycin daily for 3 days starting 4 hours after SCI in rats also
promotes neuronal survival by attenuating inflammatory responses (Song et al.,
2015). A dosage of 6 mg/kg rapamycin (i.p., every other day) administered for
three weeks post-injury in rats normalizes increased mTOR activity after
complete T10 transection in combination with passive exercise (Liu et al., 2012).
Whether the adverse cardiovascular effects of rapamycin we noted occur in the
more clinically relevant contusion SCI model remains uncertain, although rodent
contusion models of AD exist to test this (Squair et al., 2017).
3.5 Conclusion
While we sought to determine whether inhibiting mTOR activity with
rapamycin could mitigate the development of AD by preventing injury-induced
intraspinal plasticity, we found instead that rapamycin evoked significant
physiological alterations in rats with complete high-thoracic SCI, including
exacerbated body weight loss, increased resting blood pressure, increased
spontaneous AD events, and an increase in the absolute magnitude of CRDinduced AD. Since inhibition of mTOR activity with rapamycin did not correlate
with altered injury-induced sprouting of nociceptive afferents or activation of
propriospinal neurons after noxious CRD, this indicates that mTOR does not act
as a critical mediator of maladaptive plasticity thought to underlie AD. More
broadly, the adverse cardiovascular effects are due to other unidentified central
and/or peripheral mechanisms that could arise from actions of rapamycin on
dorsal root ganglia, peripheral sympathetic ganglia, or cardiovascular
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mechanisms involved in the modulation of peripheral vascular resistance.
Critically, since cardiovascular complications after SCI are among the top health
concerns clinically, studies investigating rapamycin as a neuroprotective therapy
for SCI must take precaution in interpreting any outcome measures without
considering unmonitored risks to already compromised cardiovascular and
autonomic functions.

Note:
This chapter has been reprinted with permission from Mary Ann Liebert,
Inc.: Khalid C. Eldahan, David H. Cox, Jenna L. Gollihue, Samir P. Patel, and
Alexander G. Rabchevsky. (2018) Rapamycin Exacerbates Cardiovascular
Dysfunction after Complete High-Thoracic Spinal Cord Injury. Journal of
Neurotrauma. March 15 2018 DOI: 10.1089/neu.2017.5184
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CHAPTER 4
Assessing Continuous High Dose Gabapentin Delivery for the Treatment
of Autonomic Dysreflexia
4.1 Introduction
The spinal cord is a critical component in the central control of the
cardiovascular and autonomic nervous systems. Accordingly, traumatic spinal
cord injury (SCI) can result in a constellation of related cardiovascular and
autonomic dysfunctions (Hou and Rabchevsky, 2014; Weaver et al., 2012),
notably with injuries above the sixth thoracic (T6) segment frequently resulting in
the development of a condition called autonomic dysreflexia (AD). This syndrome
is characterized by episodes of volatile and potentially lethal hypertension in
response to exaggerated sympathetic reflexes triggered by unperceived afferent
stimuli below the injury level. As described in Chapter 2, patients may
experience cardiac arrhythmia, pounding headache, anxiety, flushing of the skin
and profuse sweating above the lesion during an episode of AD. For many
people with AD, this episodic syndrome can occur frequently throughout the day
due to regular filling of the bowel and bladder creating noxious stimuli, or by
irregular and less predictable triggers such as pressure sores and seemingly
benign over-tightening of shoes or clothing (Fougere et al., 2016b; Hubli et al.,
2015; Squair et al., 2017). Because of the unpleasant and potentially dangerous
manifestation of this syndrome, prevention or effective treatment of AD is cited as
a top priority in the SCI population for enhancing quality of life (Anderson, 2004).
Several injury related mechanisms are known to contribute to the
development of AD. These include the loss of descending vasomotor modulatory
pathways, hyperreactivity of peripheral vasculature to adrenergic stimulation, and
a number of pathophysiological changes within spinal circuitry influencing
sympathetic outflow below the lesion (Cameron et al., 2006; Eldahan and
Rabchevsky, 2018; Rabchevsky, 2006; Schramm, 2006; Teasell et al., 2000).
These intraspinal changes include sprouting of both unmyelinated afferent cfibers and ascending propriospinal ‘relay’ projections towards sympathetically-
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correlated neurons in the thoracic spinal cord (Rabchevsky, 2006). In addition to
structural sprouting, dynamic alterations of synaptic inputs to sympathetic
preganglionic neurons (SPN) in the thoracolumbar cord are also known to occur.
For example, synapses derived from descending supraspinal projections onto
SPN are eliminated within one week after complete spinal transection at the
fourth thoracic (T4) segment (Llewellyn-Smith and Weaver, 2001; Weaver et al.,
1997). However, by two weeks after transection there is a restoration of the
number of synaptic terminals on SPN to normal levels indicating the formation of
new synaptic inputs derived from spinal interneurons and/or primary afferents
below the injury. Because the development of AD also becomes apparent twoweeks after SCI in rodents (Krassioukov and Weaver, 1995; Laird et al., 2006), it
has been suggested that injury induced synaptogenesis onto SPN contributes to
AD pathophysiology (Eldahan and Rabchevsky, 2018; Llewellyn-Smith and
Weaver, 2001; Weaver et al., 1997). Taken together, a model of AD development
has emerged in which the loss of supraspinal control, coupled with increased
synaptic convergence from both primary afferents and interneurons onto
sympathetically correlated interneurons, enhances the transmission of noxious
stimuli to SPN, triggering unrestricted sympathetic reflexes during AD. As part of
this model, synaptogenesis of newly sprouted c-fiber terminals onto lumbosacral
propriospinal neurons is thought to be involved in the etiology of AD, however
this has remained unexamined (Rabchevsky, 2006).
We previously reported that in rats with complete T4-transection SCI,
acute administration of the epilepsy drug gabapentin (GBP; 50 mg/kg, i.p.)
significantly reduces the magnitude of colorectal distension (CRD) induced AD
and tail spasticity shortly after treatment (Rabchevsky et al., 2011; Rabchevsky
et al., 2012). The mechanism of this clinically valuable effect, however, remains
unknown. GBP was first developed for the treatment of epilepsy and gained
subsequent traction as a treatment for neuropathic pain (Sirven, 2010). Despite
being a structural analog of y-aminobutyric-acid (GABA) with enhanced bloodbrain barrier penetration (Crawford et al., 1987), most studies suggest that it’s
actions are independent of GABAergic modulation. Purification and binding
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studies revealed GBP’s high-affinity binding site as the L-type calcium channel
a2d subunits (Gee et al., 1996). This discovery suggested that GBP may act by
modulating calcium channel activity and, subsequently, reducing presynaptic
neurotransmitter release. Others have demonstrated that large daily doses of
GBP can block the formation of excitatory glutamatergic synapses in the CNS by
interfering with the action of thrombospondin proteins (Baldwin and Eroglu, 2017;
Eroglu et al., 2009). Thrombospondins are extracellular proteins secreted by
astrocytes and are believed to play a role in astrocyte-induced synaptogenesis
(reviewed in Baldwin and Eroglu, 2017). Upon binding to the a2d1 subunit,
thrombospondin-4 can activate synaptogenic signaling to drive the formation of
new glutamatergic synapses. By competing with thrombospondin for the same
a2d1 binding site, GBP treatment has been shown to prevent aberrant excitatory
synapse formation in models of facet joint injury (Crosby et al., 2015), cortical
trauma (Lau et al., 2017; Li et al., 2012b; Takahashi et al., 2018), neuropathic
pain (Li et al., 2014; Yu et al., 2018) as well as regular neonatal development
(Eroglu et al., 2009). Based on these studies which together suggest this
mechanism may underlie the clinical actions of GBP, we sought to determine
whether continuous high dose GBP treatment after SCI can prevent aberrant
synaptogenesis of intraspinal pathways and thereby mitigate the development of
AD.
4.2 Methods and Materials
4.2.1 Cardiophysiological monitoring:
All animal housing conditions, surgical procedures, and postoperative care
were conducted according to the University of Kentucky Institutional Animal Care
and Use Committee and the National Institutes of Health animal care guidelines.
Animals were housed in a temperature and humidity-controlled room with a
12/12-hour light/dark cycle. Efforts were made to minimize unnecessary foot
traffic and other potential environmental disturbances in the room. One week
prior to SCI, a total of 24 naïve 3 to 3.5 month old female Wistar rats (250-275
grams) were anesthetized (2% isoflurane) and implanted with telemetric blood
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pressure transmitters (model HD-S10, Data Sciences International, Inc., St. Paul,
MN) into the descending abdominal aorta according to the manufacturer’s
surgical guidelines as previously reported (Eldahan et al., 2018; Rabchevsky et
al., 2012). Telemetry probes were secured intra-abdominally by tying to the
ventral abdominal wall using non-absorbable silk sutures before closing the skin
with 3-0 vicryl sutures. Animals were then treated post-operatively as described
below. Blood pressure was recorded 24/7 (500 Hz sampling rate) using the
Dataquest A.R.T. acquisition platform (Data Sciences International, Inc., St. Paul,
MN) for the duration of the study. Recordings were briefly paused during daily
animal care and re-started immediately. Rats were single-housed, with each
cage placed directly on top of its corresponding data receiver plate (model RPC1, Data Sciences International, Inc., St. Paul, MN). All recordings were binned in
a single parent folder and later analyzed in 24-hour segments beginning at 6 a.m.
each day which corresponds to the beginning of the light-cycle. “One day postinjury” is defined as the time immediately after SCI (approximately 9:30 a.m.)
until 6 am the following day. All days thereafter were defined as 6 a.m. to 5:59
a.m. the following day.
Naturally occurring spontaneous AD (sAD) was analyzed using a modified
version of our previously reported custom computer algorithm using Matlab
software (The MathWorks, Inc., Natwick, MA) (Eldahan et al., 2018; Rabchevsky
et al., 2012). Our modified algorithm screens for instances of multiple sAD
detections occurring within a 120-second window, such that multiple events
beginning within two minutes of each other are counted as a single unified event,
similar to recent AD algorithms described by West et al. (2015) and Mironets et
al. (2018). The algorithm simultaneously processes 24-hour mean arterial
pressure (MAP) and heart rate (HR) traces for instances where a rise in MAP of
either 10 or 20 mmHg or more above baseline is accompanied by a decrease in
HR of at least 10 or 20 beats per minute. While this algorithm does not require
such events to be sustained above baseline for a specific duration, it does
require the rise in MAP over baseline to occur within a 35-second window. MAP
rises that were accompanied by tachycardia (an increase in HR) were not
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included in these sAD detections. Following automated computer detected sAD
events, a single human observer manually screened all detections to remove
false-positive events stemming from technical artifacts, such as non-physiological
rises in MAP associated with movement of the pressure-sensing catheter tip
against the lumen of the aorta. For each of the four daily injections (12:00 a.m.,
6:00 a.m., 12:00 p.m. and 6:00 p.m.), recordings were stopped simultaneously
for all animals and an “event marker” was placed for each animal immediately
after injection to allow for accurate tracking of all injection timepoints. Routine
animal care, including twice daily bladder expression for the duration of the
study, was performed at 6 am and 6 pm along with corresponding treatment
injections. Cardiophysiological recordings were paused any time a cage was
moved or an animal was handled to ensure that such disruptions were not
included in any analyses.
4.2.2 Baroreflex Sensitivity
To test the hypothesis that continuous high doses of GBP suppress the
cardiac baroreflex after SCI, we quantified the sensitivity, or “gain”, of the
spontaneous baroreflex (sBR) in saline and GBP treated rats one day before
injury and the start of treatment as well as 14, 21 and 28 DPI. Assessment of the
sBR sensitivity was performed using the sequence technique developed by
Bertinieri et al. (1985). This method identifies sequences of at least three
consecutive pressure pulses in which there is a positive relationship between
systolic blood pressure and inter-beat interval, (i.e. heart rate). Linear regression
plots are then created from identified sequences and the average slope of the
fitted lines was calculated to indicate the sensitivity, or “gain” of the sBR (Figure
4.9). HemoLab software written and freely distributed by Dr. Harold Stauss was
used for this analysis. Two-hour segments of raw waveform blood pressure data
were selected at the same time of day for all animals. Peak systolic pressure
values were used to calculate the pulse intervals to compare the relationship
between blood pressure and heart rate. All detected sBR sequences were
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visually screened to remove abnormal detections caused by technical artifacts
which would otherwise skew the average slope of the regression lines.
4.2.3 Spinal cord injury
All rats were allowed to recover from telemetry probe implantation for one
week. We have observed that elevated daily blood pressure and heart rate
occurring following the abdominal probe implantation return to a normal level by
5 days post-implantation. A total of n=24 rats were anesthetized (ketamine, 80
mg/kg; xylazine 7 mg/kg i.p.) and underwent a T3 laminectomy prior to complete
transection of the T4 spinal cord (T4Tx) using a scalpel blade, as previously
described (Cameron et al., 2006; Rabchevsky et al., 2012). Two independent
observers confirmed complete spinal cord transection of each rat based on full
separation of the rostral and caudal stumps. Immediately afterwards, a square
gelfoam pledget was placed into the transection site to achieve hemostasis and
the overlying muscles were sutured with 3-0 vicryl before stapling the skin with
wound clips (Stoelting, Wood Dale, IL).
4.2.4 Drug Administration and Noxious Colorectal Distension (CRD):
Gabapentin (GBP; 100 mg/kg, i.p, 4x daily, Spectrum Chemicals, New
Brunswick, NJ) was injected after injury and then every 6 hours for 4 weeks. On
days 14, 21 and 28 post-injury, rats were subjected to 2 trials of colorectal
distention one hour after treatment using silicone balloon catheters (Coloplast
Cysto-Care Folysil 2-Way Pediatric Silicone Foley Catheter, Fr10 3 cc) inserted
into the rectum. Bladder expression was performed immediately prior to catheter
insertion. Rats were gently restrained using a surgical towel wrapped around
each rat, leaving the lower body exposed to avoid over-heating and allow for
observation of hindlimb spasticity during CRD. After removing fecal pellets in the
distal rectum, catheters were inserted a distance of 2.5 cm from the center of the
balloon and secured to the tail with two pieces of Transpore ™ tape. Following
restraint and catheter insertion, rats were allowed to acclimate for 20-30 minutes.
All efforts were made to minimize distractions and potentially stressful stimuli. A
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hood fan was left running to provide white noise and buffer unpredictable,
irregular sounds occurring outside of the experimental room. All CRD testing was
performed in the same room that all animals were regularly housed in. For each
distention cycle, the balloon was inflated with 2.2 mL of air over the course of 5
seconds. Each distention trial lasted 60 seconds, separated by 30 minutes of
rest. At 28 DPI, following the second CRD trial, a 90-minute session of
intermittent CRD (30-second inflation periods separated by 60 seconds of rest)
was performed to induce c-Fos expression. To quantify the MAP recovery time
after CRD, the length of time required for the MAP trace to revert back to the 30second baseline value was measured for each CRD trial using a modification of
the methods used by Mironets et al. (2018) and Cloutier et al. (2016). Notably,
the MAP was required to remain at or below the 30-second baseline value for at
least 6 seconds before being considered stably recovered.
4.2.5 Tissue Collection and Immunohistochemistry
Terminal body weights were recorded and rats received a fatal overdose
of sodium pentobarbital within 15-minutes following the end of the 90-minute
CRD. After the loss of pinch-reflex in the forelimbs, a lateral abdominal incision
was made to access the spleen. Bulldog clamps were applied to the vascular
bundle serving the spleen before rapid dissection. Rats were then transcardially
perfused with 0.1M PBS followed by 4% PFA (in 0.1M PBS). Excess fat and
connective tissue was removed from the spleens using and raw spleen weights
were measured prior to soaking them in 4% PFA overnight. The spinal cord
caudal to the T4-transection site was carefully dissected and post-fixed for 3-4
hours in 4% PFA before being placed in 0.2M PB solution overnight at 4o to
remove excess PFA. Cords were then cryopreserved in 20% sucrose (in 0.1M
PBS) with sodium azide until all cords sank, after which they were embedded in
gum tragacanth mixed with 20% sucrose and stored at -80o until cryosectioning.
Every fifth serial cryosection (uM) was collected and placed on a series of
Superfrost Plus™ slides (Thermo Fisher Scientific, Waltham, MA). This cutting
scheme results in 10 adjacent sets of slides with each slide containing 10
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consecutive spinal sections separated by 1mm. Slides were stored at -20
degrees C until further use. For immunohistochemistry, slides were removed
from the freezer and warmed on a 37 degree slide warmer for 10 minutes. A pappen (Ted Pella, Redding, CA) border was then applied to all tissue slides before
washing 3 x 30 minutes in 0.1M PBS. Slides were then blocked for 1-hour at
room temperature in 5% normal serum and 0.3% Triton X-100 in 0.1M PBS. To
immunoreact tissue sections with primary antibodies, slides were incubated for
either 24-hours (VGLUT2 and synaptophysin) or 72-hours (VGAT) in primary
antibody buffer containing 2 ug/ml rabbit anti-VGLUT2 (Synaptic Systems Cat
#135-403) and 1 ug/ml mouse anti-synaptophysin (Clone SY3; Synaptic Systems
Cat #101-011), or rabbit anti-VGAT (Synaptic Systems Cat #131-002) and
1:1,000 mouse anti-synaptophysin (Synaptic Systems Cat #101-011). Excess
primary antibodies were washed 3x10 minutes in 0.1 M PBS before incubation
with secondary antibodies (Goat anti-Rabbit-Alexa488 @ 1:500 or biotinylated
goat anti-mouse @ 1:200) for 24-hours at 4 degrees. Following removal of
excess secondary antibody with 3x10 minute 0.1 M PBS washes, slides were
incubated in tertiary solution containing 1:200 streptavidin conjugated Texas Red
in 0.1 M PBS. Two batches of tissue staining were performed: one with VGLUT2
and synaptophysin, and the second set with VGAT and synaptophysin. Within
each batch of staining, all treatment groups were stained simultaneously using
the same buffers and lot of antibody. Due to availability, separate lots of
synaptophysin antibody were used in each staining set.
4.2.6 Image Acquisition and Analysis
High-resolution (2048 x 2048 pixels) images were collected using a Nikon
Ti Eclipse inverted confocal microscope paired with a C2+ controller system and
Nikon NIS Elements Advanced Research software (Nikon Inc., Melville, NY,
USA). Laser settings for each fluorescent marker were optimized on naïve spinal
cord tissues and maintained constant for all sections assessed. The histogram
was used to monitor pixel intensity and ensure that the total fraction of saturated
pixels remained below 2% for all images. For each tissue section, confocal
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stacks were collected with a 40x oil-immersion lens. Image stacks were acquired
by setting the central plane of the tissue section as “home”, and acquiring two
additional optical sections 2 µM above and below the central plane (4 µM total
thickness). Each optical section represented a thickness of 0.86 µM, with an
individual pixel size of 0.16 µM. The pinhole size was maintained at 40 µM, and
pixel dwell time set to 4.4 seconds/pixel. After image acquisition, the optical
plane with the most uniform staining was selected for analysis. This selection
was performed objectively in an unbiased and blinded fashion by selecting the
optical plane with the highest mean fluorescence intensity within the desired
region of interest measured by the Nikon software. Similar selection of the optical
plane with the brightest staining has been used previously to help correct for
potential issues with antibody penetration (Ferguson et al., 2008).
Synaptic quantification was performed using densitometric analysis. For
each subject, 3 spinal sections centered on the L6/S1 spinal segment and
separated by 1 mm were analyzed (Figure 4.1). The right dorsal horn was used
for all animals, with the rare exception of tissue sections where the right horn was
unusable due to folding of the section on the slide during tissue processing, in
which case the left dorsal horn was used. A local contrast was applied using a
radius of 1.0 µM to more clearly delineate the border of individual
synaptophysin+, VGLUT2+ and VGAT+ puncta. Thereafter, each fluorescent
channel was thresholded to exclude non-specific background signal. All contrast
and threshold settings were optimized on naïve spinal cord tissues and remained
constant for all subjects thereafter (see Figure 4.2). After applying a threshold for
each fluorescent channel, a binary layer mask was created for each marker
(VGLUT2 or VGAT and synaptophysin) indicating the location of pixels above
threshold. These two layers (VGLUT2 and synaptophysin or VGAT and
synaptophysin) were then overlaid to create a third layer representing the area of
overlap between markers. Using these three binary layers, either the area
occupied by VGLUT2, VGAT, synaptophysin or the area occupied by the overlap
of VGLUT2/synaptophysin and VGAT/synaptophysin puncta was measured
using a standardized region of interest box measuring 175 x 175 µM. One ROI,
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designated “R1”, represented the upper dorsal horn (rexed laminae I-II). The top
of the ROI box was aligned with the upper edge of lamina I, and the box was
centered in the middle of the right dorsal horn. The bottom of the ROI box
extended to the approximate lower edge of laminae II. The other ROI, designated
“R2”, was similarly sized 175 x 175 µM and placed in the dorsal grey commissure
(laminae X) just above the central canal. To control for potential variation in
antibody labeling efficiency between sets of synaptic staining, data was
normalized to naïve control values within a respective set of staining. These
methods were adapted from McKillop et al. (2016), who used a threshold-based
method to quantify the area occupied by VGLUT1, synaptophysin and VGAT in
the mouse spinal ventral horn after SCI.
Quantitative colocalization analysis was also performed using the JACoP
plugin (https://imagej.nih.gov/ij/plugins/track/jacop.html) implemented in the
ImageJ/FIJI platform. This plugin, which has previously been described in depth
(Bolte and Cordelieres, 2006), contains a collection of commonly used tools to
measure intensity correlation and co-occurrence of dual-color molecular probes.
The same ROIs used for density analysis were cropped for JACoP analysis. To
reduce confounding influences of non-specific background pixels, a threshold
was applied to restrict analysis to pixels containing positive staining. The Costes’
automated thresholding algorithm was determined to yield inappropriately low
thresholds, likely due to the high density of labeling and variability of pixel
intensity which others have reported to be problematic for appropriate automated
thresholding and image segmentation (Comeau et al., 2006; Dunn et al., 2011;
Verstraelen et al., 2018). Therefore, threshold values were determined based on
the background pixel intensity in a set of negative primary antibody control slides
processed and imaged using identical settings. These threshold values were
visually validated on a set of naive group images and subsequently applied
equally to all images/treatment groups. The Manders overlap coefficient (MOC)
and fractional overlap coefficients (tM1 and tM2) were calculated using the
equations below, notably only using supra-threshold pixels with positive staining
to avoid inflated results due to low-level background signal. To determine the
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likelihood that positive colocalization results could be due to chance, the Costes’
randomization test was run on a subset of images. The resulting P values1 were
100%, along with r-values of 0.0±0.001, indicate that virtually none of the
colocalization measured in our original images could be attributed to random
chance.
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𝑅;,CDEDC : 𝑝𝑖𝑥𝑒𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑖𝑛 𝑟𝑒𝑑 𝑐ℎ𝑎𝑛𝑛𝑒𝑙 (𝑠𝑦𝑛𝑎𝑝𝑡𝑜𝑝ℎ𝑦𝑠𝑖𝑛), 𝑤ℎ𝑒𝑟𝑒 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑝𝑖𝑥𝑒𝑙 𝑣𝑎𝑙𝑢𝑒 𝑖𝑠 > 0 𝑖𝑛 𝑏𝑜𝑡ℎ 𝑐ℎ𝑎𝑛𝑛𝑒𝑙𝑠
𝐺;,CDEDC : 𝑝𝑖𝑥𝑒𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑖𝑛 𝑔𝑟𝑒𝑒𝑛 𝑐ℎ𝑎𝑛𝑛𝑒𝑙 (𝑉𝐺𝐿𝑈𝑇2/𝑉𝐺𝐴𝑇), 𝑤ℎ𝑒𝑟𝑒 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑝𝑖𝑥𝑒𝑙 𝑣𝑎𝑙𝑢𝑒 𝑖𝑠 > 0 𝑖𝑛 𝑏𝑜𝑡ℎ 𝑐ℎ𝑎𝑛𝑛𝑒𝑙𝑠

4.2.7 Statistical Analyses
For daily body-weight, MAP, HR, spontaneous AD and spasticity
measurements, a repeated measures two-way analysis of variance (2-way RM
ANOVA) was performed with Sidak’s multiple comparisons post-hoc test when
appropriate. The Geisser-Greenhouse correction was used for repeated measures
analyses to provide additional rigor and minimize type-I errors. Unpaired t-tests
were performed on CRD and spleen weight data. One-way ANOVA tests were
used for synaptic histology, with Sidak’s post-hoc analysis when appropriate. All
statistical analyses were conducted with GraphPad Prism 7 software using alpha
= 0.05.

1

The P value, not to be confused with a p-value, is a measure of how likely a set of randomized
images are to contain an equal or higher amount of signal colocalization than the original images.
A value of 100% indicates a virtually non-existent chance that colocalization in the original image
is due to random chance.
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Figure 4.1. Diagrammatic representation of synaptic quantification scheme.
Tissue from the L6/S1 spinal segment (A,B) was sampled for histological
analysis of synaptic density. High-resolution confocal images were acquired from
rexed laminae I-II of the upper dorsal horn (B, R1) and the laminae X region
containing the dorsal gray commissure (B, R2). (C) Volumetric reconstruction
shows colocalization of VGLUT2 and synaptophysin in 3D, indicating the cooccurrence of these presynaptic markers. Scale bar is 4 uM or 1 uM (inset, C).
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Figure 4.2. Representative thresholding and overlap identification.
Adjacent tissue sections were double-labeled with VGLUT2+synaptophysin (A-F)
or VGAT+synaptophysin (G-L). Contrasted images (top rows A-C; G-I) were
thresholded (bottom rows D-F; J-L) to segregate positive staining from
background, and a mask was applied representing supra-threshold pixels in
VGLUT2 (D), VGAT (J) and synaptophysin (E,K) channels. Colocalization of
VGLUT2+SYP or VGAT+SYP was determined based on overlapping of signal
(F,L). Images represent a cropped and enlarged area taken from the full R1 field
quantified as shown in Figure 4.11. Scale bar is 5 uM.
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4.3 Results
We had a 13% attrition rate with early deaths occurring during recovery in
the critical first week after injury and occured with similar frequency in the saline
and GBP groups (n=1-2 per group).
4.3.1 GBP impairs body weight recovery after SCI
We compared the effects of time and chronic GBP treatment on the
change in body weight after complete SCI and observed a significant effect of
time (p<0.0001), but no significant treatment effect (p=0.4197) (Figure 4.3).
There was, however, a significant interaction between time and treatment
(p<0.0001). Within one-week after SCI, both groups lost a significant amount of
body weight compared to their respective pre-injury values (p<0.05). Whereas
vehicle-treated rats returned to pre-injury weight by 20 DPI, rats treated
continuously with GBP did not return to their baseline body weight by the end of
the study period.
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Figure 4.3. Daily change in body weight after complete spinal cord injury
(SCI). All rats experienced an initial gain in weight in the first 2-3 days before
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losing significant body weight for the first 2 weeks. Saline-treated control rats
started to regain body weight by 14 days post injury (DPI) and returned to preinjury weights (dotted line) by 20 DPI. In contrast, injured GBP treated rats
maintained reduced body weight below pre-injury levels. N=11 Saline, N=10
GBP. Symbols are mean ± SD.
4.3.2 Daily Mean Arterial Pressure (MAP) and Heart Rate (HR) after SCI
We examined whether continuous high-dose GBP had temporal effects on
daily hemodynamics post-injury. There was an overall significant effect of time
post-injury (p<0.0001) on daily MAP (Figure 4.4A), with no treatment effect
(p=0.65). Compared to pre-injury values, the daily MAP was significantly lower
for the first three days post-injury (DPI) in both groups (p<0.0.0001) before
stabilizing to slightly below naïve levels after the first two weeks post-injury.
There was a significant effect of time post-injury on daily HR (p<0.0001), with no
treatment effect (p=0.65). HR dropped significantly in both groups from
approximately 350 beats per minute (bpm) at -1 DPI to approximately 260 bpm at
1 DPI (Figure 4.4B). Beginning at 2 DPI, however, daily HR was elevated in all
rats to approximately 400 bpm and remained statistically higher than pre-injury
values for the remainder of the study (p<0.001). While the mean daily HR of the
GBP treated group was maintained approximately 20 bpm higher than the control
group at all DPI, this observation was not statistically significant (p=0.69).
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Figure 4.4. Effects of spinal cord injury and gabapentin (GBP) treatment on
daily cardiophysiology. Daily (24-hour) mean arterial pressure (MAP, A) and
heart rate (HR, B) measured across days post-injury (DPI). Daily MAP dropped
markedly in the immediate days post-injury before returning to near-normal
values after one week. The daily HR sharply decreased the first day after injury
before rising above pre-injury levels beginning at 2 DPI. Dotted lines indicate preinjury control values. N=11 Saline, N=10 GBP. Symbols are mean ± SD.
4.3.3 Spontaneously occurring autonomic dysreflexia (sAD)
Daily MAP and HR traces were analyzed with a computer algorithm to
identify sAD events (Figure 4.5A,B). Two algorithm threshold settings were
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employed to detect relatively small events (MAP increase ≥ 10 mmHg with HR
drop ≥ 10 BPM; 10/10) as well as larger events (MAP increase ≥ 20 mmHg with
HR drop ≥ 20 BPM; 20/20). With the 10/10 threshold settings, there was an
overall effect of time post-injury (p<0.0001) on the frequency of sAD detections
(Figure 4.5C). Moreover, there was an overall significant (p=0.026) treatment
effect with GBP treated rats having a higher daily sAD frequency. The average
number of daily sAD events was 16 between 14 and 28 days post-injury in the
saline treated group, compared to 26 in the GBP treated group. Post-hoc multiple
comparisons of individual time-points revealed a significant difference at 6 DPI
(p=0.0016). When detection thresholds were set to 20/20, we similarly observed
an overall significant effect of time (p<0.0001) and treatment (p=0.0093; Figure
4.5D). GBP-treated rats had significantly more events compared to the salinetreated control group. Between 14 and 28 days post-injury, GBP treated rats had
an average of 4 events per day compared to 2 in the saline group. Post-hoc
multiple comparisons of individual time-points revealed a significant difference at
6 DPI (p=0.0049). In the 10/10 data set, the pre-injury false detection rate was 03 events/day, which was negligible compared to post-injury detections typically
between 20-40 events post-injury. Similarly, pre-injury detections rates were
typically 0-1 when thresholds were set to 20/20, compared to a higher frequency
of 2-7 events/day post-injury.
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Figure 4.5. Effects of GBP treatment on the frequency of spontaneously
occurring AD (sAD) after injury. Representative 24-hour traces show more
overall sAD events with GBP treatment compared to saline controls (A; vertical
bars indicate detected events). A typical event with a MAP rise >20 mmHg and
HR drop >20 bpm is depicted in B. The frequency of small (MAP rise ≥
10mmHg, HR drop ≥ 10 bpm; C) and larger (MAP rise ≥ 20mmHg, HR drop ≥
20 bpm, D) sAD detections was monitored increased across days post-injury
(DPI). Overall, GBP treated rats had a significantly higher frequency of both small
sAD events (10/10; C) and larger detections (20/20; D) compared to salinetreated control rats. N=10 GBP, N=11 Saline. *p<0.05 vs saline control. Symbols
represent mean ± SD.
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4.3.4 Colorectal Distension-Induced Autonomic Dysreflexia
When we examined the severity of AD as assessed by the magnitude of
hypertension during experimentally-induced AD, there was an overall significant
treatment effect on the MAP reached during noxious colorectal distension (CRD)
stimulation (p<0.0001; Figure 4.6A). GBP-treated rats had a lower MAP during
CRD stimulation, with significant reductions at 21 and 28 DPI (p<0.05) that did
not become more severe over time post-injury. In contrast, the magnitude of
CRD-induced MAP became higher over time post-injury in the saline-treated
group, with 28 DPI being significantly higher compared to 14 DPI (p=0.001).
In parallel, the baseline MAP measured immediately prior to CRD
revealed an overall treatment effect (p<0.0005; Figure 4.6B), with GBP-treated
rats having significantly lower baseline MAP at 21 (p=0.0008) and 28 DPI
(p=0.002). The baseline MAP in saline rats did not change over time but was
significantly lower at 28 DPI compared to 14 DPI in GBP-treated rats (p=0.046).
When the CRD-induced changes in MAP relative to baseline were
measured, there was a significant effect of time (p<0.0001) but not treatment
(p=0.669) on the MAP change during CRD (Figure 4.6C). The magnitude of
change increased over time in both groups, with significant increases from 14
and 21 to 28 DPI (p<0.05). There was no effect of time on the change in HR
during CRD (p=0.16), however there was an effect of treatment (p=0.0047). GBP
significantly reduced changes in HR during CRD at 28 DPI (p=0.012; Figure
4.6D). Notably, saline-treated injured rats had typical bradycardic responses
during CRD, but GBP-treated animals responded with little to no reduction in
heart rate; in fact, tachycardic responses were noted in many instances.
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Figure 4.6. Gabapentin reduces blood pressure induced by noxious
colorectal distension. AD was experimentally induced on 14, 21, and 28 days
post-injury (DPI) through noxious colorectal distension (CRD). (A) GBP reduced
the absolute mean arterial pressure (MAP) achieved during CRD at 21 and 28
DPI. (B) Similarly, the baseline MAP calculated from the 30 seconds immediately
prior to each CRD trial was significantly lower in GBP treated rats. (C) The CRD-
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induced change in MAP relative to baseline was not different between groups,
however this parameter increased over time reflecting the gradual development
of fulminant AD. (D) CRD-induced changes in heart rate were significantly altered
by GBP, notably with treated rats having little change in heart rate, or
occasionally displaying tachycardia. N=11 Saline, N=10 GBP. *p<0.05 vs saline
control. Bars are mean ± SD.
4.3.5 Blood pressure recovery after induced AD
There was a significant effect of time (p=0.0057) and treatment (p=0.017)
on the length of time for MAP to return to baseline values after CRD (Figure 4.7).
The MAP recovery period to pre-CRD levels increased with time post-injury,
paralleling the increased AD severity observed across weeks post-injury (see
Figure 4.6). Post-hoc analyses did not indicate significant treatment differences
at individual time points, but there was a significant increase between 14 and 28
DPI (p=0.0450) in the saline group, with the MAP recovery time increasing from
130 to 360 seconds.
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Figure 4.7. Gabapentin (GBP) reduces the time required for MAP to return
to baseline after CRD. MAP recovery time following each CRD trial at 14, 21
and 28 DPI revealed a significant decrease with GBP treatment. N=11 Saline,
N=10 GBP. #p<0.05 when comparing the 28 DPI saline vs 14 DPI saline group.
Symbols are mean ± SD.
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4.3.6 Effect of experimental handling and restraint on resting blood pressure
To evaluate the effect of potentially stressful handling on baseline blood
pressure, we compared the resting MAP before the start of weekly CRD to the
MAP after placing rats under gentle restraint for the CRD testing session. There
was an overall effect of treatment (p=0.004), but not time (p=0.50) on the pressor
response (Figure 4.8). Prior to CRD, saline-treated rats had resting MAP
elevations of 15-20 mmHg during handling at 14, 21 and 28 DPI, whereas GBPtreated rats had significantly lower MAP at 21 and 28 DPI (p<0.05), with an
average increase of 5 mmHg.
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Figure 4.8. Effect of experimental handling and gentle restraint on MAP
prior to CRD. The MAP measured in the mornings before the start of weekly
CRD testing sessions was compared to the MAP measured during CRD test
preparation. Pre-treatment with GBP minimized handling-induced pressor
responses at 21 and 28 DPI. N=11 Saline, N=10 GBP. *p<0.05 vs saline control.
Bars are mean ± SD.
4.3.7 Sensitivity of the spontaneous baroreflex after SCI
Based on the observation that GBP treated rats did not display reflex
bradycardia normally observed during CRD in injured rats (Figure 4.9), we
examined the spontaneous baroreflex (sBR) with the sequence method of
Bertinieri et al. (1985) to test the hypothesis that GBP decreases baroreflex
99

sensitivity, or the strength of coupling between coinciding alterations in blood
pressure and heart rate. No significant effect of time (p=0.28) or treatment
(p=0.29) was observed on sBR gain (sensitivity) with this method (Figure 9). In
both groups, the gain of the sBR was maintained near naïve values at
approximately 2-2.5 mmHg-1 throughout the study. Analysis of acute time points
in the immediate days post-injury were not included due to high variability
associated with the confounding effects of recovery from surgical anesthesia and
SCI.

Figure 4.9. Effect of SCI and GBP on the spontaneous baroreflex (sBR). The
gain (sensitivity) of the sBR was measured using 2-hour segments of raw blood
pressure data collected in a 2-hour window following the 12:00 p.m. injections at
corresponding days post-injury (DPI). (A) Representative trace depicts typical
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sequence detections (A; left) and subsequent linear regression (A; right) from
which the average slope is calculated as a measure of sBR gain. (B) No
significant effect of injury or GBP treatment was observed at the evaluated timepoints. N=11 Saline, N=10 GBP. Bars are mean ± SD.
4.3.8 Effects of SCI and GBP treatment on spleen weight
While there was no significant effect of injury on spleen size (p>0.99),
GBP treatment significantly increased spleen size after injury (Figure 4.10).
Compared to naïve and saline treated SCI rats, GBP treated SCI rats had
significantly larger spleens (p<0.05).
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Figure 4.10. Effect of injury and GBP on terminal spleen weights. Spleen wet
weights were recorded and normalized to terminal body weights at 4 weeks postinjury. While no effect of injury was observed, spleens from the GBP-treated
injured group were significantly heavier in comparison to saline treated, as well
as to age and body-weight matched naïve control rats. N=8 Naïve, N=11 Saline,

101

N=10 GBP. *p<0.05 vs naive control and saline treated SCI rats. Bars are mean
± SD.
4.3.9 Effects of SCI and GBP treatment on pre-synaptic densities
To investigate potential effects of SCI and chronic GBP treatment on
synaptic connectivity in the lumbosacral spinal cord, we measured the
immunoreactivity of presynaptic synaptophysin+, VGLUT2+ and VGAT+ puncta in
the dorsal horn (lamina I-II; R1) and dorsal gray commissure (lamina X; R2) of
the L6/S1 spinal cord. These regions of interest contain the central terminals of cfibers conveying colorectal afferent stimuli into the dorsal horn (R1) and the
ascending propriospinal neurons (R2) believed to relay afferent stimuli rostrally
towards the SPN. Representative images demonstrate apparent decreases in
immunoreactivity for synaptophysin (Figure 4.11A,B,E,F), VGLUT2 (Figure
4.11C,D) as well as VGAT (Figure 4.11G,H) associated with SCI. The
normalized percent area covered by synaptophysin in both regions of interest
was reduced by SCI (Figure 4.11I,L). In the VGAT staining set, synaptophysin
coverage was significantly lower (p<0.001; Figure 4.11L) in the SCI+saline and
SCI+GBP treated groups compared to naïve controls, however this reduction
was not significant in the VGLUT2 set (p=0.09; Figure 4.11I), perhaps due to
higher staining variability. No effect of GBP treatment on synaptophysin area was
observed in either staining set (p>0.05; Figure 4.11I,L). Similar to synaptophysin,
SCI also significantly reduced the area occupied by VGLUT2+ (p<0.01; Figure
4.11J) and VGAT+ (p<0.01; Figure 4.11M) immunoreactivity in both regions of
interest, with no observed effect of GBP treatment (p>0.1).
We also evaluated the percent area occupied by the overlap of
synaptophysin/VGLUT2 puncta as well as synaptophysin/VGAT puncta. The
area occupied by the union of synaptophysin and VGLUT2 immunoreactivity was
significantly reduced in both regions of interest after injury (p<0.05; Figure
4.11K). Moreover, injury decreased the area occupied by the overlap of
synaptophysin and VGAT puncta in R1 and R2 (p<0.05; Figure 4.11N). No effect
of GBP treatment was observed on the overlap of either synaptophysin/VGLUT2
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or synaptophysin/VGAT (p>0.5). Therefore, despite decreases in synaptic
density in the lumbosacral dorsal horn after SCI, there was no effect of GBP on
synaptic re-organization in these regions of interest believed to be involved in the
viscero-sympathetic relay pathway.
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Figure 4.11. Density of synaptic puncta following complete spinal cord
injury (SCI). Analyses were performed as described in Figures 4.1 and 4.2.
Representative images (A-H) demonstrate VGLUT2 (C,D), VGAT (G,H) and
synaptophysin (A,B and E,F) immunoreactivity in the lumbosacral dorsal horn
(inset, top left) 4 weeks after injury. Widespread punctate immunoreactivity of all
three markers was observed throughout the spinal cord gray matter. SCI
decreased the density of VGLUT2 (J), VGAT (M), synaptophysin (I,L) and the
overlap of VGLUT/synaptophysin (K) and VGAT/ synaptophysin (N), suggesting
an overall decrease in excitatory and inhibitory synapses. Immunoreactive
density was not altered by prolonged gabapentin (GBP) treatment. N=8 naïve,
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N=11 Saline, N=10 GBP. *p<0.05 vs naive control. Symbols are mean +/- SD.
Scale bar= 10 uM.
4.3.10 Effects of SCI and GBP treatment on pre-synaptic colocalization
The Manders’ coefficients, tM1 and tM2, and Manders’ overlap coefficient
(MOC) were calculated for presynaptic immunoreactivities to corroborate density
measures. The fraction of total VGLUT2 signal overlapping with SYN (tM1) was
not significantly altered by SCI or treatment in either region of interest (p>0.05),
whereas the fraction of total VGAT signal overlapping with SYN was significantly
decreased by SCI in the R2 region (p=0.014; Figure 12A). No effect of GBP
treatment was observed on tM1 in the VGLUT2 or VGAT staining sets (p>0.1).
The converse relationship, defined as the fraction of total SYN signal overlapping
with VGLUT2 or VGAT (tM2; Figure 12B) showed that in both the VGLUT2/SYN
and VGAT/SYN staining sets, tM2 was significantly decreased after injury in both
regions of interest (p<0.01). Like tM1, no significant effect of GBP treatment was
observed on the tM2 overlap coefficient (p>0.05). The MOC for each pair of
markers (VGLUT2/SYN and VGAT/SYN) indicated a high degree of signal
overlap; >0.9 in R1 and R2 regions of interest (Figure 4.12C). Injury significantly
increased the MOC of VGLUT2/SYN and VGAT/SYN relative to naïve controls in
R1 (p=0.0003; p<0.01). MOC was unaffected by GBP treatment in either staining
set (p>0.5).
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Figure 4.12. Quantitative colocalization analysis of synaptic
immunostaining. The Manders’ fractional overlap coefficients, tM1 and tM2
(A,B), and Manders’ overall overlap coefficient (MOC; C) were calculated to
assess the co-localization of VGLUT2/synaptophysin and VGAT/synaptophysin
staining in the same regions of interest (R1 and R2) used for density
measurements. (A) The fraction of total VGLUT2 or VGAT signal overlapping
with synaptophysin (tM1) was largely unaffected by injury or GBP treatment. (B)
Conversely, injury significantly decreased the fraction of synaptophysin signal
overlapping with VGLUT2 or VGAT (tM2). (C) An MOC greater than 0.9 was
observed in all groups. MOC was significantly increased by injury, with no effect
of GBP treatment. N=8 naïve, N=11 Saline, N=10 GBP. *p<0.05; **p<0.01;
***p<0.001; ****p<0.001 vs naive control. Bars are mean +/- SD.
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4.4 Discussion
We found that continuous high dose GBP treatment reduced blood
pressure during CRD, and decreased bradycardia typically observed during AD
as well as the MAP recovery time after CRD. However, GBP treated rats also
had higher sAD frequency and failed to return to pre-injury body weight.
Moreover, we observed that SCI reduced the density of putative excitatory
(VGLUT2+) and inhibitory (VGAT+) synaptic puncta in the lumbosacral cord,
although GBP did not alter these parameters. These results suggest that
continuous GBP treatment offers clinical benefit in decreasing the magnitude and
duration of CRD-induced AD, but appears to have paradoxical effects on
spontaneously occurring AD.
Our finding that continuous GBP treatment significantly lowers the MAP
achieved during CRD stimulation after complete SCI is similar to our previous
reports (Rabchevsky et al., 2011; Rabchevsky et al., 2012) in which we found
that a single acute administration of 50 mg/kg GBP reduces the magnitude of
MAP change during CRD over 4-weeks post injury. We expected to see a similar
effect on the change in MAP with our present study, since we increased both the
treatment frequency and drug dosage (4x daily, 100 mg/kg). This higher dosage
was chosen based on reports that 100-400 mg/kg of GBP daily prevents
excitatory synaptogenesis in mice (Eroglu et al., 2009; Takahashi et al., 2018).
Furthermore, we distributed the daily dosage across 4 injections to maintain
relatively stable drug concentrations in spite of the 2-3 hour half-life in rats
(Vollmer et al., 1986). However, we did not observe a significant treatment effect
on the MAP change relative to baseline. We determined that this was due to a
concomitant decrease in the baseline MAP prior to CRD which we attribute to the
well-established anxiolytic effects of GBP (Houghton et al., 2017; Markota and
Morgan, 2017). This is supported by our finding that relative to saline controls,
GBP treated rats had a significantly smaller increase in blood pressure
associated with experimental handling and restraint. As these experimental
manipulations can present considerable stressors for rodents (Crestani, 2016), it
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is likely that pretreatment with GBP attenuated levels of stress or anxiety and
subsequent cardiovascular responses.
Body weight analysis of all injured rats revealed an acute gain of body
weight in the immediate days post-injury, followed by a significant loss of body
weight over the next two weeks. The reduction in body weight observed after SCI
is likely attributable to loss of bone and muscle mass below the injury where the
musculoskeletal system undergoes atrophic plasticity in response to disuse and
unloading (Baldi et al., 1998; Castro et al., 1999; Giangregorio and McCartney,
2006; Gordon and Mao, 1994). Others have similarly reported an initial gain in
body weight after traumatic SCI in rats (Krishna et al., 2013), which may be due
to a combination of fluid retention and reduced metabolic demand as motor
activity is dramatically suppressed during recovery from surgical anesthesia and
SCI. Approximately two-weeks after injury, saline control-treated rats started to
regain weight, reaching pre-injury body weight levels by three weeks post-injury.
In contrast, GBP treated rats did not return to pre-injury body weight before
termination 4 weeks post-injury. GBP treated rats did not lose additional body
weight compared to saline controls, suggesting that treatment did not promote
weight loss after SCI, rather it impeded body weight recovery during the chronic
phase of injury.
The gradual return to pre-injury weight beginning approximately 2-weeks
after SCI occurs in parallel to the development of muscle spasticity in rats after
SCI. For example, Bennett et al. (2004) demonstrated the development of
intense and long-lasting spasms of the tail musculature by two-weeks after
complete sacral transection SCI. Multiple studies suggest that muscular
contractions during spasm after SCI can help maintain or even increase muscle
mass (Baldi et al., 1998; Gorgey and Gater, 2012). This indicates that the return
to pre-injury body weight in our study could be attributable to muscle hypertrophy
resulting from muscle spasticity. We previously demonstrated that GBP is
effective for decreasing the intensity of tail spasticity in rats after SCI
(Rabchevsky et al., 2011; Rabchevsky et al., 2012). Therefore, given the
continuous 4x daily GBP administration in our current study, it is feasible that the
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failure of GBP rats to return to pre-injury weight is due to a lack of spasticityinduced muscle hypertrophy. It is clinically important to understand whether a
continuous GBP dosage paradigm could abrogate the potentially beneficial
effects of muscle spasticity, as a preservation of muscle tone could also be
expected to help prevent musculoskeletal issues such as joint contractures
(Pingel et al., 2017).
We observed changes in daily MAP and HR after SCI which reflect the
changes in cardiovascular control associated with our complete T4-transection
model. The marked drop in MAP in the first days after injury likely reflects two
phenomena: 1) the recovery from surgical ketamine and xylazine anesthesia, the
latter of which has demonstrated cardiac depressant effects in Wistar rats
(Albrecht et al., 2014), and 2) the sudden and complete removal of supraspinal
drive to SPN. In the absence of supraspinal drive, the tonic activity of SPN is
decreased, leading to a reduction of vasomotor tone and peripheral arterial
resistance which manifests as reduced MAP (Mathias et al., 1979; Mathias and
Frankel, 1988). Daily HR similarly decreased dramatically immediately after SCI,
likely due to the potent effects of xylazine on the a2-adrenergic receptors (Hsu et
al., 1985). Xylazine functions both centrally and on peripheral vasculature,
causing side effects such as hypertension or hypotension, bradycardia and
sedation. Xylazine induced reductions in heart rate are caused by a combination
of reflex-bradycardia in response to peripheral vasoconstriction, which increases
systemic vascular resistance, and through reduced sympathetic tone as a result
of reduced norepinephrine release from sympathetic terminals (Sinclair, 2003).
By 2 DPI, daily HR was significantly increased compared to pre-injury and
remained elevated for the duration of the study. We observed that GBP treated
SCI rats had daily HR 20-30 bpm higher than saline-treated controls. This trend
was non-significant (p=0.06), perhaps due to inherent variability commonly
observed in daily HR measurements. It indicates, however, that this GBP
treatment regimen has cardiovascular effects after SCI which have not previously
been reported. Notably, the a2d1 subunit which GBP binds to is found
ubiquitously in many tissues and is highly abundant in the myocardium, vascular
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smooth muscle, skeletal muscle and many brain regions (Fuller-Bicer et al.,
2009; Klugbauer et al., 2003; Taylor and Garrido, 2008). Fuller-Bicer et al. (2009)
created a mouse knockout model with a targeted disruption of the a2d1 calcium
channel subunit and investigated electrophysiological and mechanical properties
of the heart in mice lacking this subunit. They reported decreased Ca2+ currents
in cardiomyocytes and reduced basal contractility and relaxation parameters in
ex-vivo heart preparations in knockout mice. These findings suggest important
roles of the a2d1 subunit in cardiac function and further suggest possible effects
of GBP on daily HR in our model. Based on the work of Fuller-Bicer et al. (2009),
it is feasible that SCI rats receiving GBP have reduced cardiac contractility and
output. As described in Chapter 1, the cardiovascular and autonomic nervous
systems function together to maintain an appropriate cardiac output, which is
determined by the product of stroke volume and heart rate (CO=SV x HR).
Therefore, one could expect to observe a compensatory increase in heart rate
mediated by elevated cardiac sympathetic drive in GBP treated rats if this drug
decreases myocardial contractility and stroke volume.
We set our sAD algorithm thresholds to detect small events consisting of a
MAP increase ≥ 10 with a HR reduction ≥ 10 bpm, as well as larger events with
a MAP increase ≥ 20 and HR reduction ≥ 20 bpm. Similar to our previous
studies using the smaller threshold of 10mmHg/10 bpm, we observed a
negligible number of detections prior to injury (Eldahan et al., 2018; Rabchevsky
et al., 2012). This validates that our algorithm detects abnormal physiological
phenomena reflecting the loss of regular cardiovascular control and is likely to
reflect true AD events. Compared to other sAD algorithms which utilized more
stringent threshold of a change >20 mmHg/bpm (Mironets et al., 2018; West et
al., 2015), thresholds of 10 mmHg and 10 bpm are relatively lenient. However,
the smaller events reflect abnormal physiological patterns which may be
important to monitor. Recent reports suggest that the abnormal fluctuations in
blood pressure associated with SCI may contribute to cerebrovascular
dysfunction (Phillips et al., 2016; Phillips et al., 2018). This indicates that the
moderate sAD events that we detected may be clinically relevant outcome
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measures. Moreover, there is evidence to suggest that increased blood pressure
variability is associated with poor cardiovascular outcomes (Stevens et al., 2016).
Therefore, our finding that chronic administration of GBP increases the frequency
of relatively small as well as moderate hemodynamic fluctuations after SCI
warrants careful consideration of potentially negative effects on cardiovascular
outcomes after SCI.
We hypothesized that continuous treatment with GBP would reduce the
frequency of spontaneous AD. It is surprising, therefore, that our current
treatment paradigm, which delivers eight times the daily amount of GBP, had the
effect of increasing sAD frequency. Although the exact mechanisms of sAD
generation have not been examined, it is possible that a subset of these events
could be due to spontaneous firing of the SPN or pre-sympathetic interneurons.
In this case, it would suggest that continuous GBP treatment somehow increases
spontaneous sympathetic neural activity. One intriguing possibility is that
prolonged attenuation of primary afferent activity by continual GBP delivery
deprives sympathetic interneurons of peripheral stimulation. Studies on the
effects of long-term application of gabapentinoids on spinal cord slice
preparations demonstrate that prolonged exposure to GBP decreases
spontaneous excitatory post-synaptic potentials in the substantia gelatinosa
(Biggs et al., 2014). This was associated with a significant decrease in Ca2+
release sparking, suggesting that GBP reduces overall spinal network excitability.
Similarly, Coderre et al. (2005) and Coderre et al. (2007) reported that GBP
decreases intraspinal release of glutamate from afferent terminals. These
observations present the possibility that prolonged GBP treatment increases
spontaneous spinal sympathetic activity through a homeostatic mechanism in
which sustained decreases in peripheral stimulation of SPN or sympathetically
correlated interneurons promotes increased excitability of SPN, perhaps
manifesting as increased sAD events.
Cardiovascular regulation is dynamic multifactorial. Among the many
variables involved in cardiovascular regulation, psychological and emotional
stressors can introduce acute alterations in blood pressure and heart rate.
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Indeed, many animal studies have demonstrated the importance of controlling for
potential sources of stress during monitoring of the cardiovascular or autonomic
systems (Crestani, 2016). We observed an increase in the resting blood pressure
of saline treated rats after experimental manipulations to conduct CRD, whereas
GBP treated rats had a significantly reduced pressor response to identical
handling. GBP is well known to have anxiolytic effects in humans and rodents
(Greenblatt and Greenblatt, 2018; SM et al., 2011), suggesting that the reduced
pressor response is likely attributable to a reduction in emotional distress during
handling, drug injection, gentle cloth restraint and colorectal catheter placement.
We quantified the density of synaptic puncta in the lumbosacral spinal
cord to investigate the effects of complete SCI and GBP treatment on synaptic
connectivity in regions receiving primary afferent terminations from the
colorectum (Kyloh et al., 2011). In the caudal spinal cord 4 weeks after injury, we
observed significantly reduced density of the vesicular neurotransmitter
transporters VGLUT2 and VGAT in conjunction with the pre-synaptic marker
synaptophysin, suggesting an overall decrease in excitatory and inhibitory
synapses, respectively. VGLUT2 and VGAT are widely accepted markers of
glutamatergic and GABAergic synapses, and utilizing double-labeling of VGLUT2
or VGAT in conjunction with the specific presynaptic marker synaptophysin
(Wiedenmann and Franke, 1985) shows puncta of excitatory or inhibitory
synapses, respectively (Herzog et al., 2006; Lee et al., 2017; Li et al., 2003).
The identification of neurochemical markers specific to particular synaptic
populations and structural components has been a non-trivial challenge in
neuroscience research (Rees et al., 2017). In recent decades, a number of
neurochemical markers have been identified and utilized to observe synaptic
structures in tissue. Synaptophysin is the most abundant protein in presynaptic
vesicles, accounting for approximately 7% of total vesicular membrane proteins
(Jahn and Sudhof, 1993). Despite its abundance, knockout mice lacking this
protein appear healthy and maintain normal synaptic function (McMahon et al.,
1996; Valtorta et al., 2004). While the exact function of synaptophysin remains
unknown, this vesicular glycoprotein is widely used as a universal marker of
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chemical presynaptic terminals in the brain and spinal cord (Kwon and Chapman,
2011; Vulovic et al., 2018). How specific is synaptophysin to the presynaptic
compartment compared to, for example, intra-axonal transport pathways? In their
seminal study, Wiedenmann and Franke (1985), who were the first to
characterize synaptophysin as a presynaptic identifier, observed immunogold
labeled synaptophysin virtually exclusively in synaptic terminals of the brain using
electron microscopy. Immunogold labeled puncta were markedly enriched in
presynaptic terminals but not observed in the cell bodies or axons. Wiedenmann
and Franke (1985) also observed synaptophysin in the adrenal medulla,
suggesting possible non-synaptic roles of this protein. However, this study was
not sufficient to conclusively determine whether low levels of neuronal
synaptophysin may also be found outside of synaptic vesicles. Subsequent
studies designed to assess the pre-synaptic specificity of synaptophysin within
neurons concluded that it is highly specific to small synaptic vesicles (SSV)
(Navone et al., 1986). In contrast to large dense-core vesicles, which are
continually transported to the synapse after being reloaded with peptide
transmitters in the cell body, SSVs are recycled and re-loaded locally in the
synapse and therefore do not undergo continual axonal transport from the soma
to terminal (Ceccarelli et al., 1973; Navone et al., 1986; Reichardt and Kelly,
1983). Labeling and trafficking studies have demonstrated that newly
synthesized synaptophysin is shuttled to synaptic terminals using fast transport
mechanisms (Elluru et al., 1995; Tang et al., 2013), indicating that it only briefly
exists outside of the synapse. Systematic analysis of the metabolic turnover of
synaptic proteins in primary cortical neuron cultures revealed that synaptophysin
has a half-life of approximately 96 hours and suggested that as little as 0.7% of
total synaptophysin protein is replaced every hour (Cohen et al., 2013). An earlier
study, which used intact brain tissue, estimated a half-life of approximately 500
hours, indicating that synaptophysin may have a substantially slower turnover
rate in-vivo (Price et al., 2010). The fast-transport and slow turnover of
synaptophysin suggests that newly synthesized protein en route to synaptic
terminals likely accounts for a small proportion of total observable synaptophysin.
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Lastly, the immunoreactive staining pattern of synaptophysin is also consistent
with other well-characterized and specific presynaptic markers such as synapsin
I (De Camilli et al., 1983; Fletcher et al., 1991; Navone et al., 1986). Collectively,
these studies indicate that synaptophysin is useful as a high-fidelity marker of
presynaptic terminals.
Presently, three isoforms of the VGLUT (VGLUT1-3) have been identified
in the central nervous system (Bai et al., 2001; Bellocchio et al., 2000; Gras et
al., 2002; Herzog et al., 2001; Liguz-Lecznar and Skangiel-Kramska, 2007; Ni et
al., 1994; Schafer et al., 2002; Takamori et al., 2001). Specific VGLUTs are
typically found in discrete subsets of neurons, with a mostly complementary and
non-overlapping pattern of distribution observed throughout the CNS (Herzog et
al., 2001; Kaneko and Fujiyama, 2002). In the spinal cord, VGLUT1 and VGLUT2
are the primary isoforms observed with only low levels of VGLUT3 mRNA and
protein being detected (Alvarez et al., 2004; Landry et al., 2004; Li et al., 2003;
Oliveira et al., 2003; Todd et al., 2003). We chose to examine VGLUT2+ synaptic
puncta based on previous studies showing that this is the predominant VGLUT
expressed in the upper dorsal horn and lamina X regions of interest in our model
(Alvarez et al., 2004; Landry et al., 2004; Llewellyn-Smith et al., 2007; Oliveira et
al., 2003; Todd et al., 2003; Varoqui et al., 2002). Spinal VGLUT2 may arise from
three sources: 1) incoming primary afferents, 2) descending fibers or 3) local
propriospinal neurons. Evidence suggests that most VGLUT2 in the spinal dorsal
horn is derived from propriospinal sources. For example, Alvarez et al. (2004)
and Oliveira et al. (2003) observed a marked decrease in the density of VGLUT1
varicosities in the upper dorsal horn one week following lumbar dorsal rhizotomy,
whereas VGLUT2 density was not significantly altered. Others have identified
VGLUT3 expression in dorsal root ganglia along with low-levels of VGLUT3
immunoreactivity in the upper dorsal laminae (Seal et al., 2009). These
observations indicate that primary afferent terminals are comprised mostly of
VGLUT1 and, perhaps to a lesser extent, VGLUT3. Llewellyn-Smith et al. (2007)
reported no change in VGLUT2 density throughout the thoracolumbar lateral
horn caudal to complete T4-transection and observed significantly decreased
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VGLUT1 labeling, but did not look at lower spinal levels or dorsal horn. This
suggests that intraspinal VGLUT2 may be more specific for propriospinal
sources, whereas VGLUT1 is more likely associated with supraspinal and
primary afferent fibers. Some descending tracts are known to contain VGLUT2.
For example, 97% of axons from the descending rubrospinal and vestibulospinal
tracts projecting to the spinal cord contain VGLUT2 exclusively (Du Beau et al.,
2012). However, because these tracts project to ventral motor regions they
cannot account for the reduction in VGLUT2 we have observed in dorsal horn
and lamina X regions. Others (Maxwell et al., 2007; Todd et al., 2003) have
contended that VGLUT2 in the dorsal cord is likely expressed by excitatory
interneurons, which would indicate that the reduced VGLUT2 density that we
observed is of a propriospinal origin.
4.4.1 Methodological Considerations
Advancements in confocal microscopy have enabled accurate
measurement of sub-cellular structures using immunofluorescent labeling.
Improved resolution power of confocal microscopes have permitted the use of
this technique to quantify specific synaptic populations (Vulovic et al., 2018).
While electron microscopy (EM) remains the gold standard for precise
quantification of individual synapses, confocal microscopy has the distinct
advantage of allowing comparatively high throughput of large sets of biological
replicates and analysis of larger fields of tissue. Moreover, quantified results
obtained with confocal imaging of synapses have been corroborated with
electrophysiological functional measurements (Nikonenko et al., 2006; Vulovic et
al., 2018). As previously discussed (Burette et al., 2015; Rossler et al., 2017),
confocal imaging of synapses in intact tissue has important caveats. The
resolution of conventional light microscopy compared to the relatively small size
of synapses makes it difficult to accurately resolve neighboring synapses, which
are typically very dense in tissue. Combined with inherent limitations of tissue
immunofluorescence such as uneven antibody penetration, variable tissue
fixation and light scattering at deeper optical planes, it becomes very difficult to
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obtain accurate synaptic counts from a field of tissue. We therefore chose to
quantify the density of our presynaptic markers to circumvent this limitation.
Others have used similar area measurements to quantify the density of suprathreshold immunoreactivity of presynaptic markers in the brain and spinal cord
(Beauparlant et al., 2013; Carasatorre et al., 2015; Cloutier et al., 2016; McKillop
et al., 2016). Threshold based methods have also been employed to measure
overlapping synaptic puncta (Alvarez et al., 2004). Such density-based
measurements of large regions of interest can provide broad indication of
changes synaptic connectivity. Future studies combining the use of retrograde
tracers and synaptic labeling may be useful in characterizing synaptic
connectivity within discrete neuronal pathways in our model. For example,
retrograde labeling of primary c-fiber afferents innervating the distal colon, in
conjunction with synaptic labeling after SCI could provide a method of measure
the effects of experimental treatments on specific neuronal populations known to
be involved in the etiology of AD.
Quantitative colocalization analyses were used to corroborate synaptic
density measurements. Such colocalization methods are increasingly used to
quantify the overall spatial and stoichiometric relationship between a set of
fluorescent probes on a pixel-by-pixel basis (Aaron et al., 2018; Bolte and
Cordelieres, 2006; Cordelieres and Bolte, 2014; Dunn et al., 2011). Although
some researchers rely on relatively simple visual assessments of signal overlap,
this approach is highly prone to user bias and inappropriate in cases where the
intensity of one channel overwhelms the signal from the second (Bolte and
Cordelieres, 2006; Sheng et al., 2016; Zinchuk and Zinchuk, 2008). Therefore,
we chose to implement these more rigorous colocalization techniques. The
Manders’ overlap coefficient (MOC) is well-suited for quantifying the cooccurrence of two probes. Although the MOC is primarily sensitive to spatial
overlap (Dunn et al., 2011), pixel intensity is also factored into its calculation.
Hence, in cases where a direct linear relationship exists between the number of
target antigen and fluorescence intensity, the MOC represents the colocalization
of total labeled antigens to provide a more comprehensive metric. Compared to
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the Pearson’s correlation coefficient, which is another commonly used
colocalization metric, the MOC is arguably more appropriate in cases where the
fluorescent probes utilized differ in intensity (Zinchuk and GrossenbacherZinchuk, 2009).
We observed a high degree of co-occurrence between
synaptophysin/VGLUT2 or synaptophysin/VGAT, with MOC values above 0.9.
Considering that a MOC of 1.0 indicates complete signal overlap, our results
demonstrate that these pairs of pre-synaptic markers are highly colocalized and
further suggests that the majority of staining represents pre-synaptic puncta.
While our density measurements revealed a significant decrease in the area
covered by overlapping synaptophysin/VGLUT2 and synaptophysin/VGAT
puncta after injury, we observed an increase in the MOC after injury. Since MOC
factors marker co-occurrence and pixel intensity, this could suggest a differential
effect of SCI on the co-occurrence and relative stoichiometry of these markers
(i.e. reduced co-occurrence but increased intensity correlation). However,
examination of the MOC equation suggests that alterations in pixel intensity
would have relatively minor effects on the MOC since this variable is present in
both the numerator and denominator. Alternatively, it is possible that SCI
decreases the overall area occupied by these markers but that a higher
proportion of the remaining synaptophysin, VGLUT2 and VGAT protein is present
together in the pre-synaptic compartment. For example, it is conceivable that
spinal transection and subsequent degeneration of descending fibers results in a
reduction of non-synaptic synaptophysin, VGLUT2 and VGAT protein being
transported from the soma to presynaptic terminals. Such a scenario would be
expected to result in a lower overall density but higher proportion of co-occurring
markers. Lastly, because SCI increased the MOC values from approximately 0.9
to 0.95, this relatively minor increase is consistent with the notion that the vast
majority of these markers are normally present in the presynaptic compartment
(Vulovic et al., 2018; Wiedenmann and Franke, 1985).
We also evaluated the Manders’ fractional overlap coefficients tM1 and
tM2, which reflect the proportion of total VGLUT2 or VGAT signal that overlaps
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with synaptophysin, and vice versa. Based on the reduced density we observed
with all three markers, it may be expected that the relative fraction of overlap
would not be altered after SCI. This was true of tM1, which is the proportion of
total VGLUT2 or VGAT signal coinciding with synaptophysin. However, we found
that SCI significantly decreased the proportion of synaptophysin signal that
colocalizes with VGLUT2 or VGAT (tM2). Therefore, SCI decreased the
proportion of synaptophysin signal which overlaps with VGLUT2 or VGAT (tM2),
while the amount of total VGLUT2 or VGAT signal overlapping with
synaptophysin was unaffected. These metrics might represent that the same
proportion of VGLUT2/VGAT signal after SCI remains in the pre-synaptic
compartment along with synaptophysin, whereas an increased proportion of
synaptophysin signal may be associated with other synaptic populations such as
those expressing VGLUT1 or glycine transporters GLYT1/2. This would be
consistent with studies suggesting that dorsal horn VGLUT1 is primarily derived
from incoming primary afferents (Alvarez et al., 2004; Oliveira et al., 2003) which
would not be expected to decrease after SCI.
VGAT is a presynaptic protein widely used as marker of presynaptic
inhibitory synapses. Although initially used as a GABAergic presynaptic marker, it
is now understood to be present in both GABAergic and glycinergic synapses
(Chaudhry et al., 1998). Co-release of GABA and glycine from the same synaptic
vesicle has also been observed in the brain and spinal cord, suggesting that
VGAT may be involved in the transport of both of these inhibitory
neurotransmitters (Jonas et al., 1998; Wojcik et al., 2006). It is likely, therefore,
that our observed decrease in VGAT immunoreactivity after transection SCI
indicates a reduction of both GABAergic and glycinergic synapses in our ROIs.
Sources of VGAT within the spinal cord are limited to descending pathways and
spinal interneurons, as incoming primary afferents are thought to be exclusively
excitatory. In the intact animal, descending GABAergic fibers from the
periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) innervate
ascending nociceptive neurons in the dorsal horn and are believed to play an
important role in the endogenous analgesic system (Basbaum and Fields, 1984;
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Lau and Vaughan, 2014; Taylor and Corder, 2014). GABAergic interneurons are
present throughout the spinal dorsal horn, with an estimated 25-40% of neurons
in the upper dorsal lamina being immunoreactive for GABA (Polgar et al., 2003).
Notably, decreases in the number of dorsal inhibitory neurons after SCI has been
documented and proposed to contribute to the development of injury-induced
neuropathic pain (Meisner et al., 2010). Drew et al. (2004) demonstrated a
decreased sensitivity to bicuculline (GABA antagonist) applied locally to dorsal
horn neurons, which was proposed to occur in response to decreased GABA
release resulting from reduced VGAT expression. Song et al. (2001) used
GeneChip analysis to examine shifts in gene transcription in a rat model of acute
SCI. Following T9 contusion injury, a segment of cord centered on the epicenter
was isolated and processed for RNA isolation. They demonstrated a 3.5-fold
decrease in VGAT mRNA expression at 3-hours, and a 10-fold decreased at 24hours post-injury. This study suggests that SCI may result in decreased VGAT
protein production throughout the cord immediately after injury. However, it is
unclear whether this downregulation is maintained into the chronic phase of
injury. GABAergic interneurons are also located in lamina X (Alvarez et al., 1996;
Blok et al., 1998). It is unclear in our study whether the reductions of VGAT
density are associated with the loss of descending fibers or alterations within
propriospinal circuits. Additional experiments are needed to determine the
relative contributions of these two sources. Future studies using a series of spinal
lesions may be useful in determine the relative contributions. For example,
comparison of VGAT density in rats with a rostral spinal transection to rats
receiving a subsequent second lesion in the nearby caudal cord may help
determine the relative contribution of descending vs. local inhibitory neurons.
An important limitation of our study is that, because we have not counted
the number of synapses, we are unable to determine conclusively whether the
observed decrease in immunoreactive density is attributed to a reduction in
synapse size, number of presynaptic vesicles per neurotransmitter release site,
or a general reduction of presynaptic vesicle protein expression. Evidence
indicates that the expression of VGLUT2 and VGAT protein in the neocortex is
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positively correlated with synaptic activity (De Gois et al., 2005; Doyle et al.,
2010). Therefore the loss of descending supraspinal synaptic drive after cord
transection could result in decreased expression of VGLUT2 and VGAT protein
and account for the reduced VGLUT2/VGAT density observed in our study,
rather than a decrease in the actual number of synapses.
A number of other studies in rodents have similarly observed decreased
immunoreactivity of synaptic markers caudal to a spinal lesion. Beauparlant et al.
(2013) reported decreased density of VGLUT1 and VGLUT2 in the lumbosacral
cord one week after a staggered T7/T10 hemisection before returning to intact
control levels by 9 weeks. Their study suggests that following the initial loss of
supraspinally derived synapses, the decentralized spinal cord compensates with
reactive sprouting and synaptogenesis in an attempt to re-establish a normal
level of synaptic connectivity and activity. The authors contend that this
compensatory response proceeds in an undirected manner, resulting in the
formation of aberrant circuitry contributing to neuronal dysfunction and, perhaps,
muscle spasticity, pain and autonomic dysfunction. We terminated our
experiment 4 weeks after injury, so it is unclear whether there is a similar
restoration in the density of synaptic markers in more chronic phases after
complete SCI.
Kapitza et al. (2012) reported a 10-50% decrease in the density of
VGLUT1+ and VGLUT2+ puncta in laminae VII caudal to the lesion at 1 and 12
weeks following S2 transection, however no significant decrease was observed
at 4 weeks suggesting a dynamic time-dependent shift in synaptic architecture.
These results are in contrast to a study by Kitzman (2006), who observed an
increase in the number of VGLUT2+ boutons in contact with ventral motoneurons.
This discrepancy may be related to methodological differences, or due to laminae
specific re-arrangements of glutamatergic terminals after injury. Using a
contusion model in mice, McKillop et al. (2016) quantified the immunoreactive
area of VGLUT2, synaptophysin and VGAT in the ventral horn at 48-hours and
10-weeks post-injury. Although their study utilized a different species injury
model and focused on the ventral rather than the dorsal horn, they reported
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injury-related decreases in synaptic markers at both 2 days and 10 weeks after
injury, similar to our results in the rat dorsal horn 4 weeks post injury. This study
suggests that SCI causes a widespread decrease in synaptic density throughout
the dorsal-ventral axis since they observed similar results in the ventral horn as
we observed in the dorsal horn and laminae X region.
It is difficult to compare studies directly due to differences in injury model,
spinal level, time after injury, method of quantification and laminar distribution
examined across various studies. However, with these studies in mind it is
apparent that SCI provokes temporally and spatially dynamic changes in synaptic
organization that are likely to be involved in sensorimotor and autonomic
dysfunction.
4.5 Conclusion
Our findings indicate that continuous high dose GBP treatment may offer
clinical benefit in reducing the magnitude and duration of AD induced by noxious
stimulation of the pelvic viscera, however potential deleterious effects such as
increased spontaneous AD and reduced gain in body weight must also be
considered. The absence of treatment effect on the density of synaptic
immunoreactivity after SCI suggests that prolonged high-dose GBP does not
alter synaptic density in the lumbosacral cord and likely acts through an
alternative mechanism to reduce the severity of AD. Moreover, the reduced
density of synaptic markers indicates that altered synaptic connectivity in the
lumbosacral cord may contribute to the etiology of AD. Future investigations
using more detailed approaches to study synaptic connectivity in discrete
neuronal pathways may reveal a nuanced and previously unappreciated
contribution of lumbosacral synaptic remodeling in the etiology of AD.
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CHAPTER 5
Discussion, Future Research Directions and Conclusions
5.1 Conclusions
This dissertation has presented the investigation of two FDA-approved
drugs, rapamycin (RAP) and gabapentin (GBP), for their potential to suppress
maladaptive plasticity associated with the development of AD. Collectively, our
results give important new insights into possible cellular signaling mechanisms
and synaptic re-organization involved in the development of AD, and inspire a
number of novel future research directions to push forward the effort to discover
treatments capable of mitigating AD development.
These two drugs were tested for distinct reasons. We chose to test RAP
based on an emergence of evidence implicating the mammalian target of
rapamycin (mTOR) pathway as a critical signaling hub coordinating the cellular
processes required for neurons to sprout and regenerate. RAP is employed both
as an experimental tool to investigate the role of mTOR signaling in health and
disease, as well as a clinically important immunosuppressant used to reduce the
chance of post-organ transplant rejection. Moreover, some researchers have
proposed RAP treatment after SCI to promote tissue sparing and functional
recovery, yet we are the first to critically assess this drug for potential autonomic
or cardiovascular side effects, notably in a population which is already
susceptible to cardio-autonomic dysfunction. We found that prolonged treatment
with RAP after complete SCI exacerbates cardiovascular dysfunction without
modifying markers of intraspinal plasticity associated with AD, as assessed by
CGRP+ fiber sprouting and interneuronal c-fos expression. The present results
suggest a limited role of this major signaling hub in aberrant sensory fiber
sprouting after SCI and further indicate that a number of alternative and
targetable pathways may be more critically involved.
We tested GBP based on previous reports from our lab demonstrating that
acute administration reduces the severity of experimentally induced AD
(Rabchevsky et al., 2011; Rabchevsky et al., 2012), and other research
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suggesting that daily treatment with GBP can block the formation of new
excitatory synapses in the brain and spinal cord (Eroglu et al., 2009; Lau et al.,
2017; Yu et al., 2018). For over a decade, it has been thought that the formation
of new synapses between newly sprouted c-fibers and propriospinal neurons is
necessary for the development of exaggerated sympathetic reflexes produced
during AD (Weaver et al., 2002). Therefore, we sought to determine if continuous
delivery of this purported anti-synaptogenic drug could prevent alterations in
synaptic density of intraspinal primary afferents or interneurons thought to
contribute to AD. We found that continuous delivery of high dose GBP reduced
the absolute blood pressure achieved during experimentally induced AD,
prevented normally observed bradycardia during CRD and reduced the amount
of time for blood pressure to return to baseline after an induced AD event. Our
continuous treatment paradigm was also associated with apparent anxiolytic
effects not observed in our previous studies using a smaller dosage of GBP.
Unexpectedly, GBP also increased the frequency of spontaneously occurring AD
through an uncertain mechanism. Consistent with previous reports (Beauparlant
et al., 2013; Freria et al., 2017; McKillop et al., 2016), we observed a decrease in
the density of excitatory and inhibitory pre-synaptic markers in the dorsal
lumbosacral cord from injury alone. However, these reductions in synaptic
immunoreactivity were not altered by GBP treatment, suggesting an alternative
mechanism of action in reducing the severity of AD.
This chapter discusses the relevance of these findings in the broader
context of SCI and AD research. Moreover, future directions are presented with
the ultimate goal of better understanding maladaptive changes at the molecular
and neuronal level within spinal sympathetic circuits which may aid in the
discovery of treatments capable of preventing the development of this condition.
5.2 Discussion
We investigated the possible role of the mammalian target of rapamycin
(mTOR), a major intracellular signaling pathway in mammalian cells, in the
pathophysiology of AD. mTOR signaling has been the focus of much recent
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research for its role in structural and functional plasticity of the central nervous
system and as a potential therapeutic target to promote functional recovery after
SCI. Approximately a decade ago, Park et al. (2008) demonstrated that
disinhibition of the mTOR pathway can markedly enhance axonal regeneration
after optic nerve injury. Soon after, others demonstrated that decreased mTOR
activity in adult neurons is associated with the loss of regrowth potential, but that
experimentally increased mTOR signaling can ‘re-awaken’ neuronal growth and
sprouting potential after SCI (Liu et al., 2010). These studies generated
considerable interest in the role of mTOR in CNS injury and disease. Numerous
subsequent studies demonstrated similar roles of mTOR in neuronal plasticity in
a number of models, including epilepsy, autism and neurodegenerative disease
(Lipton and Sahin, 2014).
Despite the promising studies proposing mTOR as a critical mediator of
CNS plasticity (Hu, 2015), other researchers presented evidence that mTOR may
play a more subtle and perhaps replaceable role in post-injury sprouting. For
example, Lee et al. (2014b) demonstrated that collateral branching of descending
corticospinal axons after pyramidotomy in adult mice proceeds normally during
RAP treatment, indicating that mTOR activity is dispensable for reactive
sprouting. Furthermore, collateral sprouting in young mice was shown to be
substantially impeded by RAP treatment which suggested that mTOR plays a
more essential in plasticity early in development. We observed a pattern of
enhanced intraspinal mTOR activity weeks after spinal transection, indicating a
potential role in mediating maladaptive plasticity. Our hypothesis was that
pharmacological inhibition of the mTOR pathway with RAP would impede
maladaptive c-fiber sprouting after spinal cord transection and mitigate the
development of AD. We did not, however, observe an effect of chronic mTOR
inhibition with RAP on the sprouting of primary CGRP+ afferents after SCI,
suggesting that mTOR signaling is not involved.
An important caveat with this interpretation arises in the context of studies
demonstrating cross-talk and compensatory signaling between mTOR and
parallel signaling pathways which can counteract the effects of mTOR
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suppression. As discussed in Chapter 3, the work of Melemedjian et al. (2013)
demonstrated that mTOR inhibition can increase the activity of related signaling
pathways in sensory neurons to produce paradoxical effects. This concept is well
known in the field of cancer research which often utilizes drugs targeting progrowth signaling pathways. For example, the development of rapamycin-resistant
tumors and failure of otherwise promising tumor suppressing drugs has been
attributed to the complex redundancy of important intracellular signaling
pathways (Gruppuso et al., 2011; Rozengurt et al., 2014). Notably, mTOR forms
two distinct signaling hubs: mammalian target of rapamycin complex 1 and
complex 2 (mTORC1 and mTORC2). These protein complexes mediate distinct
aspects of cellular activity and metabolism and are classically described as
“rapamycin-sensitive” (mTORC1) and “rapamycin-insensitive” (mTORC2)
pathways (Laplante and Sabatini, 2009). Acute RAP administration selectively
inhibits mTORC1, as this complex contains the specific binding protein targeted
by RAP (the FK506 binding protein) which is absent from mTORC2. However,
long-term RAP administration is also known to inhibit mTORC2 (Laplante and
Sabatini, 2009; Sarbassov et al., 2006). Therefore, it is possible that our
prolonged treatment paradigm may have inadvertently suppressed two major
signaling hubs, creating even further feedback stimulation of compensatory
pathways.
The lessons learned from cancer research elucidate an additional
challenge of inhibiting intracellular signaling pathways for therapeutic purposes
after SCI; namely that of redundancy within signal transduction networkds. This
redundancy is an important feature of intracellular signaling networks that lends
an organism resiliency on the sub-cellular level (Logue and Morrison, 2012),
however it also presents significant challenges in developing targeted drug
therapies. Newer drugs, such as the dual PI3K/mTOR inhibitors, were developed
to suppress multiple pathways in hopes of overcoming such drug resistant
tumors. Some of these dual inhibitors have been successful in blocking the
growth of tumors (Fourneaux et al., 2017; Stankovic et al., 2018). Future studies
using dual pathway inhibitors may similarly prove more successful in blocking
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maladaptive plasticity by avoiding compensatory signaling through parallel
pathways. There are, however, reports suggesting that even dual PI3K/mTOR
inhibitors can result in compensatory signaling through MEK/ERK (mitogenactivated protein kinase-kinase/extracellular signal-regulated kinases) signaling
(Fourneaux et al., 2017; Soares et al., 2015). Therefore, future experiments
utilizing such inhibitors must still assess related pathways and monitor for
paradoxical effects.
Similar to previous studies in our lab (Rabchevsky et al., 2011;
Rabchevsky et al., 2012), the current GBP study was performed with
intraperitoneal drug delivery. An important question regarding the mechanism of
GBP in treating AD is whether our observed effects on AD are due to central or
peripheral actions of GBP. As the a2d-1 and a2d-2 subunits targeted by GBP are
found throughout various central and peripheral tissues (Taylor and Garrido,
2008), there are numerous locations throughout the body which could feasibly be
involved, including the spinal cord, brain, dorsal root ganglia, peripheral
sympathetic ganglia and vasculature. Unlike GABA, which has high structural
similarity, GBP readily traverses the blood-brain barrier (BBB) and permeates
tissue of the central nervous system. In rats, high levels of GBP binding have
been documented in membrane extracts from brain, heart and skeletal muscle
tissue (Gee et al., 1996). Passage of GBP through the BBB and into neurons is
mediated by the L-type amino acid transporter 1 (LAT1) (Uchino et al., 2002).
The transport of GBP by LAT1 has been shown to increase in proportion to the
plasma concentration of GBP, although this process likely has a saturation limit
(Luer et al., 1999). These characteristics indicate that GBP can have multiple
sites of action in the central and peripheral nervous systems.
Studies conducted by Taylor and Garrido (2008) characterizing the
expression patterns of the a2d-1 subunit targeted by GBP found widespread
distribution throughout much of the body, including the central nervous system,
skeletal muscle, heart, and to a milder extent in the spleen, liver and kidneys. A
particularly high staining density is seen in the spinal dorsal and lateral horns, the
latter of which is the region containing the majority of SPN. This distribution
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pattern suggests that GBP could act on primary afferents, SPNs or some
combination thereof. Ex-vivo studies using spinal cord slice preparations indicate
that GBP reduces excitatory glutamatergic neurotransmission in the dorsal horn
through a pre-synaptic mechanism (Patel et al., 2000; Shimoyama et al., 2000).
Because the primary subunit targeted by GBP is found at a high density in the
lateral horn of the rat thoracic cord where SPN are located (Taylor and Garrido,
2008), future studies using spinal cord slice preparations could be designed to
determine whether GBP directly modulates electrophysiological properties of
SPN or pre-sympathetic interneurons. Notably, retrograde viral tracing methods
could be used to identify SPN in slice preparations from naïve and injured rats to
determine possible effects of GBP treatment on the electrophysiological
properties of SPN after injury (Derbenev et al., 2010; Ueno et al., 2016; Wilson et
al., 2002). Moreover, additional insights could be gained through future studies
comparing the effects of systemic (i.p.) versus localized (i.t.) drug delivery on the
magnitude of CRD-induced AD. These future directions could be useful for
identifying the site of action of GBP and also contribute to our understanding of
mechanisms underlying AD.
Another possible site of action is smooth muscle of the vasculature. a2d-1
is expressed throughout the smooth muscle of arteries, which indicates a
potential role of this subunit in the regulation of peripheral resistance and blood
pressure. Pregabalin (PGB), which is a gabapentinoid with similar binding
properties to the a2d-1 and a2d-2, has been shown to induce vasodilation in rat
arteries ex-vivo (Bannister et al., 2009; Bannister et al., 2012). Isolated and
pressurized cerebral arteries had significantly reduced myogenic tone following
incubation with PGB, with the arterial tone returning to normal control levels
several hours after drug washout. This effect corresponded with an increased
ratio of cytosolic:membrane-bound a2d-1 subunits suggesting that the
vasodilatory effect of PGB results from reduced membrane trafficking of calcium
channels and consequent reductions in calcium channel current. Moreover, the
12-hour delay between PGB washout and restoration of myogenic tone is
consistent with the time-frame needed for membrane density and trafficking of
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calcium channels to return to normal (Bannister et al., 2009). Because these
studies were conducted on cerebral arteries, further study is required to
determine if gabapentinoid drugs exert similar effects on the systemic
vasculature. However, these findings present the possibility that GBP attenuates
blood pressure during AD, at least in part, via actions on the peripheral
vasculature. It is conceivable that GBP reduces the capacity of vascular smooth
muscle to constrict and increase total peripheral resistance. If GBP has
vasoactive effects, we would expect a reduction in daily MAP with 4x daily drug
administration. Since we did not observe an alteration in the daily MAP in rats
receiving GBP, it does not appear that GBP altered vascular tone after SCI. On
the other hand, the slight but consistent elevation of daily HR in injured GBP rats
relative to saline controls may reflect an increase in cardiac sympathetic drive
increasing cardiac output to compensate for possible vasodilatory effects of GBP.
5.3 Alternative Approaches and Future Directions
5.3.1 Determining the mechanism by which GBP suppresses AD
Despite a long history of use in treating epilepsy, neuropathic pain and,
more recently, mental illnesses, GBP’s primary mechanism of action remains
uncertain. A number of mechanisms have been proposed over the past three
decades including activation of inhibitory GABA receptors, alteration of intra- and
extracellular amino acid concentrations, modification of glutamatergic
neurotransmission, prevention of excitatory synaptogenesis, suppression of
descending serotonergic facilitation, and inhibition of voltage-gated Na+, K+ or
Ca2+ channels (Chincholkar, 2018; Sills, 2006; Su et al., 2005; Taylor et al.,
1998). Following the discovery of Gee et al. (1996) and Wang et al. (1999) that
GBP is a ligand for the L-type Ca2+ channels (LTCC), many researchers have
focused on this interaction to generate a steady accumulation of evidence
supporting this as the primary and most clinically relevant target of the
gabapentinoid drugs. LTCCs are multimeric complexes with a vast functional
diversity (Dolphin, 2016). These channels all contain an obligate a1 pore-forming
subunit through which Ca2+ ions flow into the cell upon depolarization, as well as

127

three auxillary subunits known as the b, g and a2d subunits (Bourinet et al., 2004).
Moreover, these auxillary subunits are each found in multiple isoforms which
provide the structural basis for a wide functional diversity of the LTCCs (Dolphin,
2016). The a2d subunit is expressed in four isoforms (a2d-1, a2d-2, a2d-3 and a2d4) of which GBP and pregabalin are known to bind with high affinity to the a2d-1
and a2d-2 (Gee et al., 1996). Notably, mutation of the a2d-1 subunit has been
demonstrated to significantly decrease GBP binding and its therapeutic effect in
mice (Hendrich et al., 2008; Taylor, 2004), further implicating this subunit as the
primary pharmacologically relevant target of GBP. The functional significance of
the GBP-a2d-1 interaction on LTCCs and neuronal function remains unclear.
Work by Annette Dolphin and colleagues suggests that GBP binding to a2d-1
disrupts the trafficking of calcium channels to the surface plasma membrane of
neurons, resulting in reduced calcium flux and presynaptic neurotransmitter
release (Bauer et al., 2010; Dolphin, 2016; Hendrich et al., 2008; Sarantopoulos
et al., 2002; Taylor, 2009). Of note, this proposed mechanism is consistent with
the delayed-onset effects of GBP in some models (Baba et al., 2016),
purportedly due to the time necessary for the cell to traffic new Ca2+ channels to
the plasma membrane which is likely between 6 and 16 hours in vitro (Bauer et
al., 2010; Heblich et al., 2008). However, because gabapentin has rapid onset
effects with some in vivo models this mechanism does not satisfactorily account
for its clinical properties (Alles and Smith, 2017; Chincholkar, 2018). In relation to
our studies, reduced membrane trafficking of calcium channels also fails to
explain the rapid effect of acutely delivered GBP to reduce the magnitude of
induced AD (Rabchevsky et al., 2011; Rabchevsky et al., 2012).
Recently, Chen et al. (2018) presented a novel mechanism of action of
GBP which involves modulation of N-Methyl-D-aspartic acid receptor (NMDAR)
activity. Their study showed that the a2d-1subunit coimmunoprecipitates with
NMDAR subunits in membrane fractions of rat dorsal spinal cord extract as well
as membrane extracts from HEK293 cells in vitro, suggesting the formation of a
a2d-1-NMDAR complex (Chen et al., 2018). Moreover, they demonstrated that
exposure to GBP decreases the trafficking of a2d-1-NMDAR complexes to
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synaptic terminals and reduces NMDA current, suggesting that the a2d-1NMDAR complex potentiates excitatory neurotransmission. This was a
remarkable finding, as Chen et al. (2018) challenge the notion that a2d-1
functions solely in the context of LTCCs and instead suggest more broad
functions independent of LTCCs. Interestingly, this research group has found that
the a2d-1-NMDAR interaction is involved in spinal cord primary afferents, as well
as nuclei within the brain involved in sympathetic nerve activity regulation. These
studies suggest that the a2d-1-NMDAR is relevant in multiple physiological
systems and may account for discrepancies between studies. These novel
findings also indicate that GBP may decrease the magnitude of AD by
decreasing the density of a2d-1-NMDA complexes in primary afferent terminals,
leading to a reduction of excitatory neurotransmission through c-fiber afferents
during CRD. Notably, a2d-1 expression is particularly dense in the spinal cord
dorsal horn (Taylor and Garrido, 2008), which supports the hypothesis that GBP
suppresses AD by blocking the a2d-1-NMDA interaction in the dorsal horn.
Future studies may elucidate whether this novel mechanism accounts for the
effect of GBP in mitigating experimental AD. Chen et al. (2018) demonstrated
that nerve injury increases a2d-1-NMDA complexes, implicating this interaction
part of the underlying mechanism of GBP. Similar co-immunoprecipitation
experiments after T4x SCI would be an important future direction to test the
hypothesis that SCI increases a2d-1-NMDA complexes in correlation with the
development of AD. Moreover, it is feasible to intrathecally or intraperitoneally
inject the a2d-1 Tat c-terminus peptide as used by Chen et al. (2018) to disrupt
the interaction between a2d-1 and NMDAR subunits to determine whether
blocking this interaction mimics the effects of GBP.
How might this recently proposed mechanism relate to the findings of
Eroglu and colleagues (Eroglu et al., 2009; Lau et al., 2017; Yu et al., 2018)
indicating that GBP’s clinical effects are associated with reduced excitatory
synaptogenesis? An intriguing possibility is that a reduction in excitatory
neurotransmitter release resulting from GBP’s interference with the a2d-1-NMDA
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complex decreases synapse formation driven by neurotransmitter release (Chen
et al., 2018). Viewed in light of other recent findings that suggest
thrombospondin-4 (TSP-4) does not interact with a2d-1 expressed on the cell
surface (Lana et al., 2016), and therefore may not be physiologically relevant, it
is possible that much of GBP’s purported anti-synaptogenic effects are
alternatively due to a reduction of activity-driven synapse formation. The role of
neurotransmission in the formation of new synapses has been the subject of
investigation for some time. This relationship remains incompletely understood
and appears to depend on the specific circuits being investigated and
experimental conditions (Andreae and Burrone, 2014). However, a considerable
number of studies indicate that synapse formation or maintenance may be driven
or enhanced by neurotransmitter release in some systems (Andreae and
Burrone, 2014; Brandon et al., 2003; Kozorovitskiy et al., 2015; Reese and
Kavalali, 2015).
If GBP prevents the formation of new synapses without altering existing
connections (Eroglu et al., 2009), we would expect deleterious effects on
memory and learning. Moreover, in utero exposure to this commonly prescribed
drug might be expected to create developmental defects. However, studies
investigating potential effects of in utero GBP exposure on the incidence of major
birth defects have not reported such a relationship (Fujii et al., 2013; MolgaardNielsen and Hviid, 2011; Morrow et al., 2006). This suggests that typical clinical
dosages of GBP do not block de novo synapse formation in vivo. Investigations
in rats examining the effect of three weeks of daily GBP treatment (30 mg/kg i.p.)
on memory formation also did not find such a relationship, although the closely
related drug pregabalin (PGB, 30 mg/kg i.p.) significantly reduced indices of
memory consolidation (Salimzade et al., 2017). One important consideration is
the relatively short 2-4 hour half-life of GBP in rats, suggesting that plasma
concentrations are minimal for the majority of the day when single daily doses
are used (Vollmer et al., 1986). In addition, the discrepancy between the effects
of GBP and PGB, both of which bind to the a2d-1 and a2d-2 subunits, may be
due to the significantly higher potency of PGB (Shamsi Meymandi and
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Keyhanfar, 2013). Several studies examining memory and cognition in humans
did not observe an effect of GBP treatment on memory and cognition (Cilio et al.,
2001; Leach et al., 1997; Shannon and Love, 2004). However, some conflicting
reports exist as well that indicate GBP may actually enhance memory retention
and cognitive performance (Acosta et al., 2000; Celikyurt et al., 2011). Recently,
Zhou et al. (2018) found that the a2d-1-NMDA complex plays an important role in
long term potentiation within the corticostriatal pathway and that treatment with
either GBP or a2d-1 c-terminus peptide interrupts the a2d-1-NMDA complex to
interfere with memory formation in mice. These discrepant findings likely reflect
the inconsistencies in drug dosage, route of delivery, cognitive tests and
experimental models utilized.
Could GBP treatment be optimized to more efficiently mitigate AD without
numerous possible off-target effects? As described above, the passage of GBP
through the BBB and into cells is mediated by LAT1 (Uchino et al., 2002). LAT1
transport of GBP increases in proportion to the plasma concentration of GBP,
however this transporter is relatively slow (Palacin et al., 1998) and has a
saturation limit beyond which increased plasma GBP does not increase the rate
of exposure to central neurons (Luer et al., 1999). Because numerous other
tissues throughout the body also bind GBP and can sequester it from the
circulation (Gong et al., 2001; Taylor and Garrido, 2008), it is challenging to
deliver large doses of GBP to the central nervous system specifically by way of
systemic administration. Moreover, LAT1 is found in many cell types and
therefore cellular uptake of GBP is non-specific. Intriguing work by Biggs et al.
(2015) indicates that the capsaicin-activated TRPV1 (transient receptor/vanilloid
receptor 1) cation channel can provide an additional route of entry for GBP into
cells that is hundreds of times faster than LAT1 transport (Biggs et al., 2015).
Because TRPV1+ sensory neurons play an important role in AD (Ramer et al.,
2012), this suggests that combined treatment with GBP and TRPV1 activators
could markedly increase the specificity of GBP for TRPV1+ neurons to more
potently suppress AD at lower systemic dosages. Additionally, it is currently
unclear whether GBP acts at an extracellular or intracellular site to suppress AD.
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Therefore, enhancing the cytoplasmic concentration of GBP in TRPV1+ cells
could also help elucidate the relevant site of action.
5.3.2 Dissecting the cellular signaling driving maladaptive plasticity
What other signaling pathways might drive maladaptive sprouting
associated with the development of AD? One clue in the relevant signaling
pathway comes from studies demonstrating the role of nerve growth factor (NGF)
in sprouting of c-fibers after SCI (Brown et al., 2004; Cameron et al., 2006; Krenz
et al., 1999). As discussed in Chapter 2, NGF expression is upregulated
throughout the spinal cord in response to traumatic SCI (Bakhit et al., 1991).
Sequestration of intraspinal NGF with anti-NGF antibodies decreases c-fiber
sprouting in correlation with a reduced magnitude of AD (Krenz et al., 1999), and
viral-mediated overexpression of NGF has been shown to increase c-fiber
sprouting and AD severity (Cameron et al., 2006). Upon binding to its highaffinity receptor, tropomyosin receptor kinase A (trkA), NGF can stimulate a
number of intracellular signaling cascades (Wang et al., 2014). Protein kinase B
(a.k.a. Akt) has garnered interest for its role in mediating the protective effects of
NGF on neurons (Crowder and Freeman, 1998; Xia et al., 2015). The survival of
rat sympathetic neurons maintained in vitro is enhanced with NGF treatment,
though this effect is blocked with PI3K-Akt inhibitors (Crowder and Freeman,
1998). The mitogen-activated protein kinase (MAPK) pathway is also believed to
function downstream of NGF to promote neuronal plasticity (Blum and Konnerth,
2005). Further experimentation in rodent AD models using Akt or MAPK
inhibitors (English and Cobb, 2002; Nitulescu et al., 2016), for example, may
provide new insight into pathways related to AD development.
An important consideration that must be addressed when attempting to
block maladaptive plasticity is that many aspects of post-injury plasticity are
desirable for functional recovery (Brown and Weaver, 2012). Therefore, an ideal
prophylactic treatment for AD would be capable of blocking pathways involved
specifically with maladaptive plasticity without compromising signaling pathways
driving adaptive plasticity. Because unmyelinated c-fibers are thought to be the

132

primary fiber type involved in the pathophysiology of AD (Hou et al., 2009), it may
be possible to target signaling pathways specific to these neurons without
impeding beneficial plasticity of motoneuron circuits or other myelinated sensory
fibers. This would require a detailed comparative understanding of the
transcriptional and proteomic profiles of specific neuronal populations after SCI.
Modern technologies such as single-cell laser capture microdissection and highfidelity transcriptome sequencing allow for such characterization of transcriptional
programs in specific cell types. For example, these methods have been used
recently in the rodent spinal cord to characterize the transcriptomes of spatially
distinct neuronal populations isolated with laser microdissection (Bandyopadhyay
et al., 2014; Nichterwitz et al., 2016). These studies indicate that this may be a
viable approach to drive forward our understanding of cellular mechanisms
involved in maladaptive sprouting.
5.3.3 Homeostatic plasticity: does it play a role in the pathogenesis of AD?
Homeostatic control is found in many biological systems and is a powerful
mechanism that allows cells and organisms to operate with optimal physiological
function despite changing environmental conditions. In the nervous system,
homeostatic plasticity (HP) refers to a process whereby neurons behave in a selfregulatory manner to maintain activity within a relatively stable range. These
mechanisms may include alterations in the number of synapses, ion channel
expression, altered neurotransmitter release quanta, and changes in
neurotransmitter receptor expression (Lazarevic et al., 2013; O'Brien et al., 1998;
Turrigiano, 2012; Turrigiano, 2008; Wenner, 2014). Schaukowitch et al. (2017)
demonstrated in vitro that a global decrease in network activity following
exposure to the Na+ channel blocker tetrodotoxin triggers a specific
transcriptional program which enhances synaptic strength, indicating that
neurons have archetypal transcription programs for mechanisms of HP.
Substantial evidence suggests a role of HP in the pathophysiology of SCI and
subsequent dysfunctions. For example, previous studies show that the loss of
descending inputs onto spinal neurons after SCI results in increased
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spontaneous neuronal firing and compensatory sprouting in attempt to maintain
an normal level of activity (Beauparlant et al., 2013; Ferguson et al., 2012).
Studies on spinal respiratory networks indicate that HP is a feature of respiratory
neurons that helps to maintain appropriate blood arterial gas levels
(Braegelmann et al., 2017) and also indicates that mechanisms of HP may be
seen in other spinal networks including autonomic neurons.
Within the theoretical framework of HP, a potential role in the etiology of
AD can be speculated. Presently, it is known that primary afferent c-fibers and
ascending propriospinal neurons sprout after SCI (Hou et al., 2008; Hou et al.,
2009). This plasticity is believed to be a compensatory response to the
denervation and loss of supraspinal inputs. What is not yet clear, however, is
whether the sprouting of these two populations are interrelated. One possibility is
that the reactive sprouting of primary afferents and subsequent increase in
sensory input provides the stimulus for the sprouting and plasticity of
propriospinal neurons. Future studies designed to limit the effects of primary
afferent sprouting may elucidate a possible relationship. Dorsal rhizotomy, which
triggers the degeneration of intraspinal afferents from the associated
dermatome(s) (Coimbra et al., 1984; Muneton-Gomez et al., 2004), may be
performed after SCI to test the hypothesis that segmental propriospinal sprouting
is driven or enhanced by sprouting of primary afferents. Combined with
propriospinal labeling methods such as those previously employed in our lab
(Hou et al., 2008), deafferentation may yield insights into a possible relationship
between the sprouting of these two neuronal populations. Conversely, it is also
possible that the sprouting of both populations is driven by a common stimulus
such as increased NGF expression (Brown et al., 2004). Although injury-induced
upregulation of NGF has been demonstrated to induce c-fiber sprouting after SCI
(Cameron et al., 2006; Krenz et al., 1999), the hypothesis that ascending
propriospinal neurons similarly sprout in response to elevated NGF remains
untested.
Prolonged exposure to GBP has been observed to decrease the overall
activity of dorsal horn networks (Biggs et al., 2014). This implies that our 4x daily
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treatment paradigm feasibly reduced overall sensory input into the spinal cord
after injury. In this case, we can speculate that a long-term reduction in afferent
stimulation would also reduce activity of intraspinal networks influenced by
sensory inputs, such as the SPN. Large-scale changes in network activity are
known to induce HP, whereby a sustained reduction of synaptic inputs or activity
results in an increase of spontaneous activity or membrane excitability
(Braegelmann et al., 2017). When extended to our current GBP study, this
indicates that a prolonged reduction in afferent stimulation of sympathetic or presympathetic interneurons could provide impetus for SPN to increase their
intrinsic excitability in effort to maintain their activity around a “set-point”. While
this hypothesis must be assessed directly with future experiments, it may explain
our finding that continuous high dose GBP treatment paradoxically increases the
frequency of spontaneous AD.
5.3.4 Further elucidation of the neuronal circuitry underlying AD
Our current understanding of the interneurons influencing SPN in both the
naïve and injured spinal cord remains fragmented, in part because of earlier
technical challenges of confidently identifying sympathetic interneurons as
described by Schramm (2006) and Deuchars (2007). In the intact animal, spinal
interneurons are believed to play a minor role in regulating SPN. Rather, the
descending inputs from supraspinal sympathetic nuclei are the major controllers
of SPN (Laskey and Polosa, 1988; Schramm, 2006). After SCI, the loss of
descending connections leaves the SPN isolated from the brain and completely
reliant on spinal interneurons or primary afferents for excitatory or inhibitory
modulation. Because spinal interneuron networks undergo extensive
reorganization and form new circuits after injury (Bareyre et al., 2004; Cote et al.,
2012; Hou et al., 2008; Rabchevsky, 2006; Ueno et al., 2016), it is not presently
clear how sympathetic and pre-sympathetic spinal interneurons are organized
after SCI.
During CRD, the activation of thoracic SPN by lumbosacral pelvic
afferents originating several spinal segments caudal to the IML indicates the
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presence of long-distance intersegmental interneurons or a series of shorter
segmental interneurons relaying afferent inputs to rostral thoracic SPN. These
propriospinal “relay” neurons are known to sprout after transection SCI,
suggesting that plasticity of this pathway may contribute to the development of
AD (Hou et al., 2008). What is not clear, however, is the relative contribution of
long inter-segmental interneurons traversing several segments to form a disynaptic pathway (pelvic afferentàintersegmental interneuronàSPN), compared
to a series of segmental interneurons connected to form a poly-synaptic pathway
(primary afferentàsegmental interneuronàsegmental neuron(nx)à SPN; Figure
5.1).

Figure 5.1. Proposed ascending pathways relaying visceral stimulation to
sympathetic preganglionic neurons (SPN). Segmental (dotted red lines) and
intersegmental (solid red, orange and black lines) interneurons may contribute to
AD. These “relay” neurons may be a single long projection spanning several
segments or a series of shorter segmental connections. These propriospinal
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projection neurons originating in the dorsal gray commissure have been identified
in lamina VII (red), V (orange) and X (black). The relative importance of these
distinct neural pathways in relaying noxious pelvic stimulation to the SPN is
currently unknown, however the future use of chemogenetic or optogenetic
silencing methods may enable the dissection of circuitry critical in AD elicited by
noxious pelvic stimuli.
Novel tract tracing and silencing techniques may be applied in our AD
model to dissect this pathway in more detail. As discussed in Chapter 2,
chemogenetic silencing of discrete neuronal pathways has been applied in the
CNS to examine the role of specific neuronal tracts (Figure 2.1). In addition to
the experiments proposed in Chapter 2, DREADDs and chemogenetic silencing
methods may also be applied to determine the relative contributions of long
intersegmental projections compared to series of short segmental projections in
relaying lumbosacral visceral afferents to thoracic SPN. The two-vector system
described in Chapter 2 is comprised of a high-efficiency retrograde virus
expressing tetanus toxin (HiRET-eTeNT) and a second virus carrying a
doxycycline sensitive activation gene (AAV-rtTAV). After doxycycline treatment,
HiRET-eTeNT becomes activated to block pre-synaptic neurotransmitter release.
Notably, however, only neurons transfected with both vectors are silenced. With
this system, it is feasible to inject HiRET-eTeNT into thoracic segments
containing vasomotor SPN and AAV-rtTAV into the lumbosacral laminae X to
silence long intersegmental projection neurons. Alternatively, HiRET-eTeNT may
be injected throughout intervening thoracolumbar segments with AAV-rtTAV
similarly injected into the lumbosacral lamina X in order to silence shorter
segmental projection neurons. Pairing this silencing paradigm with
cardiophysiological monitoring in SCI rats, it may be possible to compare the
importance of these two proposed pathways to the magnitude of CRD-induced
AD. As described in the review by Roth (2016), similar approaches have been
used with vectors expressing the hM4Di DREADD (designer receptor exclusively
activated by designer drugs), which activates K+ channels to hyperpolarize
neurons when the designer drug clozapine-n-oxide (CNO) is delivered.
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While DREADDs and other chemogenetic methods hold the potential for
significantly advancing our understanding of the pathophysiology of SCI and AD,
caution must be used in interpreting the results of CNO mediated DREADD
activation in lieu of recent studies demonstrating that metabolites of CNO create
confounding physiological effects (Manvich et al., 2018). Additionally, while
double vector systems can target specific neuronal projections, chemogenetic
techniques do not provide temporal and spatial precision as the activation drugs
require time to become active and may last for several hours before elimination.
An alternative technique is that of optogenetic modulation of neural activity. This
technology utilizes the light-activated cation or anion-conducting
channelrhodopsins to excite or inhibit neural activity, respectively (Iyer et al.,
2014). In contrast to chemogenetic methods, optogenetic modulation provides a
high degree of temporal and spatial precision due to the ability to expose discrete
areas of tissue with a controllable light source. These characteristics make it well
suited for identifying the role of specific neurons in network-level activity such as
viscerosympathetic circuits important to AD. While a majority of optogenetic
studies have been focused on brain pathways, a number of groups have adapted
this technique for use in the spinal cord (Christensen et al., 2016; Rahman et al.,
2018). Considerable technical challenges exist in the implementation of spinal
cord optogenetics (Montgomery et al., 2016), although researchers have recently
developed a wireless, battery free and flexible optical device which circumvents
several technical hurdles (Samineni et al., 2017).
5.3.5 Interaction between AD and the Immune System
As discussed in detail in Chapter 2, we are now beginning to appreciate
that the dramatic fluctuations in blood pressure and circulating catecholamines
(Leman et al., 2000) during recurrent AD can produce deleterious effects on
multiple physiological functions. SCI-induced immune depression syndrome
(SCI-IDS), which has been linked with recurrent AD in mice, is one example
which has significant clinical relevance (Riegger et al., 2007; Zhang et al., 2013).
This relationship is believed to be mediated through abnormal levels of
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immunosuppressive catecholamine and glucocorticoids released during AD,
although other mechanisms such as atrophy of the hemaepoetic niche in bone
marrow have been proposed as well (see Chapter 2). Unlike studies in mice
(Zhang et al., 2013), we did not observe gross spleen atrophy in our rat AD
model despite using a similar injury method and experimental timeline. Taken
alone, our data implies that the association between AD and SCI-IDS may be
species specific. In contrast, Mironets et al. (2018) recently utilized flow
cytometry and reported splenic leucopenia (decreased white blood cells) in wistar
rats after T3-transection SCI. They did not, however, report spleen wet weights
for comparison to our data. It is possible that leucopenia occurred after injury in
our study without being reflected in spleen size or weight. Future AD studies in
rats should employ flow-cytometry to quantify markers of white blood cells such
as CD45R (B cell), CD4 (T cell), CD8 (T cell), CD11b/c and CD68. Notably, flow
cytometry is the preferred method of analysis, as spleen tissue is notoriously
difficult to analyze histologically due to high levels of autofluorescence which
contribute significant false-positive readings (Franken et al., 2015; Li et al.,
2012a).
Paradoxically, we found that continuous GBP treatment after SCI caused
splenomegaly (enlarged spleen). Although there are no readily apparent
connections between GBP and spleen weight, there are clinical reports of
splenomegaly associated with GBP administration. Ragucci and Cohen (2001)
described a patient receiving 200 mg/kg GBP once daily who developed GBP
hypersensitivity syndrome, which included splenomegaly and elevated hepatic
enzymes. The spleen returned to normal size rapidly after discontinuation of
GBP. A number of possible causes of GBP-induced splenomegaly can be
speculated. The primary calcium channel subunit targeted by GBP is modestly
expressed in splenic tissue, indicating a possible direct effect of GBP on spleen.
As reviewed by (Petroianu, 2007), a variety of drugs can cause splenomegaly
through direct effects on spleen cells or through indirect effects on other organ
systems leading to congestion and enlargement of the spleen. The a2d-1 subunit
is sparsely expressed in the spleen, however liver hepatocytes show moderate
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expression (Taylor and Garrido, 2008). As the portal vein carries blood from the
spleen to the liver, it is feasible that an effect of GBP on venous resistance in the
liver led to splenic congestion. Furthermore, blood vessels express the a2d-1
subunit (Bannister et al., 2009) and, therefore, splenic congestion and
enlargement may have resulted from effects on the vascular smooth muscle.
5.4 Summary of Thesis
This dissertation has confirmed maladaptive neuroanatomical changes
which contribute to autonomic dysfunction and AD after SCI, as well as the
investigation of two drugs that were hypothesized to impede maladaptive
plasticity and prevent the development of AD. We discovered previously
undescribed cardiovascular side effects of RAP after SCI. Our results
demonstrate that prolonged RAP treatment exacerbates cardiovascular
dysfunction without modifying c-fiber sprouting, and suggest that mTOR signaling
plays a minor or dispensable role in maladaptive plasticity. Our findings also
highlight the challenges involved in targeting complex signaling pathways for
therapeutic outcomes. However other viable research avenues exist such as the
dual-kinase inhibitors which may prove more effective in suppressing the cellular
processes required for maladaptive sprouting.
Continuous GBP treatment was found to decrease the magnitude of
hypertension during AD and to reduce the time required for blood pressure to
return to normal after CRD. These represent clinically valuable effects, however
the dosage paradigm we used was also associated with more frequent sAD and
inhibited weight gain. We found that SCI decreases markers of excitatory and
inhibitory synapses in the lumbosacral cord, suggesting that synaptic remodeling
in the dorsal horn may contribute to dysfunctional sympathetic activity after SCI.
Further and more detailed analyses will be necessary to better understand how
synaptic re-arrangements contribute to AD. Although GBP treatment did not alter
synaptic measurements as hypothesized, multiple other unexplored mechanisms
have been presented that may be the subject of valuable future research.
Ultimately, GBP remains a valuable tool in the current arsenal of drugs which can
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alleviate AD, however the dosage, frequency and route of delivery must be
optimized to reduce potentially deleterious side effects.

Copyright © Khalid C. Eldahan 2019

141

Appendix 1. Abbreviations
ACh

Acetylcholine

AD

Autonomic dysreflexia

ADP

Adenosine diphosphate

AMPA

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor

APN

Ascending propriospinal neuron

BTX

Botulinum toxin

CGRP

Calcitonin gene related peptide

CNO

Clozapine-n-oxide

CRD

Colorectal distension

CVS

Cardiovascular system

DGC

Dorsal gray commissure

DREADD

Designer receptor exclusively activated by designer drug

GABA

Gamma-aminobutyric acid

GBP

Gabapentin

GC

Glucocorticoid

GIRK

G protein-coupled inwardly rectifying potassium channel

HP

Homeostatic plasticity

HPA

Hypothalamic pituitary axis

IML

Intermediolateral cell column

mTOR

Mammalian target of rapamycin

NDO

Neurogenic detrusor overactivity

NE

Norepinephrine

NGF

Nerve growth factor

NMDA

N-methyl-d-aspartic acid

NMDAR

N-methyl-D-aspartate receptor

PI3K

Phosphoinositide 3-kinase

RAP

Rapamycin

sAD

Spontaneous autonomic dysreflexia

sBR

Spontaneous baroreflex
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SCI

Spinal cord injury

SCI-IDS

Spinal cord injury-induced immune depression syndrome

SHR

Spontaneously hypertensive rats

SNS

Sympathetic nervous system

SPN

Sympathetic preganglionic neurons

SYP

Synaptophysin

VGAT

Vesicular gamma-aminobutyric acid transporter

VGLUT

Vesicular glutamate transporter
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